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SUMMARY 
Pulmonary hypertension (PH), a disease state affecting the pulmonary 
circulation, was first recognised in the 1950s. Obliteration of pulmonary 
capillary beds and vasoconstriction lead to elevated pulmonary vascular 
resistance (PVR) and increased right ventricular afterload. The direct 
consequence is impaired cardiac output (CO) response to exercise, resulting in 
progressive exercise limitation, and ultimately premature death from right heart 
failure. Despite the considerable expansion in pulmonary vasodilatory therapy in 
recent years, PH remains an incurable disease associated with high morbidity 
and mortality.  
Exercise CO is an important outcome measure in PH as it is directly linked to the 
consequences of disease. Cardiac output is conventionally measured at right 
heart catheterisation (RHC). The invasive nature of this procedure does not 
permit serial measurements to be made readily during follow-up to assess 
disease progression or treatment response. As a result, six-minute walk distance 
(6MWD), a simple measure of submaximal exercise capacity, has been used as a 
surrogate of exercise CO and the primary end-point in most randomised 
controlled trials of pulmonary vasodilatory agents to date. However, there are 
recognised limitations to the ability of 6MWD to predict outcome, and this 
necessitates the development of alternative outcome measures which are non-
invasive, reproducible and responsive to change. Measurement of CO using the 
inert gas rebreathing method (IGR) may be such an alternative to 6MWD. It is a 
direct measure of right heart function and hence disease-specific. It can be 
combined with submaximal constant-load exercise to provide an objective 
assessment independent of patient effort. This form of exercise would also 
allow isotime comparison of metabolic variables which were shown to be more 
sensitive than variables measured at peak exercise in demonstrating improved 
exercise capacity from therapeutic interventions in chronic obstructive 
pulmonary disease (COPD). Another potential alternative outcome measure is 
end-tidal carbon dioxide partial pressure (PETCO2). It is a marker of ventilatory 
inefficiency and was shown to correlate with disease severity in PH.  
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Accurate prognostication is central to PH management as it would inform 
treatment planning and patient counselling. Different strategies could be 
adopted to optimise the performance of existing prognostic factors. The 
predictive value of 6MWD may be improved by using % predicted 6MWD which 
adjusts for age, gender and anthropometric factors, and hence would give a 
more accurate representation of disease severity. A composite scoring system, 
combining key prognostic variables, would be more discriminatory than 
individual variables in predicting survival. Such prognostic equations have been 
derived from contemporary PH cohorts in France and the United States. 
Validation data published so far support their predictive value, but these 
equations may not perform as well in the United Kingdom (UK) as a locally 
derived risk score, due to differences in patient demographics and healthcare 
systems.  
The aims of this thesis were to investigate the use of novel non-invasive exercise 
variables and prognostic algorithms as outcome measures in PH.  
1. The first two studies evaluate the ability of IGR haemodynamic measurements 
and isotime metabolic variables during submaximal constant-load exercise, and 
PETCO2 during the six-minute walk test (6MWT) to predict treatment response. 
2. The last two studies explore the prognostic value of % predicted 6MWD and a 
novel UK-based composite risk score. 
The reproducibility and clinical correlates of IGR pulmonary blood flow (PBF) 
and stroke volume (SV) were determined. Changes in IGR PBF and SV and 
isotime metabolic variables, at rest and during submaximal constant-load 
exercise, were assessed after three months of new or modified disease-targeted 
therapy in patients with precapillary PH. IGR measurements were found to have 
good intersession reproducibility and correlate with conventional outcome 
measures including World Health Organisation functional class (WHO FC), 6MWD, 
N-terminal pro-brain natriuretic peptide (NT-proBNP) and Cambridge Pulmonary 
Hypertension Outcome Review (CAMHPOR) score. Resting and submaximal 
exercise IGR PBF and SV were able to detect treatment response, and may be 
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more sensitive than 6MWD in detecting the effects of therapy in fitter patients. 
In comparison, isotime metabolic variables were less useful in detecting a 
treatment effect.  
The metabolic response during the 6MWT was determined and changes in PETCO2 
were assessed after 3 months of new or modified disease-targeted therapy. 
Therapy-induced changes in the nadir of PETCO2 (PETCO2 nadir) correlated with 
changes in 6MWD, but resting, end-of-walk or PETCO2 nadir did not improve 
significantly at follow-up. Post-hoc analysis demonstrated that the study was 
under-powered to detect a change in PETCO2 with therapy.  
The prognostic performance of % predicted 6MWD, calculated using four 
different published reference equations, was compared with that of absolute 
6MWD, at baseline and on treatment. Despite adjusting for physiological inter-
subject variance, % predicted 6MWD is not superior to absolute 6MWD in 
predicting all-cause mortality. This may be related to limitations of existing 
reference equations or the use of all-cause rather than disease-specific 
mortality as the end-point. 
Baseline mortality predictors were identified from a Scottish cohort of incident 
and treatment-naive PH patients, and used to derive a simple scoring system for 
survival prediction over time. When validated in an independent UK PH cohort, 
the Scottish Composite Score (SCS) was predictive of survival and able to 
provide further risk stratification in WHO FC III patients. It may perform better 
in UK populations than other published equations derived from PH cohorts in 
France and the United States.  
In conclusion, IGR haemodynamic measurements may be useful as alternative 
outcome measures to 6MWD, and the SCS shows promise as the first UK-based 
composite risk score in PH. Further studies in larger cohorts are warranted to 
confirm their clinical utility. 
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1 INTRODUCTION 
This chapter aims to discuss the background and the rationale of the work 
undertaken for this thesis. It begins with an overview of PH focusing on its 
clinical classification, pathobiology, pathophysiology, natural history and 
current outcome measures. Following this is a discussion on the use of 
cardiopulmonary exercise testing (CPET) and prognostic algorithms in PH. 
Finally, the hypotheses and aims of this thesis are outlined.   
1.1 Overview of pulmonary hypertension 
PH is defined as elevated mean pulmonary artery pressure (mPAP) ≥25 mmHg at 
rest as measured by RHC. This could be caused by a number of conditions 
directly or indirectly affecting the pulmonary vasculature. Its clinical 
characteristics and prognosis were first defined in a prospective National 
Institutes of Health (NIH) study of 198 patients treated across 32 centres in the 
United States in 1980s 1. In that era, there was no effective pharmacological 
therapy and the median survival was only 2.8 years. Two decades on, substantial 
progress has been made in the understanding of PH pathobiology and 
pathophysiology. More importantly, over 20 randomised controlled trials of 
pulmonary vasodilatory therapy have been conducted leading to an expansion of 
therapeutic options. However PH remains an incurable condition associated with 
high morbidity and mortality 2.   
1.1.1 Clinical classification 
The first case of PH was described in 1891 and the name “primary pulmonary 
hypertension” was first used in 1951 3. Since then, the clinical classification of 
PH has evolved as a result of increased understanding of its natural history. The 
most recent review of PH management took place at the 4th World Symposium 
on Pulmonary Hypertension in 2008. The updated classification from this 
meeting classifies PH into five WHO groups based on the underlying mechanisms 
of disease 4.  
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WHO Group 1 Pulmonary arterial hypertension  
   1.1  Idiopathic  
   1.2  Heritable 
   1.3  Drugs and toxins induced 
   1.4  Associated with 
    1.4.1 Connective tissue diseases 
    1.4.2 Portal hypertension 
    1.4.3 Congenital heart disease 
    1.4.4  Human immunodeficiency virus infection  
    1.4.5 Schistosomiasis 
    1.4.6 Chronic haemolytic anaemia 
 
   1’ Pulmonary veno-occlusive disease and/or pulmonary  
    capillary haemangiomatosis 
 
WHO Group 2 Pulmonary hypertension due to left heart disease 
 
WHO Group 3 Pulmonary hypertension due to lung diseases and/or  
   hypoxia   
    
WHO Group 4 Chronic thromboembolic pulmonary hypertension 
 
WHO Group 5 Unclear and/or multifactorial mechanisms  
 
WHO group 1 pulmonary arterial hypertension (PAH) includes idiopathic PAH 
which was formerly known as primary pulmonary hypertension and other 
conditions with similar clinical presentation and pathological changes in the 
pulmonary microcirculation. This is the group of patients who have been the 
subjects of most randomised controlled trials of pulmonary vasodilatory 
therapy, epidemiological studies and basic science research.  
PH is also classified into precapillary and postcapillary according to the 
underlying haemodynamic profile. In precapillary PH, mPAP is ≥25 mmHg, CO is 
normal or reduced, and pulmonary capillary wedge pressure (PCWP) is ≤15 
mmHg. In postcapillary PH, mPAP is ≥25 mmHg, CO is normal or reduced, and 
PCWP is >15 mmHg. This haemodynamic definition aims to distinguish between 
conditions that directly affect the pulmonary vasculature resulting in increased 
PVR, and those that cause raised pulmonary venous pressure leading to a passive 
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increase in mPAP. Precapillary PH includes WHO groups 1,3,4 and 5. Post-
capillary PH includes WHO group 2.   
Only patients with WHO group 1 PAH and group 4 chronic thromboembolic 
pulmonary hypertension (CTEPH) were included in the studies of this thesis and 
are referred as having precapillary PH thereafter. These are the only groups of 
patients for whom the use of PAH-specific therapy is recommended by 
contemporary guidelines 2;5.   
1.1.2 Pathobiology  
In WHO group 1 PAH, a pulmonary arteriopathy affects distal pulmonary arteries 
of <500 μm in diameter resulting in an elevation of PVR 6;7. The pathological 
changes are characterised by thickening and fibrosis of all three layers of the 
vessel wall leading to luminal occlusion (known as pulmonary vascular 
remodelling), plexiform lesions (tumour-like lesions of endothelial cells at 
pulmonary artery bifurcation) and in-situ thrombus formation. The pulmonary 
veins are unaffected. The precise trigger for these changes is unknown, but is 
likely to involve a number of cell types and biochemical pathways 8-10. 
Endothelial dysfunction is thought to play an important role by over-expressing 
vasoconstrictive and proliferative mediators such as thromboxane A2 and 
endothelin-1, and under-producing vasodilatory and anti-proliferative mediators 
such as nitric oxide and prostacyclin, thereby leading to excessive 
vasoconstriction and proliferative pulmonary vascular remodelling. A 
prothrombotic state may be responsible for in-situ thrombosis which further 
reduces lumen calibre. Other cell types such as inflammatory cells, smooth 
muscle cells, fibroblasts and platelets, and plasma mediators such as vasoactive 
intestinal peptide have also been implicated.  
The precise pathogenesis of CTEPH is unclear. The primary pathological 
abnormality is the presence of organised thrombi causing thickening of the 
vessel wall and luminal occlusion in proximal pulmonary arteries. In some 
patients, there is an additional distal arteriopathy affecting occluded and non-
occluded subsegmental pulmonary arteries indistinguishable from that seen in 
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WHO group 1 PAH 11. CTEPH may occur as a sequelae of acute pulmonary 
embolism. Non-resolution of the thrombotic mass leads to mechanical 
obstruction and pulmonary vascular remodelling through increased shear force, 
pressure elevation and endothelial dysfunction in both occluded and non-
occluded areas. The incidence of CTEPH after the first thromboembolic episode 
was estimated to be around 4% at 2 years in a prospective long-term follow-up 
study 12. However, CTEPH may also develop in the absence of a previous 
thromboembolic episode. A recent multicentred international CTEPH registry 
study showed that around 30% of patients did not have a history of acute 
pulmonary embolism 13. In such patients, the process of pulmonary vascular 
remodelling may be initiated by thrombotic or inflammatory lesions in the 
pulmonary vasculature. Clotting abnormalities involving Factor VIII, platelets 
and anti-phospholipid antibodies may also play a part 14.  
Currently available pulmonary vasodilatory therapy targets three biochemical 
pathways aimed to ameliorate pulmonary vasoconstriction and pulmonary 
vascular remodelling. Endothelin receptor antagonists (bosentan, ambrisentan) 
counteract the vasoconstrictive and proliferative activities of endothelin-1. 
Phosphodiesterase-5 inhibitors (sildenafil, tadalafil) and prostacyclin analogues 
(epoprostenol, treprostinil, iloprost) potentiate the vasodilatory and anti-
proliferative activities of nitric oxide and prostacyclin. The efficacy of these 
agents in WHO group 1 PAH has been proven in over 20 randomised controlled 
trials, and this has been extrapolated to support their off-label use in CTEPH 
patients. Great efforts are underway to develop new therapeutic agents that 
would reverse or prevent PH. Those under investigation include tyrosine kinase 
inhibitors and guanylate cyclase agonists.  
1.2 Pathophysiology and natural history 
Elevated PVR results in increased impedance to PBF and increased right 
ventricular afterload. The success of right ventricular adaptation is the main 
determinant of clinical outcome and survival 15. In early disease, vasodilatation 
of non-diseased pulmonary capillary beds compensates for the loss of functional 
beds elsewhere, thereby maintaining PVR and pulmonary artery pressures. 
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Patients often have few symptoms as SV and CO at rest and during exercise are 
preserved. The negative impact on cardiopulmonary function becomes clinically 
apparent when around 70% of the pulmonary capillary beds are occluded. 
Patients experience increasing exertional limitation as SV and CO response to 
exercise become progressively restricted. In advanced disease, CO eventually 
becomes compromised at rest resulting in overt right heart failure, 
cardiovascular collapse and death (figure 1.1).  
 
Figure 1.1. Natural history of pulmonary hypertension 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients are asymptomatic when both resting and exercise cardiac output are preserved. 
Non-specific symptoms develop on exertion when exercise cardiac output becomes 
restricted without affecting resting cardiac output. Right heart failure ensues when resting 
cardac output is also compromised.   
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1.2.1 Right ventricular structure and function 
It was previously thought that the right ventricle (RV) simply existed as a 
conduit to transfer systemic venous blood to the lungs and the cardiovascular 
system can function adequately without RV ejection 16. This was recognised to 
be untrue as congenital RV hypoplasia would result in circulatory collapse and 
premature death. Recent advances in imaging techniques such as 
echocardiography and magnetic resonance imaging (MRI) have allowed 
sophisticated studies of RV structure and function, and aided the understanding 
of RV pathophysiology in PH. 
The RV is the most anteriorly placed cardiac chamber behind the sternum. It has 
a larger volume but smaller muscle mass than the left ventricle (LV) 17. In 
contrast to the ellipsoidal shape of the LV, it is triangular when viewed from the 
side and crescent shaped in cross-section (figure 1.2) 18. It can be divided into 
three parts: 1) the inlet portion consisting of the tricuspid valve, chordae 
tendineae and papillary muscles; 2) trabeculated apical myocardium; and 3) the 
infundibulum consisting of smooth myocardium and the pulmonary valve. Under 
normal conditions, LV pressures are higher than RV pressures during both systole 
and diastole, so the interventricular septum (IVS) bows into the RV under a 
positive left-to-right trans-septal pressure gradient throughout the cardiac cycle 
18.  
The ventricles are composed of multiple layers of muscle fibres arranged in an 
interlacing fashion 19. The RV free wall is made up of deep and superficial 
muscle layers. The deep fibres run longitudinally from base to apex and are 
continuous with those of the IVS. The superficial fibres are arranged 
circumferentially parallel to the atrio-ventricular groove. They turn obliquely 
near the apex and continue into the superficial layer of the LV. In comparison, 
the LV wall is composed of superficial obliquely orientated muscle fibres, sub-
endocardial longitudinal fibres and intervening circumferential fibres. Right 
ventricular contraction starts at the inlet portion, and spreads sequentially to 
the trabeculated myocardium and infundibulum 20. Shortening of longitudinal 
fibres causes the tricuspid annulus to move towards the apex, and that of 
 
 
27 
 
circumferential fibres produces inward movement of the RV free wall. There is a 
greater degree of longitudinal than circumferential shortening. In contrast, LV 
contraction is concentric involving twisting and rotation in addition to 
shortening, due to the action of oblique fibres. The continuous nature of 
ventricular wall musculature allows mechanical interaction between ventricles 
throughout the cardiac cycle, known as “ventricular interdependence” 20. 
The RV performs differently from the LV due to differences in muscle mass, 
chamber geometry and orientation of myocardial fibres 21-23. The RV has a 
smaller ejection fraction and less contractile reserve than the LV, and is 
therefore more sensitive to changes in afterload 24;25. Comparison between LV 
and RV is summarised in table 1.1. 
 
Figure 1.2. Two-chamber view of a normal heart by magnetic resonance 
imaging  
 
 
The left ventricle is spherical and the right ventricle triangular when viewed from  the side.  
Left ventricle 
Right ventricle 
   Interventricular septum 
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Table 1.1. Comparison of left and right ventricular structure and function 
  Right ventricle (RV) Left ventricle (LV) 
Structure 
inflow region, tracbeculated 
apical myocardium and 
infundibulum 
inflow region, myocardium 
and outflow tract  
Shape 
triangular from the side, 
crescent shaped in cross-
section 
ellipsoidal 
Mass One sixth of LV - 
Wall thickness, mm 2 to 5 7 to 11 
Muscle fibre orientation  
superficial: circumferential 
deep: longitudinal 
superficial: oblique 
middle: circumferential 
deep: longitudinal 
Contractile pattern 
long axis shortening, inward 
movement of RV free wall 
twisting, rotation, wall 
thickening  
Ventricular pressure, mmHg average 25/4  average 130/8  
Compliance at end-diastole higher lower 
Filling profiles 
starts earlier and finishes later 
lower filling velocities 
starts later and finishes earlier 
higher filling velocities 
End-diastolic volume, ml/m
2
 75±13  66±12  
Ejection fraction, % 61±7  67±5  
Adaptation to disease state 
more sensitive to pressure 
overload 
    more sensitive to volume 
overload    
Modified from Haddad et al. Right ventricular function in cardiovascular disease, Part I. Circulation. 
2008;117:1436-1448 
26
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1.2.2 Right ventricular response to increased afterload 
Right ventricular adaption to increased afterload determines the clinical course 
and outcome in PH. This adaptive process, consisting of dilatation, hypertrophy 
and a compensatory increase in contractile performance, is influenced by 
several factors including the time course of disease, the age of onset (congenital 
versus adult-onset heart disease) and the pattern of RV remodelling. Right 
ventricular failure occurs early in situations such as acute pulmonary embolism 
where RV adaptation is outpaced by an acute and rapid increase in afterload 
from a significant embolic burden 27. In congenital heart disease (CHD) 
associated with left-to-right shunting, longstanding exposure to systemic blood 
pressure causes the RV to undergo hypertrophic growth in parallel with the LV 
from birth. When PH and consequent reversal of shunt develop, the 
appropriately hypertrophied RV is able to maintain its systolic function against 
an increased afterload for decades before the onset of RV failure. The 
preservation of RV function accounts for the superior survival of these patients 
over those with other forms of PH 28-30. The pattern of RV remodelling is also 
influenced by altered gene expression, neurohormonal and cytokine activation 
as some patients develop RV failure earlier than others with the same degree of 
PH 31.  
1.2.3 Pathophysiology of right ventricular failure 
In the early stages of pulmonary vascular disease, RV responds to an increased 
afterload by undergoing concentric hypertrophy 32. The muscle mass increase 
results from increased protein synthesis and cardiomyocyte size through the 
addition of sarcomeres in response to increased systolic and diastolic stretch 
caused by rising systolic and diastolic ventricular pressures 33. This adaptive 
hypertrophy serves to enhance systolic contraction and maintain CO but can 
only be sustained for a finite period of time. It eventually gives way to 
ventricular dilatation as disease progresses. The mechanisms initiating this 
switch are unclear but there is increasing evidence to support the importance of 
oxygen demand/supply imbalance 34, resulting in complex changes in the 
cardiomyocytes and their extracellular matrix 33. Right ventricular dilatation is 
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associated with disruption of the normal pressure-volume relationship and a 
progressive decline in contractility. It also results in greater right ventricular 
wall tension which further compromises contractility by increasing myocardial 
oxygen demand and reducing ventricular perfusion. As RV systolic function is 
reduced, contraction time becomes prolonged resulting in interventricular 
mechanical asynchrony (RV is still contracting as LV enters diastole) 35-37. This 
causes leftward bowing the IVS into the LV cavity during early diastole under a 
positive right to left trans-septal pressure gradient (figure 1.3) and reduction in 
left ventricular end-diastolic volume. Combined with reduced RV SV, it leads to 
impaired left ventricular diastolic filling and consequently a marked decline in 
CO seen in PAH. RV dilatation also causes functional tricuspid regurgitation 
through annular dilatation and chordal traction, which further worsens right 
ventricular volume overload 38. Additional factors that have been implicated in 
the development of right heart failure include sympathetic activation 39;40, 
oxidative stress, immune activation and cardiomyocyte apoptosis 33. Therefore 
the development of RV dilatation signals the beginning of a vicious cycle of 
events culminating in right heart failure. 
Figure 1.3. Leftward septal bowing in right ventricular volume overload 
 
  
Left ventricle 
Right ventricle 
Interventricular septum 
The right ventricle is dilated and the 
interventricular septum is shifted to the 
left altering the size and shape of the left 
ventricle.  
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1.2.4 Compensatory changes in systemic oxygen transport 
The direct consequence of a restricted exercise SV and CO response is impaired 
systemic oxygen delivery to exercising muscles. This is partially compensated by 
increased oxygen extraction from the peripheral blood. As a result, the arterio-
venous oxygen content difference (Ca-vO2) is widened and mixed venous oxygen 
saturation (SvO2) falls 
41. This relationship between CO, oxygen uptake (VO2) and 
Ca-vO2 is described by the Fick Principle. 
VO2 = CO x Ca-vO2 
Peak VO2 is reduced despite a compensatory increase in Ca-vO2 and is manifest as 
impaired exercise capacity. A low SVO2 reflects a low CO state and is associated 
with poor prognosis 42-44.   
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Figure 1.4. Pathophysiology of right ventricular failure 
 
 
CO: cardiac output; LV: left ventricle; PVR: pulmonary vascular resistance; RV: right 
ventricle; SV: stroke volume; O2: oxygen.  
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1.3 Outcome measures in pulmonary hypertension 
The availability of effective pulmonary vasodilatory therapy has expanded 
considerably since the efficacy of the first agent, intravenous epoprostenol, was 
proven in a randomised controlled trial two decades ago 45. After a 12-week 
treatment period, actively treated patients were shown to have improved 
6MWD, pulmonary haemodynamics, quality of life (QOL) and survival compared 
with those on conventional therapy only. With identification of new molecular 
targets, eight oral agents have since been developed and their efficacy proven 
in randomised controlled trials using change in 6MWD as the primary end-point 2. 
Other co-primary or secondary end-points include WHO FC, pulmonary 
haemodynamics, brain natriuretic peptide (BNP) and NT-proBNP, health-related 
QOL and time to clinical worsening (TTCW). 
1.3.1 Six-minute walk distance 
Exercise assessment is an integral part of disease management in PH. Lowering 
of PVR by pulmonary vasodilatory therapy would off-load the RV and improve CO 
response to exercise. Exercise capacity is therefore directly linked to right heart 
function. Depending on the measurements of interest, exercise assessment 
could be undertaken in a variety of forms: field tests versus laboratory-based 
tests, incremental exercise versus endurance exercise, treadmill testing versus 
cycle ergometry. The principal form of exercise assessment adopted in PH is the 
6MWT which measures the distance walked in 6 min 2. The distance covered is 
proportional to the maximal average walking speed achieved over this period of 
time, and therefore represents the maximal sustainable aerobic exercise 
capacity. It correlates with peak VO2 and oxygen pulse (VO2/HR) measured at 
CPET 46, and metabolic equivalent measured at treadmill testing 47. Unlike these 
laboratory-based tests, 6MWT can be performed in a hospital corridor without 
the need for technical expertise or sophisticated equipment. It has been shown 
to be reproducible with <10% change on initial repeated testing 48. International 
guidelines on the standardisation of 6MWT exist to ensure results are 
interpretable across centres 49.  
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6MWD correlates with other markers of disease severity such as pulmonary 
haemodynamics and WHO FC 46. Since its ability to detect a treatment effect 
and survival benefit was first demonstrated in the landmark trial of intravenous 
epoprostenol 45, 6MWD has been used as a primary end-point in most randomised 
controlled trials of currently available oral pulmonary vasodilatory agents 50-56. 
Its prognostic value was subsequently confirmed in a series of observational 
studies on the long-term effects of PAH-specific therapy 57-60. Currently, 6MWD 
is the only exercise end-point accepted by the Food and Drug Administration in 
the Unites States and European Agency for the Evaluation of Medicinal Products 
to study the effects of pulmonary vasodilatory therapy. However, it is 
increasingly recognised that there are limitations to 6MWD that compromise its 
reliability as the primary end-point, and there is a need to develop alternative 
outcome measures that are more robust and disease-specific 61;62 as the 
treatment strategy for PH continues to evolve. 
As with other physiological measurements such as lung function and 
cardiopulmonary exercise capacity, 6MWD varies greatly in healthy individuals 
due to age, gender, height and weight. Meaningful interpretation of abnormal 
values can only be made in the context of known normality. Although several 
reference equations have been developed to correct for these physiological 
factors and predict normal values 63-66, there is no standardisation on which 
equation to use and how 6MWD results should be presented. Prognostic 6MWD 
thresholds identified in different studies are all based on absolute values 46;60. 
This makes interpretation difficult in patients at the extremes of age and body 
habitus. Percent predicted 6MWD (% predicted 6MWD) could give a more 
objective measure of deviation from normality, but there are so far no 
published data on its use in the clinical evaluation of PH patients. 
Performance at the 6MWT can be influenced by a number of factors unrelated to 
PH, such as co-existing cardiopulmonary, neurological and musculoskeletal 
problems, subject volition and walking efficiency 49. These factors may be more 
important determinants of 6MWD than the cardiopulmonary effect of PH such 
that any treatment-induced change in exercise capacity may be masked. The 
validity of 6MWD as an end-point in patients with milder disease (WHO FC I and 
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II) has also been called into question. In the EARLY (Endothelin Antagonist tRial 
in mildLY symptomatic pulmonary arterial hypertension) trial, 6 months of 
bosentan treatment in WHO FC II patients had no significant effect on 6MWD 
despite reducing PVR (co-primary end-point) and TTCW (secondary end-point) 67. 
Another study showed that PAH-specific therapy induced an improvement in 
haemodynamic measurements and WHO FC, but had no significant effects on 
6MWD in patients walking >450 m at diagnosis 68. These findings suggest that 
6MWD loses sensitivity as an outcome measure in fitter patients or those with 
early disease presumably due to a ceiling effect. During the walk test, VO2 
increases initially and reaches a plateau as the subject reaches the maximal 
average walking speed 69. VO2 cannot increase further beyond this point as the 
subject is not permitted to run. Hence 6MWD becomes disconnected with 
maximal exercise capacity as measured by peak VO2. This ceiling effect is 
illustrated in a study of healthy subjects and heart failure patients where a 
curvilinear relationship between peak VO2 and 6MWD was demonstrated with 
overlapping of 6MWD between patients in WHO FC II and healthy controls (figure 
1.6) 70. Any improvement in exercise capacity would be less evident when 
measured by a change in 6MWD if initial 6MWD approaches the normal range.  
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Figure 1.5. Ceiling effect of six-minute walk distance  
 
Modified from Lipkin DP et al. B Med J 1986;292:653-655 70; 6MWD: six-minute walk 
distance; VO2: oxygen uptake; WHO FC: World Health Organisation functional class.  
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1.3.2 Other outcome measures 
Pulmonary haemodynamics 
Patient outcome is closely linked to the severity of pulmonary haemodynamic 
impairment. Right atrial pressure (RAP) 1;43;44;59;60;71;72, mPAP 1;60, CO 73, PVR 71 
and SvO2 
42;57 have all been shown to predict survival with RAP and CO providing 
the strongest  prognostic signals. These haemodynamic indices also correlate 
with WHO FC and exercise capacity, but the relationships are not tight. 
Miyamoto et al found that there was no significant correlation between mPAP 
and 6MWD 46, which could be explained by the fact that mPAP may fall as RV 
fails in advanced disease. Kawut et al found that despite having similar 
pulmonary haemodynamics, patients with connective tissue disease associated 
pulmonary arterial hypertension (CTDPAH) had worse prognosis than those with 
idiopathic pulmonary arterial hypertension (IPAH) 74. The conventional method 
of calculating PVR based on resting measurements is also problematic. PVR is 
derived by the quotient of driving pressure (difference between mPAP and 
PCWP) and flow (CO). If only single point measurements at rest are used, the 
gradient of the pressure-flow relationship may be under- or over-estimated due 
to the assumption that it is linear and crosses zero 75;76. This relationship could 
be more reliably determined by taking multi-point measurements at rest and 
then on exercise, and defining incremental PVR as the slope of the pressure-
flow plot 77. Provencher et al demonstrated that exercise haemodynamics were 
more closely linked with therapy-induced improvement in exercise capacity than 
resting haemodynamics 78. The findings from this study further highlight the 
importance of exercise assessment in PH.  
World Health Organisation functional class 
WHO FC has been used to define functional status in PH patients and is a strong 
prognostic marker. Historical data on untreated patients with idiopathic or 
heritable PAH showed that the median survival was 6 months for WHO FC IV, 2.5 
years for WHO FC III and 6 years for WHO FC I and II 1. A more recent study on 
the long-term outcome of IPAH patients receiving intravenous epoprostenol 
showed that patients in WHO FC IV at baseline had worse prognosis than those in 
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FC III, and patients whose FC improved to I and II after treatment had better 
survival than those remaining in FC III and IV 60. In current practice, WHO FC is a 
vital part of clinical evaluation to assess stability and prognosis. 
N-terminal pro-brain natriuretic peptide 
NT-proBNP has emerged as the biomarker of RV function/dysfunction in recent 
years. It is released when BNP precursor is cleaved to form BNP in response to 
increased ventricular wall tension. Measurement of NT-proBNP is preferred to 
BNP as NT-proBNP is more stable in the peripheral blood and hence less 
susceptible to the influence of posture or activities. Baseline and/or follow-up 
NT-proBNP/BNP levels have been shown to correlate with survival and other 
markers of disease severity such as WHO FC, pulmonary haemodynamics, 6MWD 
79-82. Serial BNP/NT-proBNP measurements may be used to track RV function in 
deteriorating or improving patients during follow-up 83. In one study where the 
efficacy of pulmonary thromboendarterectomy in CTEPH patients was assessed 
by BNP, post-operative improvement in pulmonary haemodynamics was 
paralleled by a fall in BNP levels, and the levels remained elevated in patients 
with residual PH 84. NT-proBNP has been included as a secondary end-point in 
recent clinical trials of PAH-specific therapy, and significant decreases in its 
level were observed in the treatment group versus placebo group 54;67. Further 
large scale studies are awaited to confirm its usefulness as a biomarker of RV 
function.    
Quality of life measures 
The impact of PH and its treatments on patient QOL has not been systematically 
studied in clinical practice. Generic QOL measures have been included as 
secondary end-points in some clinical trials of PAH-specific therapy such as the 
36-item Short-Form Health Survey, European Quality of Life Scale, and 
Minnesota Living with Heart Failure Questionnaire. The content of these 
measures is not disease-specific and hence may not adequately describe the 
specific symptoms experienced by PH patients. A new PH-specific QOL 
assessment tool, the CAMPHOR score, has been developed by a group in 
Cambridge based on interviews of 35 PH patients and analysis of their responses 
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to PH-specific questions 85. It has been shown to have good internal consistency 
and test re-test reliability. However, before CAMPHOR score could be widely 
used in multi-national clinical trials, adaptations for different languages and 
countries need to be developed and validated. Its routine use in the clinical 
evaluation of PH patients is recommended by current UK and Ireland PH 
guidelines 5.  
Time to clinical worsening and survival  
Contrary to the survival benefit shown in the epoprostenol trial 45, a meta-
analysis of 16 randomised clinical trials of pulmonary vasodilatory agents 
conducted between 1985 and 2005 including 1962 patients found that 
treatments produced a modest improvement in exercise capacity (a mean 
change in 6MWD of 42.8 m), but this change was not predictive of survival 86. On 
the other hand, a more recent meta-analysis of 21 randomised controlled trials 
including 3140 patients conducted between 1990 and 2008 demonstrated active 
treatments conferred a 43% relative reduction in mortality 87. Although several 
registry studies have demonstrated improved survival of patients treated with 
modern PAH-specific therapy compared with historical cohorts 71-73;88, the 
survival benefit of PAH-specific therapy (other than intravenous epoprostenol) 
has not been proven directly in randomised controlled trials. In order to address 
this issue, future clinical trials should ideally use mortality as the primary end-
point, but this approach would require large sample sizes and relatively long 
study periods 89. A composite end-point, TTCW, has been developed as a 
surrogate of mortality to overcome this. It is defined as the time to the first 
adverse event, which may include 1) all-cause mortality; 2) hospitalisation due 
to PH; 3) the need for additional PAH-specific therapy; 4) the need for lung 
transplantation or atrial septostomy and 5) clinical progression of PH. It has 
been successfully used to demonstrate the efficacy of treatments in more 
recent clinical trials 54;90;91. 
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1.4 Cardiopulmonary exercise testing in pulmonary 
hypertension 
Patients affected by PH typically present with exercise intolerance due to 
breathlessness, fatigue, chest pain and/or pre-syncope. CPET allows a detailed 
and non-invasive examination of the integrated response to exercise from the 
cardiovascular, respiratory and musculoskeletal systems. It provides insights into 
the mechanisms of exercise limitation, and helps to differentiate between 
pulmonary vascular and other causes in patients with comorbid conditions. Its 
safety and reproducibility have been demonstrated in patients with PH 92. Unlike 
the 6MWT, it is not subject to a ceiling effect, and may be more discriminatory 
in assessing younger patients or those with early disease in whom 6MWD may be 
preserved 70;93. More importantly, several CPET variables have been shown to 
predict survival in PH 94 and have the potential to be used as markers of 
therapeutic response. Current guidelines recommend that CPET should be part 
of routine diagnostic and prognostic assessment in PH 2.  
1.4.1 Cardiopulmonary exercise profile in pulmonary 
hypertension 
PH impacts negatively on exercise capacity through its effects on oxygen 
transport and pulmonary gas exchange 95, which could be assessed by measuring 
specific variables at CPET (table 1.2).  
Oxygen transport (figure 1.6) 
In PH, oxygen delivery to peripheral muscles is reduced due to impaired SV 
augmentation on exercise. Muscle work is more dependent on anaerobic 
metabolism, giving rise to an early anaerobic threshold (AT) (reached at less 
than 50% of peak VO2) and reduced work efficiency measured by the gradient of 
VO2/work rate relationship (VO2/WR slope). Peak VO2 and peak VO2/HR, 
respective markers of maximal CO and SV, are reduced. There is a greater 
dependence on heart rate (HR) increase to augment CO during exercise, giving 
rise to an increased HR/VO2 slope. On the other hand, chronotropic response to 
exercise is impaired due to autonomic dysfunction 96 and peak HR is often not 
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reached. Oxygen transport is further compromised if profound hypoxaemia 
develops during exercise.  
 
 
Figure 1.6. Oxygen transport in pulmonary hypertension  
 
             
    
Hb: haemoglobin concentration; HR: heart rate; SaO2: arterial oxygen saturation; SvO2: 
mixed venous oxygen saturation; SV: stroke volume; VO2: oxygen uptake.  
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Pulmonary gas exchange (figure 1.7) 
The gas exchange abnormalities in PH are characterised by V/Q mismatch with 
increased perfusion to low V/Q units, increased dead space and a shift of the 
mean V/Q ratio to higher than normal (>1), leading to increased PA-aO2 (and 
consequently hypoxaemia) and ventilatory inefficiency 97. Hypoxaemia is 
compounded by a low SvO2 due to increased peripheral oxygen extraction caused 
by a low CO, which has the greatest effects in the presence of low V/Q units 
and shunts. Increase in dead space to tidal volume ratio (VD/VT) leads to wasted 
ventilation, thereby increasing the ventilatory requirement to eliminate a given 
amount of carbon dioxide produced from metabolism and hence reducing 
ventilatory efficiency. This is recognised by an increased minute ventilation to 
carbon dioxide output ratio (VE/VCO2) at AT (also known as the ventilatory 
equivalent for carbon dioxide), an increased gradient of the VE/VCO2 
relationship (VE/VCO2 slope) and reduced end-tidal carbon dioxide partial 
pressure (PETCO2) at AT.  
Patients with PH hyperventilate at rest and during exercise out of proportion to 
VCO2 resulting in hypocapnia which has been associated with a poor prognosis 
98. 
The disproportionate increase in ventilation is thought to be linked to 
sympathetic nervous system activation mediated by overactive ergoreflexes and 
chemoreflexes in exercising muscles, but the precise mechanisms remain 
incompletely understood 99. The relationship between VE, VCO2, PaCO2 and VD/VT 
is defined by the modified alveolar ventilation equation. 
     
During exercise, V/Q matching does not deteriorate significantly but ventilatory 
efficiency worsens with a further increase in the mean V/Q ratio. Hypoxaemia 
occurs primarily as a result of reduced SvO2 caused by a low CO. Ventilatory 
response is further heightened if peripheral chemoreceptors are stimulated by 
profound hypoxaemia resulting from right-to-left shunting through a patent 
foramen ovale (PFO). This can be recognised at CPET with an overall accuracy of 
863 
VE/VCO2 
PaCO2 x (1- VD/VT) 
 
VE/VCO2 
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90-96% by an abrupt and sustained decrease in PETCO2, a concurrent abrupt and 
sustained increase in end-tidal oxygen partial pressure (PETO2), an abrupt and 
sustained increase in respiratory exchange ratio (RER) and arterial oxygen 
desaturation 100.  
 
Figure 1.7. Pulmonary gas exchange in pulmonary hypertension 
 
PFO: patent foramen ovale; PaCO2: arterial carbon dioxide partial pressure; PETCO2: end-
tidal carbon dioxide partial pressure; SaO2: arterial oxygen saturation; SvO2: mixed venous 
oxygen saturation; V/Q: ventilation/perfusion; VD/VT: dead space to tidal volume ratio: 
VE/VCO2: ventilation equivalent for carbon dioxide. 
 
  
Reduced red cell  
transit time 
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Table 1.2. Cardiopulmonary exercise characteristics in pulmonary 
hypertension 
  Oxygen transport Reduced peak VO2 
 
Reduced VO2 at AT 
 
Reduced VO2/HR 
 
Increased HR/VO2 slope 
 
Reduced peak HR 
 
Reduced VO2/WR slope towards peak 
exercise 
   
Pulmonary gas exchange  Increased VE/VCO2 at AT 
 
Increased VE/VCO2 slope 
 
Reduced PETCO2 at AT 
 
Increased VD/VT 
 
Increased PA-aO2 gradient 
  
AT: anaerobic threshold; HR: heart rate; PETCO2: end-tidal carbon dioxide partial 
pressure; PA-aO2 gradient: alveolar-arterial oxygen partial pressure gradient; VE: minute 
ventilation; VCO2: carbon dioixde output; VO2: oxygen uptake; VO2/HR: oxygen pulse; 
VD/VT: dead space to tidal volume ratio; VE/VCO2: ventilatory equivalent for carbon 
dioxide output; WR: work rate. 
 
 
1.4.2 Clinical applications 
CPET is useful in providing an objective assessment of maximal exercise 
capacity and identifying patients who demonstrate a pulmonary vascular limit to 
exercise for further diagnostic evaluation. Once the diagnosis of PH is 
confirmed, the main applications of CPET lie in the areas of therapeutic and 
prognostic assessments. 
Therapeutic assessment 
Published data on the use of CPET variables to assess response from therapeutic 
interventions are primarily from studies on patients with COPD. Most of these 
studies looked at changes in peak VO2, VO2 at AT, peak HR and VE during 
incremental CPET. The results were equivocal with some studies showing 
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modest improvement in peak VO2 
101-103, while others failing to do so 104;105. 
Changes in peak HR and VE with therapy were not observed 
103;105;106. In recent 
years, the focus of exercise assessment has shifted from incremental symptom-
limited protocols to constant-load endurance protocols as a means to detect 
therapy-induced changes in exercise capacity. In constant-load endurance 
protocols, subjects perform cycle ergometry at a constant submaximal work rate 
until exhaustion. High-intensity (i.e. 75-80% of peak VO2) or moderate-intensity 
exercise (i.e. below AT) has been used. The measurements of interest are 
endurance time, defined as the time to symptom limitation, and metabolic 
variables (such as inspiratory capacity, VO2, VE, VE/VCO2, and HR) at a 
standardised time (for instance, after 5 min of exercise). This “isotime” analysis 
allows assessment of treatment-induced changes in metabolic variables at points 
of identical physiological stress, and identification of the physiological 
mechanisms responsible for improved exercise capacity. A positive effect of 
intervention is indicated by an increase in endurance time or improvements in 
isotime metabolic variables at identical submaximal work rates. High-intensity 
constant-load endurance protocols have been used to demonstrate the benefit 
of interventions such as bronchodilator therapy 107, oxygen 108 and heliox 
administration during exercise 109, bronchoscopic lung volume reduction surgery 
110 and pulmonary rehabilitation in COPD patients 111. Improvements in 
endurance time in these studies were accompanied by reductions in dynamic 
hyperinflation and dyspnoea at isotime. One study compared the effect of 
bronchodilator therapy on changes in exercise performance measured by three 
different modes of exercise (6MWT, incremental cycle ergometry and high-
intensity endurance cycle ergometry) and showed that there was no significant 
improvement in peak VO2, a small increase in 6MWD (1%), and a significant 
increase in endurance time (19%) 112. Metabolic measurement during endurance 
exercise is increasingly used for therapeutic assessments in COPD patients 113.  
Incremental CPET variables have been used to assess the effect of pulmonary 
vasodilatory therapy in PH in eight studies published between 1999 and 2007. A 
majority of these were uncontrolled single-centre studies including small 
numbers of patients (<30) except for two multicentre randomised controlled 
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trials which included >100 patients. In the small studies, intravenous 
prostacyclin 114, inhaled iloprost 115 and oral sildenafil 116 were shown to alter 
CPET response. The variables that improved significantly with therapy included 
peak VO2, PETCO2 at AT, VE/VCO2 at rest and at AT, and the VE/VCO2 slope. On 
the other hand, the larger scale randomised controlled trials on sitaxentan 117 
and beraprost 118 failed to demonstrate an improvement in CPET response 
despite a significant increase in 6MWD with therapy. On further data analyses, 
the authors concluded that a lack of standardisation of CPET procedures and 
variations in CPET experience among study centres may account for the negative 
results as data from centres with less CPET experience were found to be less 
reliable 119. Therefore, it is essential to ensure uniformity of exercise protocols 
and technical standards in future clinical trials intended to use CPET variables 
as primary end-points. Although the mechanisms of exercise limitation in 
patients with PH are distinctly different from those experienced by COPD 
patients (cardiac versus pulmonary), constant-load endurance exercise may have 
a role in therapeutic assessments in PH. However, there are so far little 
published data on the use of endurance time or isotime metabolic variables in 
detecting treatment response in PH. These measurements may be potentially 
more sensitive outcome measures than incremental CPET variables or 6MWD.  
Prognostic assessment 
Current European PH guidelines recommend that CPET be part of baseline 
evaluation and should be repeated during follow-up to reassess disease severity 
and prognosis 2. However, there have been relatively few studies evaluating the 
prognostic value of CPET variables in PH. Wensel et al first evaluated the ability 
of CPET responses to predict survival in a group of patients with primary 
pulmonary hypertension (now classified as idiopathic, heritable and anorexigen-
associated PAH) 94. Peak VO2 and peak systolic blood pressure (SBP) were shown 
to be independent mortality predictors at multivariate analysis. Patients with 
both risk factors (peak VO2 ≤10.4 ml/kg/min and peak SBP ≤120mmHg) had the 
worst survival (23% at 1 year). Those with one of these risk factors had 
intermediate survival (79% at 1 year) and those with no risk factors had the best 
survival (97% at 1 year). The prognostic significance of CPET responses was 
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confirmed in another cohort of PH patients with mixed aetiologies 120. A recent 
study by Deboeck et al was the first to address the questions if exercise capacity 
predicts TTCW and if CPET variables are equally predictive in patients with IPAH 
and those with associated PAH 121. It showed that in IPAH patients, 6MWD and 
VE/VCO2 at AT predicted survival, and peak VO2 predicted TTCW independently. 
The optimal cut-off values to predict survival at 4 years were 54 for VE/VCO2 at 
AT and 307 m for 6MWD, and that to predict TTCW was 11.6 ml/kg/min for peak 
VO2. On the other hand, none of the CPET variables or 6MWD predicted survival 
or TTCW in patients with associated PAH. This may be related to the 
heterogeneous nature of conditions in the associated PAH group including both 
patients with relatively good prognosis (CHD) and those with worse prognosis 
(systemic sclerosis, SSc). The findings in this study have raised uncertainty about 
the reliability of CPET to assess disease status in patients with co-existing 
medical conditions that are likely to compound exercise limitation.  
1.5 Non-invasive cardiac output measurement during 
exercise 
1.5.1 Importance of cardiac output measurement 
The progressive increase in VO2 during incremental exercise is brought about by 
a concomitant increase in CO (determined by cardiac function) and Ca-vO2 
(determined by the ability of exercising muscles to extract oxygen assuming that 
arterial oxygen content is normal). In healthy individuals, there is a predictable 
linear relationship between Ca-vO2 and relative exercise intensity expressed as % 
predicted peak VO2, described by the equation Ca-vO2 = 5.72+(0.1x % predicted 
peak VO2) 
122. Hence CO could be reliably estimated from VO2 by applying the 
direct Fick principle (CO = VO2/Ca-vO2). However, this relationship cannot be 
applied to patients with cardiopulmonary diseases, and thus CO needs to be 
measured directly. The value of CO measurement during exercise was first 
recognised in patients with chronic heart failure (CHF). Several studies showed 
that CO derived parameters at peak exercise were more closely related to 
prognosis than peak VO2 
123-126. They may also be more sensitive than peak VO2 in 
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assessing response from therapeutic interventions, although published data in 
this area are limited. Furthermore, direct CO measurement may allow clinicians 
to distinguish patients with poor exercise capacity due to pump failure from 
those with muscle de-conditioning, hence selecting those who would benefit 
most from cardiac transplantation.  
In PH, 6MWD has been established as an indirect marker of exercise CO due to 
its simplicity and reproducibility. However, several drawbacks exist that 
compromise its reliability as an outcome measure in PH, namely loose 
correlations with other markers of disease severity and loss of sensitivity in 
detecting clinical change in fitter patients (ceiling effect). Moreover changes in 
6MWD are not disease-specific and may not signify an improvement in pulmonary 
haemodynamics (discussed in Chapter 1.3.1). Therefore it would be of clinical 
value to measure exercise CO directly as a specific marker of right heart 
function. The “gold standard” of CO measurement is the direct Fick method 
whereby CO is calculated as a quotient of VO2 and Ca-vO2 
127. VO2 needs to be 
measured directly at bedside and determination of Ca-vO2 requires sampling of 
mixed venous blood from the pulmonary artery at RHC. This has been 
superseded by the more convenient thermodilution technique (TD) 128, but the 
invasive nature of RHC remains an obstacle to the use of repeated CO 
measurements for follow-up assessment in routine clinical practice. Several non-
invasive techniques have been developed to measure CO obviating the need for 
RHC. These include impedance cardiography 129 and pulse contour analysis 130, 
but they have not been proven useful during exercise in PH.  
1.5.2 Inert gas rebreathing method 
The IGR method measures PBF during rebreathing of an oxygen enriched mixture 
of blood-soluble and blood–insoluble gases 131. As inert gases are non-
physiological, their serum concentrations in systemic venous blood can be 
assumed to be zero. As the subject re-breathes through a respiratory apparatus 
from a bag prefilled with the gas mixture for about 30 s, the blood-soluble gas 
dissolves rapidly in the pulmonary capillary blood, and its rate of disappearance 
from the alveoli is proportion to the effective PBF. The blood-insoluble gas is 
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not taken up in the pulmonary capillary blood, and remains in the alveoli to 
correct for changes in total alveolar volume during the rebreathing manoeuvre. 
Cardiac output is equivalent to PBF in the absence of significant intrapulmonary 
or intracardiac shunts.  
Acetylene rebreathing method using a mass spectrometer has been shown to 
provide an accurate estimate of CO compared with TD and the Fick method in 
PH patients 132. Reliability and reproducibility of CO measured by a more 
recently developed metabolic system (Innocor, Innovision, Odense, Denmark) 
using rebreathing of nitrous oxide (N2O) and sulphur hexafluoride (SF6) has been 
demonstrated in PH patients and patients with interstitial lung disease 133;134. 
Compared with a mass spectrometer, this new system is more portable and 
easier to maintain. It also has the added advantage of providing simultaneous 
metabolic measurements at rest and during exercise. Its ease of use has been 
demonstrated in CHF patients 135;136, but this remains to be explored in PH 
patients.   
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1.6 Use of prognostic algorithms in pulmonary 
hypertension 
Accurate prognostic assessment is integral to optimal management in PH as it 
guides treatment decisions and patient counselling. Observational studies on the 
long-term outcome of patients treated with PAH-specific therapy 58-60;137;138 and 
registry studies from different treatment eras 1;71-73 have demonstrated the 
prognostic significance of a multitude of clinical, functional and laboratory 
variables. A recent systemic review found that most factors that prognosticate 
mortality in IPAH were assessed in very few studies, and there is discrepancy 
between studies on the prognostic value of many factors 139. Only 10 out of 107 
factors identified had a reproducible association with mortality demonstrated in 
more than three studies. These include WHO FC, HR, 6MWD, pericardial 
effusion, mPAP, RAP, cardiac index (CI), stroke volume index, PVR and SvO2. 
The current European PH guidelines laid out clear recommendations on the use 
of established prognostic parameters to assess disease severity and predict 
patient outcome 2. These parameters reflect the impact of disease on symptoms 
(clinical evidence of RV failure, syncope, WHO FC), exercise capacity (6MWD 
and CPET indices) and RV function (BNP/NT-proBNP, echocardiography and 
pulmonary haemodynamics), and can be used to stratify patients into good and 
poor prognostic groups (table 1.3). For patients with intermediate 
abnormalities, other factors such as age, PH aetiology and comorbidities should 
also be taken into consideration.  
  
 
 
51 
 
Table 1.3. Established prognostic parameters to assess disease severity 
and prognosis in pulmonary hypertension 2 
Determinants of prognosis Better prognosis Worse prognosis 
   
Presence of RV failure no yes 
Progression of symptoms slow rapid 
Syncope no yes 
WHO FC I, II IV 
6MWD >500 m* <300 m* 
CPET Peak VO2 >15 ml/min/kg Peak VO2 <12 ml/min/kg 
BNP/NT-proBNP normal or near-normal 
(BNP <100 pg/ml or NT-
proBNP <125pg/ml) 
 
very high and rising 
(BNP >180 pg/ml or NT-
proBNP >1400 pg/ml) 
Echocardiography no pericardial effusion  
TAPSE >2 cm 
pericardial effusion 
TAPSE <1.5 cm 
 
Pulmonary haemodynamics RAP <8 mmHg 
CI ≥ 2.5 l/min/m2 
RAP >15 mmHg 
CI ≤ 2.0 l/min/m2 
6MWD: six-minute walk distance; CI: cardiac index; CPET: cardiopulmonary exercise test: RAP: 
right atrial pressure; RV: right ventricular; VO2: oxygen uptake; WHO FC: World Health 
organisation functional class. *Depends on age, gender, height and weight.  
 
 
Given the importance of accurate prognostication, a number of equations have 
been developed to maximise the predictive power of existing prognostic 
variables. The first equation was derived from a prospective registry of primary 
pulmonary hypertension (now classified as idiopathic, familial and anorexigen-
associated PAH) initiated by the NIH in the United States before the advent of 
modern PAH-specific therapy in 1980s 1. This was the first systematic 
epidemiological study of PAH undertaken to characterise its natural history and 
identify prognostic determinants. Data were collected on 194 patients treated in 
32 centres across the United States between 1981 and 1985. The survival rates 
were poor with 68%, 48% and 34% at 1, 3 and 5 years respectively. Adverse 
prognostic factors included raised RAP, raised mPAP, reduced CI, WHO FC III and 
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IV, decreased carbon monoxide diffusing capacity (DLco) and Raynaud 
phenomenon. Haemodynamic variables at diagnosis were found to be most 
closely associated with mortality, and were used to derive an equation to 
estimate survival probabilities over time, P(t).   
 
 
NIH equation: 
P(t) = H(t)A(x,y,z) 
H(t) = 0.88 – 0.14t + 0.01t2 
A(x,y,z) = e(0.007325x + 0.0526y -0.3275z) 
where t: number of years from diagnosis ; x: mPAP; y: RAP; z: CI.  
 
Validation of the NIH equation was limited to one study conducted in 61 Mexican 
patients with primary pulmonary hypertension 43. Variables associated with poor 
prognosis were elevated RAP, decreased CI, decreased SvO2, reduced forced 
vital capacity (FVC) and absence of pulmonary vasodilatory treatment. The 
equation was found to have a high sensitivity but a relatively low specificity for 
predicting survival. The overall positive predictive values were 87%, 91% and 89% 
at 1, 2 and 3 years respectively. The NIH equation is now obsolete, but 
continues to provide a benchmark for patient outcome if untreated for 
comparative purposes in epidemiological studies. Recently, three new 
prognostic equations have been developed from contemporary cohorts taking 
into account the effect of modern drug therapy on survival 71;72;140.  
Pulmonary Hypertension Connection (PHC) Registry  
The PHC Registry was initiated in 2004 to collect data on patients treated in a 
single practice based in Chicago United States 72. A total of 576 incident cases of 
WHO group I PAH diagnosed between 1991 and 2007 were included with 247 
patients in the idiopathic, familial and anorexigen-associated PAH subgroup. The 
observed 1-, 3- and 5-year survival rates for the whole cohort were 86%, 69% and 
61% respectively. In the idiopathic, familial and anorexigen-associated PAH 
subgroup, the observed 1-, 3-, and 5-year survival rates were 92%, 75% and 66% 
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respectively, which are significantly better than those predicted using the NIH 
equation (65%, 43% and 32% respectively). Age, WHO FC, RAP and CI were 
independent predictors of survival. A new equation was developed using the 
same baseline haemodynamic variables and methodology as the NIH equation to 
predict survival in idiopathic, familial and anorexigen-associated PAH. 
PHC Registry equation:  
P(t) = e-A(x,y,z)t 
where t: number of years from diagnosis; A(x,y,z): e(-1.270-0.0148x+0.0402y-0.361z) in 
calcium channel blocker (CCB) non-responders or e(-3.012-0.0148x+0.0402y-0.361z) in CCB 
responders ; x: mPAP; y: RAP; z: CI. 
When the PHC Registry equation was applied to a prospective cohort of PAH 
patients followed up in four randomised controlled clinical trials and their 
extension studies, there was good agreement between predicted and observed 
survival 141.  
French Registry  
This is a prospective multicentre registry initiated by the French Network on 
Pulmonary Hypertension in 2002 to study the outcome of patients with WHO 
group I PAH during a three-year follow-up period 73. A total of 674 consecutive 
patients were enrolled between 2002 and 2003, and among those 354 patients 
had idiopathic, familial and anorexigen-associated PAH. Survival analysis was 
performed in a combined analysis population including prevalent patients 
diagnosed within three years of enrolment and incident patients with idiopathic, 
familial and anorexigen-associated PAH. The 1-, 2- and 3-year survival rates for 
the whole PAH cohort were 87%, 76% and 67% respectively. In the combined 
analysis population, 1-, 2- and 3-year survival rates were 83%, 67% and 58% 
respectively. Female gender, 6MWD and CO were found to predict survival 
independently. A risk equation based on these variables was developed to 
estimate survival probabilities over time up to three years post-diagnosis 140. 
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French Registry equation: 
P(t) = H(t)A(x,y,z) 
H(t) = e(-0.02-0.28t) 
A(x,y,z) = e[-(0.004x + 0.98y + 0.28z)] 
where t: number of years from diagnosis; x: 6MWD at diagnosis minus 280 m; y: 
female=1, y: male=0; z: CO at diagnosis minus 4.0 l/min  
When the French Registry equation was applied to a prospective cohort of PAH 
patients followed up in four randomised controlled clinical trials and their 
extension studies, there was good agreement between predicted and observed 
survival 141. 
Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension 
Disease Management (REVEAL)  
REVEAL was initiated in the United States in 2006 to study the clinical course 
and disease management of WHO group I PAH patients 71 and is the largest 
prospective multicentre PAH registry to date. Data from 2716 PAH patients 
treated in 54 centres were analysed to identify predictors of 1-year survival 
which were then used to derive a prognostic equation. One-year survival of the 
whole cohort from the date of enrolment was 91%. Eleven variables were found 
to be independently associated with mortality: aetiology, men >60 years of age, 
renal insufficiency, WHO FC, SBP, HR, 6MWD, BNP or NT-proBNP, pericardial 
effusion, % predicted DLco, RAP and PVR.  
REVEAL equation:  
Predicted 1-year survival: S0(1)exp(Z’βγ) 
    S0(1) = 0.9698 (baseline survival function) 
    Z’β = linear component from the Cox model 
    γ = 0.939 (shrinkage factor) 
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The linear component is calculated by summing up coefficients for each variable 
or subgroup of variables (β). The starting value is 0. It increases if β is positive 
(associated with increased mortality) and decreases if negative (associated with 
decreased mortality) (table 1.4). Missing data are permitted in the model 
provided that they are randomly distributed. The REVEAL equation and its 
simplified 22-point risk score were found to have good discriminatory power in a 
prospective cohort of newly diagnosed WHO group I PAH patients 142.  
Preliminary validation data show that all three equations are potentially useful 
prognostic tools, but their applicability in other clinical settings may be limited 
due to differences in study populations used for model development, 
recruitment periods and methodological approaches. The French Registry and 
PHC equations were designed to be used for patients with idiopathic, familial 
and anorexigen-associated PAH only whereas the REVEAL equation is applicable 
across all subgroups of WHO group I PAH. The PHC cohort consisted of patients 
recruited over a period of 16 years during which treatment strategies changed 
considerably with the expansion PAH-specific therapy, and this may have 
affected the results of survival analyses. In comparison, patient cohorts in the 
French and REVEAL equations were enrolled over a shorter period of time in the 
modern treatment era. The French Registry and PHC equations were developed 
to predict survival over time after diagnosis, whilst the REVEAL equation was 
designed to predict survival at one year after diagnosis. It is unclear if they 
would perform equally well in UK PH populations given the variations in patient 
demographics and healthcare systems across countries, and prognostic 
algorithms based on UK data are currently lacking.  
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Table 1.4. Variable coefficients for the linear component of the Cox model in 
the REVEAL equation 71 
        
    
WHO group I subgroup FPAH, +0.7737 
APAH-PoPH, 
+1.2801 
APAH-CTD, 
+0.4624 
Demographics and  
comorbidities 
Male >60 years of 
age, +0.7779  
Renal insufficiency, 
+0.6422  
WHO FC FC I, -0.8740 FC III, +0.3454 FC IV, +1.1402 
Vital signs 
SBP <110 mmHg, 
+0.5128 
Heart rate >92 bpm, 
+0.3322  
6MWD 
6MWD ≥ 440 m,     
-0.5455 
6MWD <165 m, 
+0.5210  
BNP or NT-proBNP 
BNP <50 pg/ml or 
NT-proBNP <300 
pg/ml, -0.6922 
BNP >180 pg/ml or 
NT-proBNP >1500 
pg/ml, +0.6791 
 
Echocardiogram 
Any pericardial 
effusion, +0.3014   
Pulmonary function test 
% predicted DLco 
≥ 80%, -0.5317 
% predicted DLco  
≤ 32%, +0.3756  
Right heart 
catheterisation 
Mean RAP >20 
mmHg within 1 
year, +0.5816 
PVR >32 Wood 
units, +1.4062  
        
6MWD: six-minute walk distance; APAH: associated pulmonary hypertension; BNP: brain 
natriuretic peptide; CTD: connective tissue disease; DLco: carbon monoxide diffusing capacity; 
FPAH: familial pulmonary arterial hypertension; RAP: right atrial pressure; NT-proBNP: N-terminal 
pro-brain natriuretic peptide; PoPH: portopulmonary hypertension; PVR: pulmonary vascular 
resistance; SBP: systolic blood pressure; WHO FC: World Health Organisation functional class. 
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1.7 Hypotheses and aims 
The aims of this thesis are to explore the use of novel non-invasive exercise 
variables and prognostic algorithms as alternative outcome measures to 6MWD in 
PH. The following hypotheses are examined in four clinical studies: 
1. Non-invasive exercise variables could be used to detect treatment response in 
PH. These comprise: 
 IGR haemodynamic measurements and isotime metabolic variables during 
submaximal constant-load exercise  
 PETCO2 during the 6MWT 
2. Prognostication in PH could be improved by the use of % predicted 6MWD and 
a composite risk score combining key prognostic factors.  
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2 METHODS 
2.1 The Scottish national pulmonary hypertension 
service  
The Scottish Pulmonary Vascular Unit (SPVU) provides a tertiary PH service for 
the whole population in Scotland of around five millions. An epidemiology study 
performed in 2007 estimated the incidence of PAH in Scotland to be 7.6 cases 
per million per annum and the prevalence 26 cases per million 143. A recent 
national audit of PH services in the UK conducted between April 2010 and March 
2011 estimated the prevalence of PAH in Scotland to be 42.9 per million 144. 
Patients are referred onwards to the national Pulmonary 
Thromboendarterectomy Service based at Papworth Hospital, Cambridge and 
the Cardiopulmonary Transplant Service based at Freeman Hospital, Newcastle.  
Newly referred treatment-naive patients undergo a comprehensive diagnostic 
evaluation consisting of cardiac MRI, computed tomography, radioisotope 
ventilation-perfusion scan, echocardiography, lung function testing, CPET and 
6MWT prior to RHC. The diagnosis of PH is based on RHC in accordance with 
contemporary guidelines. Prior to the publication of new consensus guidelines in 
August 2009, PH was defined as mPAP >25 mmHg at rest or >30 mmHg on 
exercise, with PCWP ≤15 mmHg and PVR >3 Wood units 145. For patients 
diagnosed after August 2009, PH was defined as mPAP ≥25 mmHg at rest and 
was further divided into precapillary PH (PCWP ≤15 mmHg, normal or reduced 
CO) and postcapillary PH (PCWP >15 mmHg, normal or reduced CO) 2). 
Precapillary PH consists of WHO group I PAH, WHO group III PH due to lung 
disease and/or hypoxia, WHO group IV CTEPH and Group V PH due to 
multifactorial mechanisms. Postcapillary PH consists of WHO group II PH due to 
heart disease. The term “PAH” is used specifically for WHO group I disease 
whereas “PH” is used as a general term to describe any group. Positive acute 
vasodilator response is defined as a drop in mPAP to <40mmHg and by >10mmHg 
with maintained or increased CO.   
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All patients diagnosed with PH receive conventional therapy including long-term 
warfarin, diuretics and/or supplemental oxygen. Patients with WHO group I PAH 
are treated with PAH-specific monotherapy (prostacyclin analogues: iloprost, 
treprostinil or epoprostenol; phosphodiesterase-5 inhibitors: sildenafil, tadalafil 
or sitaxentan [withdrawn from marketing in 2010]; endothelin receptor 
antagonists: bosentan or ambrisentan) and sequential combination therapy as 
clinically indicated. Patients with CTEPH are referred to Papworth Hospital for 
consideration of pulmonary thromboendarterectomy. A trial of PAH-specific 
therapy is offered to symptomatic CTEPH patients with inoperable distal 
disease, as a bridge to surgery or those with persistent PH following surgery, and 
selected patients with PH disproportionate to underlying heart or lung diseases 
or PH due to multifactorial mechanisms. Patients are followed up in the 
outpatient clinic every three to six months. Follow-up assessment consists of 
clinical evaluation, WHO FC, 6MWT, NT-proBNP and CAMPHOR score. Right heart 
catheterisation is not routinely repeated after initial diagnosis for monitoring 
purposes. Repeat CPET and cardiac MRI are carried out in selected patients as 
clinically indicated.  
Right heart catheterisation is carried out by SPVU physicians using standard 
techniques. Patients breathe room air or oxygen to maintain arterial oxygen 
saturation (SaO2) above 90% in a supine position. Central venous access is 
obtained by inserting an 8 Fr introducer sheath in the internal jugular or femoral 
vein. A balloon-tipped 7 Fr Swan-Ganz catheter is passed to the RV to measure 
RAP, right ventricular end-diastolic pressure, mPAP and PCWP. Cardiac output is 
measured by TD. The final result is calculated by averaging three measurements 
with ≤10% variation.  
PVR is calculated according to the equation: 
                   
Mixed venous blood is sampled from the main pulmonary artery to measure SvO2. 
Acute vasodilator study is carried out using inhaled nitric oxide (40 parts per 
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million) for 5 min to identify CCB responders. Pulmonary haemodynamics on 
exercise are measured using straight leg raising or supine ergometry in selected 
patients. Pulmonary angiogram is performed in patients with clinical evidence of 
CTEPH. 
2.2 World Health Organisation functional class 
Functional classification in PH was based on modified New York Heart 
Association functional classification for CHF patients 2 (Appendix 1). 
 
2.3 N-terminal pro-brain natriuretic peptide 
Venous blood samples were drawn into blood tubes containing ethylenediamine 
tetraacetic acid. No rest period or specific posture for venepuncture was 
required. Serum samples were frozen within 4 hours on the day of acquisition 
and stored at -80°C. Immunoassays for NT-proBNP (Roche) were subsequently 
performed in batches. 
2.4 CAMPHOR score 
CAMPHOR questionnaire was used to assess health-related patient self-reported 
outcome (Appendix 2) 85. Patients were asked to answer questions in relation to 
their symptoms (25 items), activities (15 items) and QOL (25 items). The 
maximum score is 80, with higher scores indicating worse health status.  
2.5 Six-minute walk test 
2.5.1 Test protocol 
Six-minute walk test was performed by a respiratory physiologist on a 20-metre 
hospital corridor according to American Thoracic  Society guidelines 49.  
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2.5.2 Telemetric metabolic measurements  
Ventilatory and gas exchange variables during the 6MWT were measured using a 
portable metabolic device (Cortex Metamax 3B, Cranlea, Birmingham, UK) 
(figure 2.1). Subjects breathed through a tightly fitted face mask and carried 
the device (around 1 kg in weight) in a shoulder harness which allowed them to 
walk freely. They had previously performed a conventional 6MWT to familiarise 
with the test. Breath-by-breath VO2, VCO2, VE, VE/VO2, VE/VCO2, VO2/HR, PETO2, 
PETCO2, and RER were measured continuously. These data were transmitted to a 
laptop by telemetry and were analysed as moving averages of 8 consecutive 
breaths. Heart rate was recorded by a sensor strip placed around the anterior 
chest (Polar™) and SaO2 by pulse oximetry. End-6MWT values were defined as the 
moving average at the end of 6 min. VE/VCO2 slope was determined by 
regression analysis of VE as a function of VCO2.
 
 
Figure 2.1. Six-minute walk test performed using a telemetric metabolic 
device 
 
The subject breathed through a tightly fitted face mask and carried the device (Cortex 
Metamax 3B) in a shoulder harness. The 6MWT was otherwise performed according to a 
standardised protocol  
 
 
62 
 
2.6 Incremental cardiopulmonary exercise testing 
Cardiopulmonary exercise testing was performed on an electromagnetically 
braked cycle ergometer (Ergoline Select 200, Ergoline) under medical 
supervision (Dr W.T.N. Lee). Absolute contraindications included exercise-
induced syncope and arrhythmias. The incremental exercise protocol consisted 
of rest for 2 min, followed by unloaded cycling for 3 min and then cycling at a 
ramp rate of 5 to 20 Watts/min to achieve peak work rate in 8 to 12 min (Bitz, 
Germany; Ergocard, Medisoft, Dinant, Belgium). Patients were asked to maintain 
a cadence rate of around 60 revolutions/min. SaO2 and HR were monitored 
continuously using pulse oximetry and 12-lead electrocardiography (ECG). Non-
invasive blood pressure was measured at rest and at peak exercise. Breath-by-
breath VO2, VCO2, VE, ventilatory equivalent for oxygen (VE/VO2), VE/VCO2, 
VO2/HR, PETO2, PETCO2 and RER were measured via a tightly fitted face mask and 
averaged over 20 s. Peak VO2 was defined as the highest averaged value within 
30 s of peak exercise. Anaerobic threshold was determined by the V-slope 
method. Standardised reference equations were used to calculate predicted 
values 41. The development of right-to-left shunt through a PFO during exercise 
was assessed using a set of published pulmonary gas exchange criteria 100. 
2.7 Inert gas rebreathing haemodynamic measurement  
2.7.1 Principles and operational detail 
Pulmonary blood flow was measured at rest and during exercise non-invasively 
using the IGR method (Innocor, Innovision, Odense, Denmark) 135;146;147. Exercise 
was performed on a cycle ergometer (Ergoline Select 200, Ergoline, Bitz, 
Germany). Breath-by-breath respired gases were continuously sampled as 
patients breathed into a respiratory valve via a mouthpiece with the nose 
clipped. Gas concentrations were analysed using infrared photoacoustic gas 
analysers. 
Prior to each IGR measurement, a 3 l Douglas bag was pre-filled with an oxygen 
enriched mixture containing two inert gases, N2O and SF6 
148. This was obtained 
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by mixing a bolus from a gas bottle containing 94% oxygen, 5% N2O and 1% SF6 
with ambient air. Under normal resting conditions, a bolus fraction of 10% and 
air fraction of 90% would be used to give a gas mixture of 28.3% oxygen, 0.5% 
N2O and 0.1% SF6. The volume in the rebreathing bag was adjusted continuously 
to accommodate for the increasing tidal volume and oxygen demand during 
exercise. The target volume was the highest of the following volumes: 44% of 
predicted vital capacity, averaged tidal volume during the preceding five 
breaths and the volume required to meet the maximum carbon dioxide (default 
6%) and minimum oxygen limits (default 13%) in the rebreathing bag. At higher 
work rates, the increased oxygen demand was met by either increasing the bolus 
fraction or rebreathing bag volume. 
IGR measurements were initiated by the operator (Dr W.T.N. Lee) at the end of 
expiration. At this point, the respiratory value was activated so that the patient 
rebreathed into the rebreathing bag in a closed circuit. The patient was 
instructed to empty the bag during each inspiration and breathe at a rate of at 
least 20 breaths/min. N2O, being highly blood-soluble and diffusion-
independent, disappeared from the alveoli into the pulmonary capillary blood at 
a rate proportional to PBF. SF6, being insoluble in blood, remained in the alveoli 
and served to determine the final lung volume from which N2O was removed.  
The total lung volume was calculated using the following formula: 
 
   
[   ] 
[   ]
  
     
 
where 
VL   =  total systemic volume (STDP) 
VRB  =  rebreathing bag volume 
[SF6]0   =  initial SF6 concentration in the rebreathing bag 
[SF6]eq  =  SF6 concentration after good mixing (back extrapolated to  
         time zero)  
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After a few breaths, SF6 was mixed in the lungs and its concentration stabilised. 
The difference between maximum and minimum SF6 concentrations within a 
breath was continuously analysed. Calculation of PBF would start when this 
difference fell below a predefined level indicating good gas mixing (set at 15% 
of the average of maximum and minimum SF6 concentrations) (figure 2.2). It 
would usually be achieved after three breaths and calculation of PBF would take 
place over the subsequent three breaths. The rebreathing time should not 
exceed 30 seconds as re-circulation of N2O may occur. At rest, successive 
measurements at rest should be performed at least 5 min apart to ensure 
complete washout of inert gases from the alveoli. The wash-out interval would 
be shorter during exercise. 
 
Figure 2.2. SF6 concentration during rebreathing 
 
 
 
  
Good gas mixing achieved and PBF calculation starts. 
3 breaths are included in the calculation indicated by 
the blue bars. 
[SF6]eq 
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During the rebreathing period, the lung volume varied slightly due to changes in 
the rate of carbon dioxide output relative to oxygen uptake. At the start, due to 
slight hyperventilation, more carbon dioxide entered the alveoli whereas oxygen 
uptake remained constant. The lung volume increased. As the alveolar carbon 
dioxide concentration increased, the diffusion gradient decreased. The rate of 
carbon dioxide output slowed and the lung volume shrunk. Alveolar N2O 
concentration was normalised for changes in lung volume using SF6 
concentration before the start of each PBF calculation. As the rate of N2O 
concentration decrease was proportional to PBF and N2O concentration itself, 
N2O concentration was a mono-exponentially decreasing function of time giving 
rise to a linear semi-logarithmic plot of normalised N2O against time (figure 
2.3).  
Figure 2.3. A semi-logarithmic plot of normalised N2O concentration against 
time 
 
 
 
  
Regression line through the end-expiratory points of 3 breaths 
after good gas mixing. The slope of the line (β) is calculated 
directly from the plot. 
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PBF was calculated using the following formula: 
 
        
        
  
  
 
where 
β =  slope of regression line  
VL  =  total systemic volume (STDP) 
C1 =  760 mmHg/(ambient pressure in mmHg – 47 mmHg) 
C2  =  constant to account for absorption of N2O into lung tissue 
=  Bunsen solubility coefficient of N2O in tissue (0.407 STPD) x       
lung tissue volume (default 0.6 L) 
αb  =  Bunsen solubility coefficient of N2O in blood (0.412 STPD) 
 
PBF is equivalent to CO in the absence of significant intracardiac or 
intrapulmonary shunt. SV was derived from PBF and HR.  
 
   
   
  
 
 
2.7.2 Shunt correction 
The Innocor device has a built-in algorithm to correct for intrapulmonary or 
intracardiac shunt flow. In the algorithm, CO is derived from PBF, oxygen 
content in arterial blood (CaO2), oxygen content in pulmonary end-capillary 
blood (CcO2) and VO2 according to the formula: 
CO = 1/(1/PBF+(CaO2-CcO2)/VO2) 
where 
CaO2 = 0.000139 x haemoglobin concentration (in g/dL) x SaO2  
CcO2 = 0.000139 x haemoglobin concentration (in g/dL) x ScO2  
SaO2 = arterial oxygen saturation measured by pulse oximetry  
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ScO2 = pulmonary end-capillary oxygen saturation assumed to be 98% 
Haemoglobin concentration is assumed or measured by operator separately  
 
However, the assumption that ScO2 reaches 98% may not apply to PH patients 
due to V/Q mismatch with an increase in low V/Q units combined with a low 
SvO2 as previously discussed (Chapter 1.4.1). Applying this shunt correction 
algorithm would overestimate the shunt flow and hence CO, especially for 
exercise measurements. Therefore, PBF was used instead of derived CO in the 
clinical studies conducted in this thesis.  
2.7.3 Stepwise constant-load exercise protocol 
This protocol consisted of unloaded cycling for 3 min and then cycling for 3 min 
successively at 20%, 40%, 60% and 80% of maximal work rate (WRmax) 
predetermined in an incremental CPET (figure 2.4). Pulmonary blood flow was 
measured after 10 min of rest on the cycle ergometer. Following that, PBF was 
measured on completion of each stage of the exercise protocol whilst cycling 
continued. Stroke volume was derived from PBF and HR (SV = PBF/HR). Each 
subject was coached on how to perform the rebreathing manoeuvre and had 2-3 
practices prior to testing. Breath-by-breath metabolic data were recorded 
continuously during exercise except during IGR measurements each lasting for 
25-30 s. 
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Figure 2.4. Stepwise constant-load exercise protocol 
 
Inert gas rebreathing measurements were carried out after 10 min of rest, 3 min of 
unloaded cycling and 3 min of cycling successively at 20%, 40%, 60% and 80% of 
maximal work rate (indicated by bold arrows). 
 
  
10 min 
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2.7.4 Submaximal constant-load exercise protocol 
This protocol consisted of cycling for 3 min at 40% WRmax pre-determined in an 
incremental CPET (figure 2.5). First, successive duplicate PBF measurements 
were performed after 10 min of rest in the supine position, and then after 10 
min of rest in the erect position on the cycle ergometer. A 5-minute interval 
was lapsed between duplicate measurements to allow complete washout of 
inert gases from the lungs. Following resting measurements, PBF was measured 
on completion of the exercise protocol whilst cycling continued. This was 
repeated after 15-20 min of rest. Stroke volume was derived from PBF and HR 
(SV=PBF/HR). Duplicate measurements at each stage were averaged to give the 
final results. Each subject was coached on how to perform the rebreathing 
manoeuvre and had 2-3 practices prior to testing. Breath-by-breath metabolic 
data were recorded continuously during exercise except during IGR 
measurements each lasting for 25-30 s. 
Figure 2.5. Submaximal constant-load exercise protocol 
 
Inert gas rebreathing measurements were carried out after 3 min of cycling at 40% 
maximal work rate (indicated by the bold arrow). 
  
10 min 
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2.8 Survival analysis 
2.8.1 Cox proportional hazards analysis 
Cox proportional hazards model with right censoring was used to identify 
predictors of all-cause mortality. Survival time was calculated from the date of 
diagnostic RHC to censor date or date of death. Patients were censored at the 
time of data cut-off, lung transplantation or last clinical contact if lost to 
follow-up. Univariate analysis was first performed to identify predictors of 
mortality from candidate variables. These variables were tested for collinearity 
using Pearson or Spearman correlation coefficients depending on data 
distribution. Variables with p value less than a predefined level in the univariate 
analysis or those considered clinically relevant based on previous studies were 
analysed in a multivariate Cox proportional model using a backward selection 
procedure. Highly correlated variables (r or ρ >0.7) were not included. To avoid 
over-fitting, one covariate was included in the final model for every ten deaths. 
A p value <0.05 by likelihood ratio test was defined as statistically significant.  
2.8.2 Kaplan Meier analysis 
Kaplan Meier analysis was used to estimate survival rates using all-cause 
mortality as the end-point. Log-rank test/log-rank test for trends were used for 
group comparison. Survival time was calculated from the date of diagnostic RHC 
to censor date or date of death. Patients were censored at the time of data cut-
off, lung transplantation or last clinical contact if lost to follow-up. Results were 
presented as Kaplan Meier survival curves and the number of subjects at risk at 
regular time intervals. A p value <0.05 was defined as statistically significant. 
2.8.3 Receiver operating characteristics analysis 
Receiver-operating characteristics (ROC) analysis was used to determine the 
discriminatory power and optimal threshold of a continuous variable in 
predicting all-cause mortality at a defined time point 149. A ROC curve was 
constructed by plotting sensitivity (y axis) against 1-specificity (x axis). The 
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optimal threshold was identified from the curve by locating the point closest to 
the coordinate y=1 (100% sensitivity), x=0 (100% specificity). The discriminatory 
power of a predictor variable was determined by calculating the area under the 
ROC curve (AUC). An AUC of 0.5 indicated that the variable had no 
discriminatory power whereas an AUC of 1 indicated that the variable had 
perfect discriminatory power. A paired or unpaired z test was used to compare 
the AUC of different predictor variables 150.  
2.8.4 Brier score 
The Brier score (BS) was used to assess the accuracy of a prognostic algorithm to 
predict survival. It measures the mean squared deviation of predicted 
probability from the actual outcome 151-153. A BS of 0 indicates perfect 
prediction. A BS of 0.25 indicates that the prediction is equivalent to the 
outcome occurring by chance alone. A BS of 1 indicates that prediction is 
invariably wrong. Hence a lower BS indicates higher prediction accuracy. The 
performance of different prognostic algorithms was compared by determining a 
point estimate of the difference in BS between them and its 95% confidence 
interval from 200,000 bootstrap re-samples. A difference in BS of >0.02 was 
considered clinically relevant. A p value<0.05 was defined as statistically 
significant. 
2.9 Patient recruitment 
For the clinical studies, subjects with a diagnosis of precapillary PH confirmed 
at RHC were recruited at the time of diagnosis or at follow-up visits in the 
outpatient clinic between July 2008 and June 2010. The exclusion criteria were 
significant left heart dysfunction on echocardiography or lung disease (defined 
as forced vital capacity in one second (FEV1) <60% predicted or FVC <60% 
predicted or total lung capacity (TLC) <60% predicted based on European Steel 
and Coal Community reference values 154), or inability to perform exercise tests 
either due to absolute contraindications or disabling symptoms. All subjects 
received written information prior to consent. 
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2.10 Ethical approval 
All clinical studies conducted in this thesis were reviewed and approved by the 
West Glasgow Research Ethics Committee. For the epidemiological studies 
involving retrospective collection and analysis of survival data, formal ethical 
review was deemed not necessary by the West Glasgow Research Ethics 
Committee and Papworth Hospital Research Ethics Committee. 
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3 INERT GAS REBREATHING HAEMODYNAMIC 
MEASUREMENTS IN PULMONARY 
HYPERTENSION 
This chapter describes four studies conducted to evaluate the utility of non-
invasive PBF and SV measurements by the IGR method as outcome measures in 
precapillary PH.  
Chapter 3.1 - The relationship between work rate and IGR haemodynamic  
   measurements during incremental exercise in precapillary PH 
Chapter 3.2 - Reproducibility of IGR haemodynamic measurements in   
   precapillary PH 
Chapter 3.3 – Clinical correlates of IGR haemodynamic measurements in   
   precapillary PH 
Chapter 3.4 – Use of IGR haemodynamic measurements to detect treatment  
   response in precapillary PH 
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3.1 The relationship between work rate and inert gas 
rebreathing haemodynamic measurements during 
incremental exercise in precapillary pulmonary 
hypertension 
3.1.1 Summary 
Rationale: Haemodynamic measurements are directly linked to the mechanisms 
of disease and influence prognosis in PH. The IGR method allows non-invasive 
measurement of PBF, which is equivalent to CO in the absence of significant 
intrapulmonary or intracardiac shunt.  
Aims: The aims of the study were to evaluate the use of the IGR method to 
measure PBF and SV during incremental exercise, and to study their pattern of 
response to increasing work rate in patients with precapillary PH.  
Methods: Ten healthy subjects and 10 PH patients performed stepwise constant-
load exercise where they cycled for 3 min unloaded and 3 min successively at 
20%, 40%, 60% and 80% of WRmax pre-determined in a symptom-limited 
incremental CPET. Pulmonary blood flow during cycling was determined using 
the IGR method. Stroke volume was derived from PBF and HR. Metabolic 
variables were simultaneously measured throughout exercise. 
Results: IGR measurements at rest and during exercise were performed with 
ease in all subjects. Stroke volume started to plateau after unloaded cycling 
with maximal SV achieved at 40% WRmax (PH patients:68±18 ml versus healthy 
subjects:106±22 ml, p<0.01), whereas PBF rose continuously with increasing 
work rate in both groups. In PH patients, exercise SV tended to fall at higher 
work rates. 
Conclusions: PBF and SV during exercise could be measured readily using the 
IGR method in patients with precapillary PH. Maximal SV is reached at 
submaximal exercise which may be used to monitor right heart function in these 
patients.   
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3.1.2 Introduction 
Patients with PH have reduced SV response to exercise due to increased right 
ventricular afterload 155-158. As a result, CO augmentation during exercise is 
blunted and is more dependent on HR rise. In healthy subjects, SV has been 
shown to rise with early exercise and plateau around 40%-50% of peak VO2 
whereas CO rises linearly towards peak exercise 159. In comparison, less is known 
about the haemodynamic response to exercise in patients with PH. This is of 
clinical interest as it would provide further insights into disease severity. 
Previous studies using cardiac MRI 160 and electron beam computed tomography 
161 showed that patients with IPAH were unable to augment SV during exercise. 
In these studies, exercise was performed in a supine position outside the 
scanner and measurements were made after exercise had ceased, therefore the 
true SV response to exercise may be underestimated. 
Cardiac output and SV, markers of right heart function, are directly linked to 
the mechanisms of disease and have prognostic significance in PH. Serial 
measurements would be useful for monitoring  disease progression and 
treatment response, but as they are measured invasively at RHC, repeated 
measurements cannot be made readily for follow-up assessment in routine 
clinical practice. In comparison, the IGR method allows PBF and SV to be 
measured non-invasively at rest and during exercise. Respired gas analysis can 
also be performed simultaneously to provide metabolic data on exercise 
response. The IGR method has been shown to be useful in the assessment of 
patients with CHF. The aims of this study were to explore the use of the IGR 
method in measuring the haemodynamic response during incremental exercise 
and its relationship with work rate in patients with precapillary PH. 
3.1.3 Methods 
Study subjects 
Ten healthy subjects and 10 patients with precapillary PH participated in the 
study. The healthy subjects were recruited from staff members of the SPVU. 
They had no cardiopulmonary disease by history, physical examination, 12-lead 
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ECG or incremental CPET. Patients who were unable to perform CPET, receiving 
beta-blockers, had significant left heart dysfunction or lung disease were 
excluded.  
Study design 
The subjects first underwent an incremental CPET to determine their peak VO2 
and WRmax (described in Chapter 2.6). They then underwent stepwise constant-
load exercise with IGR measurements within 2 weeks (described in Chapter 
2.7.3). 
Statistical analysis 
Statistical analysis was performed using Graphpad Prism version 5.00 (Graphpad 
Software, La Jolla, CA, USA). Data are presented as mean ± standard deviation 
(SD). Unpaired Student’s t test was used to compare variables between healthy 
subjects and PH patients. Paired Student’s test was used to compare variables 
within each group. A p value<0.05 was defined as statistically significant. 
3.1.4 Results 
Subject characteristics 
The healthy subjects had a range of physical activity (sedentary: n=2; regular 
physical activity 1-3 hours per week: n=5; endurance trained: n=3). The PH 
group was characterised by WHO FC I (n=1), II (n=7) and III (n=2). The underlying 
aetiologies of PH included IPAH (n=5), CTDPAH (n=1), portopulmonary 
hypertension (PoPH) (n=1) and distal CTEPH (n=3). Eight patients were on stable 
PAH-specific therapy and two were due to start therapy. All subjects underwent 
incremental CPET to symptom limitation without adverse events. The PH 
patients had reduced WRmax, peak VO2, peak VO2/kg, peak VO2/HR and VO2 at 
AT, elevated VE/VO2 and VE/VCO2 at AT. These CPET abnormalities were 
characteristic of pulmonary vascular disease (table 3.1.1) 162. 
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Practicality of the inert gas rebreathing method 
All healthy subjects and PH patients were able to perform the rebreathing 
manoeuvres effectively after a maximum of three practices. IGR PBF 
measurements were successful in all healthy subjects and 90% of occasions in PH 
patients. The reasons for incomplete data in the PH group were due to mask-
subject interface leakage, incomplete bag emptying during the rebreathing 
manoeuvre and software problems leading to interruption of the exercise 
protocol. Overall, IGR measurements were easy to perform. The work rates at 
which IGR measurements were successful ranged from 28 to 260 Watts in 
healthy subjects and from 8 to 128 Watts in PH patients.   
Table 3.1.1. Cardiopulmonary exercise characteristics 
  
Healthy subjects  PH patients  
   
Subject, n 10 10 
Age, years 34±6 49±11 
Male/female, n 7/3 5/5 
Peak VO2 , l/min 2.61±0.6 1.13±0.4 
Peak VO2 , % predicted 94±14 62±30 
Peak VO2/kg, ml/min/kg 35.9±7.0 14.0±5.9 
Peak WR, Watts 250±67 92±43 
Peak WR, % predicted 121±24 68±39 
Peak VO2/HR, ml 14.9±3.4 8.6±2.4 
Peak VO2/HR, % predicted 100±15 78±28 
VO2 at AT, l/min 1.51±0.50 0.79±0.29 
VO2 at AT/predicted peak VO2, % 55±15 43±20 
VE/VO2 at AT 23±2 36±10 
VE/VCO2 at AT 
 
26±3 
 
43±13 
 
AT: anaerobic threshold; PH: pulmonary hypertension; VO2: oxygen uptake; VO2/HR: oxygen 
pulse; VE/VCO2: ventilatory equivalent for carbon dioxide; VE/VO2: ventilatory equivalent for 
oxygen ; WR: work rate. 
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Haemodynamic response to incremental exercise  
The relationship between HR, PBF, SV and VO2 and increasing work rate during 
stepwise constant-load cycle exercise in a representative healthy subject and an 
age- and sex-matched IPAH patient is outlined in figure 3.1.1. The IPAH patient 
had a higher resting HR with a smaller chronotropic response and a smaller rise 
in PBF and SV on exercise. These patterns were also observed when group values 
were compared (table 3.1.2). Pulmonary blood flow and SV were lower in PH 
patients than healthy subjects, at rest and at each exercise level (p<0.01). In 
both groups, SV rose on exercise with the largest increase achieved between 
rest and unloaded cycling. Thereafter, SV started to plateau and peaked at 40% 
WRmax whereas PBF increased continuously towards peak exercise. The mean 
maximal % SV rise from rest on exercise was smaller in PH patients (29±28%) 
compared with healthy subjects (44±30%). Stroke volume was maintained in 
healthy subjects at work rates higher than 40% WRmax. In PH patients, SV tended 
to fall at higher work rates, but remained above resting values (SV at 40% 
WRmax: 68±18 ml versus SV at 80% WRmax: 60±17 ml, p=0.20) (figure 3.1.2).  
 
 
 
 
 
Figure 3.1.1. The haemodynamic response to incremental exercise in A) a healthy subject and B) an age-and sex-matched 
patient  
 
          
Heart rate (HR), stroke volume (SV), pulmonary blood flow (PBF) and oxygen uptake (VO2) are plotted against exercise intensity expressed as 
% maximum work rate.  
A  B 
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 Table 3.1.2. Inert gas rebreathing haemodynamic measurements during incremental exercise 
     
    
 
% maximal work rate 
 
 
Study groups 
Rest Unloaded 
cycling 20% 40% 60% 80% 
        
 
Healthy subjects       
PBF, l/min 5.4±1.0 7.6±1.3* 9.8±1.7* 12.4±2.3* 15±2.9* 16.9±3.5* 
HR, beats/min 74±18 80±17 96±14* 119±13* 146±15* 166±12* 
SV, ml 74±18 100±23* 104±22* 106±22* 106±25* 105±28* 
∆SV from rest, ml — +22±13 +28±16 +31±15 +29±18 +29±19 
% ∆SV from rest — 33±23 41±30 44±30 43±34 41±32 
 
PH patients       
PBF, l/min 4.2±1.1
§ 6.0±1.3**§ 6.2±1.5**§§ 7.1±2.1**§§ 7.7±2.3**§§ 8.0±2.8**§§ 
HR, beats/min 81±12 91±11** 97±12** 106±13** 123±14**
§§ 140±18**§§ 
SV, ml 54±13
§ 67±11**§§ 65±15**§§ 68±18*§§ 64±16*§§ 60±17*§§ 
∆SV from rest, ml — +11±9§ +10±8§§ +13±13§ +11±11§ +8±8§ 
% ∆SV from rest — 23±20 22±14 29±28 25±19 16±14 
       
 
HR: heart rate; PBF: pulmonary blood flow; SV: stroke volume; ∆SV: change in SV from rest.  
**p<0.01, *p<0.05 versus rest by paired Student's test.  
§§p<0.01, §p<0.05 versus healthy subjects by unpaired Student’s t test.  
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Figure 3.1.2. The relationship between stroke volume and work rate during incremental exercise  
 
 
Stroke volume (SV) is plotted against exercise intensity expressed as % maximum work rate. The data are presented as mean (symbols) and 
SD (error bars). 
A) Healthy subjects B) Pulmonary hypertension patients 
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3.1.5 Discussion 
This study demonstrated that PBF and SV during exercise could be readily 
measured using the non-invasive IGR method in patients with precapillary PH. 
Exercise augmentation in PBF and SV was smaller in PH patients compared to 
healthy subjects. In both groups, PBF increased linearly with work rate whereas 
maximal SV was reached at around 40% WRmax with the largest increase observed 
from rest to unloaded cycling .   
As VO2/HR = SV x Ca-vO2 by the Fick principle, VO2/HR measured at CPET is 
considered a surrogate marker of SV, and could be used to assess SV response to 
exercise non-invasively. D’Alonzo et al identified an inverse relationship 
between VO2/HR and PVR, and found that changes in VO2/HR predicted changes 
in PVR after pulmonary vasodilator therapy 163. However, VO2/HR could be 
reduced as a result of abnormal oxygen extraction (Ca-vO2) by exercising muscles 
due to myopathy. There is increasing evidence that peripheral muscle 
dysfunction may contribute to exercise limitation in patients with PH 164, and 
exercise training could significantly improve exercise capacity independent of 
drug treatment 165;166. Therefore the IGR method could potentially be used to 
measure Ca-vO2 non-invasively and thereby identify patients who may benefit 
from exercise training as an adjunct to PAH-specific therapy. 
The main limitation of the study is the small sample size. As a result, it was not 
possible to study the haemodynamic response to exercise in subgroups stratified 
by WHO FC or PH aetiology. Secondly, the healthy subjects and PH patients 
were not matched for age or gender, but comparison of exercise response 
between these two groups was not the focus of this study.  
3.1.6 Conclusions 
Pulmonary blood flow and SV at rest and during exercise could be measured 
readily using the non-invasive IGR method in patients with precapillary PH. 
Maximal SV could be measured at submaximal exercise to give an objective 
assessment of right heart function independent of patient effort.  
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3.2 Reproducibility of inert gas rebreathing 
haemodynamic measurements 
3.2.1 Summary 
Rationale: More data on the reproducibility of IGR haemodynamic 
measurements are needed to evaluate their potential use as outcome measures 
in PH.  
Aim: The aim of this study was to determine the intersession reproducibility of 
IGR PBF and SV measurements in healthy subjects and patients with precapillary 
PH. 
Methods: Duplicate IGR PBF and SV measurements at rest and during 
submaximal constant-load exercise were obtained in ten healthy subjects and 
nine patients with precapillary PH on two separate days one week to one month 
apart. Intersession reproducibility was assessed using Bland-Altman analysis and 
the coefficient of variation (CoV). 
Results: In healthy subjects, the mean difference between duplicate 
measurements of PBF was 0.0±0.9 l/min with 95% limits of agreement -1.8 to 
1.9 l/min, and that of SV was 3±11 ml with 95% limits of agreement -18 to 24 
ml. Median CoV was 3.8% for PBF and 4.4% for SV. In PH patients, the mean 
difference between duplicate measurements was 0.1±0.3 l/min for PBF and 1±4 
ml for SV. Median CoV was 2.9% for PBF and 4.2% for SV.  
Conclusions: IGR PBF and SV measurements are reproducible in both healthy 
subjects and patients with precapillary PH. 
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3.2.2 Introduction 
In a study investigating the use of IGR method in patients with fibrotic lung 
disease, resting IGR measurements were found to be reproducible with a mean 
difference of 0.12±0.49 l/min between duplicate measurements and a CoV of 
9.3% 133. Data analysis from our unit showed that the intrasession repeatability 
of resting IGR SV in PH patients was good with a CoV of 6.9% 134. However, the 
reproducibility of IGR measurements during exercise may differ from that at rest 
due to a number of factors and such data are currently lacking. The rebreathing 
manoeuvre is more difficult to perform during exercise especially at high work 
rates, and this may affect data quality. Variations in breathing patterns and 
changes in ventilation/perfusion matching during exercise may affect gas mixing 
and the uptake of inert gases from the alveoli into the pulmonary circulation. In 
order to explore the potential use of IGR haemodynamic measurements as 
outcome measures in PH, more reproducibility data are needed. The aims of this 
study were to determine the intersession reproducibility of IGR PBF and SV in 
healthy subjects and patients with precapillary PH, at rest and during exercise. 
3.2.3 Methods 
Study subjects  
The study cohort consisted of ten healthy subjects who also took part in the 
study discussed in Chapter 3.1 and nine patients with precapillary PH recruited 
from the outpatient clinic. The exclusion criteria were inability to perform 
CPET, current use of beta-blockers, significant left heart dysfunction or lung 
disease. 
Study design 
The healthy subjects performed two sequential stepwise constant-load exercise 
tests and the PH patients performed 2 sequential submaximal constant-load 
exercise tests one day to one month apart. There was no change in medication 
or clinical status in PH patients during this interval. The exercise protocols are 
described in Chapters 2.7.3 and 2.7.4.  
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Statistical analysis 
Statistical analysis was performed using Graphpad Prism version 5.00 (Graphpad 
Software, La Jolla, CA, USA). Data are presented as median (range). Bland-
Altman analysis was used to determine the mean difference between duplicate 
IGR measurements, SD and the 95% limits of agreement. The CoV was defined as 
SD of each pair of duplicate measurements as a percentage of the mean of the 
respective pair. The overall CoV was defined as the median CoV of the whole 
group. A p value<0.05 was defined as statistically significant. 
3.2.4 Results 
Healthy subjects 
Forty four pairs of duplicate IGR PBF and SV measurements during exercise were 
obtained from 10 healthy subjects [female: n=3; male: n=7; age 33 (28-44)]. The 
mean difference between duplicate exercise PBF measurements was 0.0±0.9 
l/min with 95% limits of agreement -1.8 to 1.9 l/min (figure 3.2.1). The mean 
difference between duplicate exercise SV measurements was 3±11 ml with 95% 
limits of agreement -18 to 24 ml (figure 3.2.2). Median CoV was 3.8% for PBF 
and 4.4% for SV.  
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Figure 3.2.1. Bland-Altman plot of duplicate exercise IGR PBF 
measurements in healthy subjects  
 
IGR: inert gas rebreathing; PBF: pulmonary blood flow; SD: standard deviation. The 
dashed lines represent 95% limits of agreement. 
 
 
Figure 3.2.2. Bland-Altman plot of duplicate exercise IGR SV measurements 
in healthy subjects 
 
IGR: inert gas rebreathing; SD: standard deviation; SV: stroke volume. The dashed lines 
represent 95% limits of agreement.  
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Pulmonary hypertension patients 
Patient characteristics are shown in table 3.2.1. Twenty seven pairs of duplicate 
IGR PBF and SV measurements were obtained (67% at rest, 33% during exercise). 
The mean difference between duplicate PBF measurements was 0.1±0.3 with 
95% limits of agreement -0.5 to 0.7 l/min (figure 3.2.3). The mean difference 
between duplicate SV measurements was 1±4 with 95% limits of agreement -7 to 
10 ml (figure 3.2.4). Median CoV was 2.9% for PBF and 4.2% for SV.  
Table 3.2.1. Patient characteristics 
  
Age, years 63 (30-79) 
Female/male, n 4/5 
Aetiology, n (%) 
 IPAH 3 (33%) 
CTEPH 6 (66%) 
Exercise work rate, Watts 
 Peak  60 (38-180) 
40% 24 (15-72) 
IGR measurements  
 PBF, l/min 
 supine rest 3.5 (2.8-7.3) 
erect rest 3.2 (2.7-5.8) 
submaximal exercise 5.3 (3.7-8.1) 
SV, ml 
 supine rest 57 (32-95) 
erect rest 44 (30-82) 
submaximal exercise 54 (30-92) 
    
Data are represented as median (range).  
CTEPH: chronic thromboembolic pulmonary hypertension; IGR: inert gas rebreathing; 
IPAH: idiopathic pulmonary arterial hypertension; PBF: pulmonary blood flow; SV: stroke 
volume. IGR measurements from the first test are shown.  
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Figure 3.2.3. Bland-Altman plot of duplicate IGR PBF measurements in 
pulmonary hypertension patients.  
 
IGR: inert gas rebreathing; PBF: pulmonary blood flow; SD: standard deviation. The 
dashed lines represent 95% limits of agreement. 
 
 
Figure 3.2.4. Bland-Altman plot of duplicate IGR SV measurements in 
pulmonary hypertension patients.  
 
IGR: inert gas rebreathing; SD: standard deviation; SV: stroke volume. The dashed lines 
represent 95% limits of agreement.  
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3.2.5 Discussion 
This study showed that the intersession reproducibility of IGR PBF and SV 
measurements is good in both healthy subjects and patients with precapillary 
PH. The reproducibility of IGR SV was poorer than that of PBF in both groups 
though still within acceptable limits. This may be related to the fact that SV is 
derived from PBF and HR, and is hence subject to more variation. The 
reproducibility of IGR PBF and SV is maintained during exercise in healthy 
subjects, but it was not possible to make a direct comparison between resting 
state and exercise in PH patients as the number of duplicate exercise 
measurements was relatively small. However, based on our data analysis, it 
would be reasonable to assume that the reproducibility of IGR PBF and SV during 
exercise in PH patients is comparable to that at rest.  
3.2.6 Conclusions 
IGR PBF and SV measurements demonstrate good intersession reproducibility in 
both healthy subjects and patients with precapillary PH.  
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3.3 Clinical correlates of inert gas rebreathing 
haemodynamic measurements 
3.3.1 Summary 
Rationale: IGR PBF and SV at rest and during exercise are direct measures of 
right heart function, and should correlate with other established markers of 
disease of severity in PH. 
Aim: The aim of this study was to determine the clinical correlates of IGR PBF 
and SV in PH. 
Methods: Data on patient demographics, RHC, lung function, WHO FC, NT-
proBNP, CAMPHOR, incremental CPET variables and 6MWD were collected in 42 
patients with precapillary PH. Correlations between these variables and IGR PBF 
and SV, measured at rest and at submaximal exercise (40% WRmax), were 
determined by Pearson or Spearman correlation coefficients depending on data 
distribution.  
Results: IGR measurements at supine rest correlated with 6MWD, WHO FC, NT-
proBNP, CAMPHOR (except PBF), CPET variables (peak VO2, peak VO2/HR, 
VE/VCO2 at AT, PETCO2 at AT) and RHC variables (RAP, mPAP, CO by TD, SV by 
TD, PVR and SvO2). IGR measurements at erect rest correlated with 6MWD, WHO 
FC (except PBF), NT-proBNP, CAMPHOR (except PBF), CPET variables (peak VO2, 
peak VO2/HR, VE/VCO2 at AT, PETCO2 at AT) and RHC variables (CO by TD, SV by 
TD and PVR). IGR measurements at submaximal exercise correlated with 6MWD, 
WHO FC (except PBF), NT-proBNP, CAMPHOR, CPET variables (peak VO2, peak 
VO2/HR, VE/VCO2 at AT, PETCO2 at AT) and RHC variables (mPAP (except PBF), 
CO by TD, SV by TD, PVR and SvO2). There was no significant correlation 
between % predicted DLco and IGR measurements at rest or at submaximal 
exercise.  
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Conclusions: Resting and submaximal exercise IGR PBF and SV correlate with 
other conventional markers of disease severity in PH and have the potential to 
be used as alternative outcome measures. 
3.3.2 Introduction 
A number of clinical, exercise, haemodynamic and biological parameters have 
established prognostic importance and are widely used to guide clinical 
management in PH 2. These include WHO FC, 6MWD, peak VO2, RHC variables 
and biomarkers such as NT-proBNP. Among them, the most relevant 
prognosticator is 6MWD which has been used as the primary end-point in most 
clinical trials of currently approved PAH-specific therapy. The efficacy of any 
new pharmacological agents will also be judged on their ability to improve 
6MWD. Other potential outcome measures include CAMPHOR, the first health-
status assessment tool developed specifically for PH patients 85 and % predicted 
DLco which was shown to predict mortality independently of age, lung 
parenchymal abnormalities on computed tomography, WHO FC and 
haemodynamic variables in a large cohort of patients with WHO group I PAH 167. 
IGR PBF and SV are direct measures of right heart function and hence closely 
linked to the mechanisms of disease in PH. The aim of this study was to 
determine the clinical correlates of IGR PBF and SV, at rest and during 
submaximal exercise.  
3.3.3 Methods 
Study subjects  
42 patients with precapillary PH who were either newly diagnosed or on stable 
PAH-specific therapy over a period of at least 6 months were included. The 
exclusion criteria were inability to perform exercise tests, current use of beta-
blockers, significant left heart dysfunction or lung disease. 
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Study design 
Study patients first underwent a symptom-limited incremental CPET. On a 
separate day within 2 weeks, they performed a 6MWT (described in Chapter 
2.5.1) and a submaximal constant-load CPET with IGR measurements (described 
in Chapter 2.7.4) on the same day at least 30 min apart and in this order. IGR 
PBF and SV were measured at supine rest, erect rest and after 3 min of cycling 
at 40% WRmax predetermined in the incremental CPET. Data on demographics, 
lung function, incremental CPET, RHC, WHO FC, NT-proBNP, CAMPHOR were 
collected at diagnosis for newly diagnosed patients, and within three months for 
stable patients (except RHC and lung function as these tests were not routinely 
repeated during follow-up). For newly diagnosed patients, exercise tests were 
performed after RHC prior to initiation of PAH-specific therapy (mean 2.1 
weeks, range 1 day to 5.4 weeks). 
Statistical analysis 
Statistical analysis was performed using Graphpad Prism version 5.00 (Graphpad 
Software, La Jolla, CA, USA). Continuous variables were tested for normality 
using D’Agostino and Pearson omnibus normality test. Normally distributed 
variables are shown as mean ± SD and non-normally distributed variables are 
shown as median (interquartile range, IQR). Categorical variables are presented 
as number (%). Correlations between demographics, RHC, lung function, WHO 
FC, NT-proBNP, CAMPHOR, incremental CPET variables, 6MWD and IGR PBF and 
SV, measured at rest and during submaximal exercise, respectively, was 
determined by Pearson correlation coefficient (r) if both variables were 
normally distributed or otherwise by Spearman correlation coefficient (ρ). A p 
value<0.05 was defined as statistically significant. 
3.3.4 Results 
Patient characteristics are shown in tables 3.3.1.and 3.3.2 
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Correlates of resting IGR measurements 
IGR measurements at supine rest correlated with 6MWD, WHO FC, NT-proBNP, 
CAMPHOR (except PBF), incremental CPET variables (peak VO2, peak VO2/HR, 
VE/VCO2 at AT and PETCO2 at AT) and RHC variables (mRAP, mPAP, CO by TD, SV 
by TD, PVR and SvO2). IGR measurements at erect rest correlated with 6MWD, 
WHO FC (except PBF), NT-proBNP, CAMPHOR score (except PBF), incremental 
CPET variables (peak VO2, peak VO2/HR, VE/VCO2 at AT and PETCO2 at AT) and 
RHC variables (CO by TD, SV by TD and PVR) (table 3.3.3). There was no 
correlation between lung function and IGR PBF or SV.  
Correlates of submaximal exercise IGR measurements 
IGR measurements during submaximal exercise correlated with 6MWD, WHO FC 
(except PBF), NT-proBNP, CAMPHOR, incremental CPET variables (peak VO2, 
peak VO2/HR, VE/VCO2 at AT and PETCO2 at AT) and RHC variables (mPAP (except 
PBF), CO by TD, SV by TD, PVR and SvO2) (table 3.3.4). There was no correlation 
between lung function (% predicted FEV1, FVC or DLco) and IGR PBF or SV. 
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Table 3.3.1. Characteristics of the whole cohort 
 
 
Age, years 57±15 
Gender, n (%) 
 
Female 19 (45) 
Male 23 (55) 
Aetiology, n (%) 
 
IPAH 20 (46) 
CTDPAH 5 (12) 
PoPH 2 (5) 
CTEPH 14 (33) 
sarcoidosis 1 (2) 
6MWD, m 414±112 
WHO FC, n (%) 
 I 1 (2) 
II 24 (57) 
III 17 (40) 
NT-proBNP, pg/ml 239 (88-1602) 
CAMPHOR  25±20 
Incremental CPET variables 
 
Peak VO2, l/min 0.891 (0.764-1.20) 
Peak VO2/HR, ml 7.6±2.2 
VE/VCO2 at AT 48 (41-53) 
PETCO2 at AT, mmHg 27±6 
IGR measurements 
 supine rest 
 PBF, l/min 4.1±1.1 
SV, ml 56±20 
erect rest  
 PBF, l/min 3.5±0.9 
SV, ml 45±14 
submaximal exercise  
 PBF, l/min 5.6±2.0 
SV, ml 53±20 
    
Data are presented as mean ± SD or median (IQR). 6MWD: six-minute walk distance; CAMPHOR: 
Cambridge Pulmonary Hypertension Outcome Review; CPET: cardiopulmonary exercise test; 
CTDPAH: connective tissue disease associated pulmonary arterial hypertension; CTEPH: chronic 
thromboembolic pulmonary hypertension; IGR: inert gas rebreathing; IPAH: idiopathic pulmonary 
arterial hypertension; PBF: pulmonary blood flow; PETCO2: end-tidal carbon dioxide partial 
pressure; PoPH: portopulmonary hypertension; NT-proBNP: N-terminal pro-brain natriuretic 
peptide; SV: stroke volume; VO2: oxygen uptake; VO2/HR: oxygen pulse; VE/VCO2 at AT: 
ventilatory equivalent for carbon dioxide at anaerobic threshold; WHO FC: World Health 
Organisation functional class.  
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Table 3.3.2. Characteristics of newly diagnosed patients  
  Patient number, n 26 
  
RHC haemodynamics 
 RAP, mmHg 7 (5-10) 
mPAP, mmHg 47±13 
CO by TD, l/min 4.3±1.6 
SV by TD, ml 61±28 
PVR, Wood units 8.4 (6.1-16.0) 
SvO2, % 66±11 
  
Lung function, % predicted 
 FEV1 84±17 
FVC 101 (84-107) 
DLco  54±21 
    
Data are presented as mean ± SD or median (IQR).  
CO: cardiac output; DLco: diffusing capacity for carbon dioxide; mPAP: mean pulmonary 
artery pressure; PVR: pulmonary vascular resistance; RAP: right atrial pressure; RHC: 
right heart catheterisation; SvO2: mixed venous saturation; SV: stroke volume; TD: 
thermodilution. 
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Table 3.3.3. Correlates of IGR measurements  
r: Pearson correlation coefficient; ρ: Spearman correlation coefficient. 
6MWD: six-minute walk distance; CAMPHOR: Cambridge Pulmonary Hypertension Outcome Review; IGR: inert gas rebreathing; NT-proBNP: N-terminal 
pro-brain natriuretic peptide; PBFer: pulmonary blood flow at erect rest; PBFex: pulmonary blood flow at exercise; PBFsr: pulmonary blood flow at supine 
rest; PETCO2 at AT: end-tidal carbon dioxide partial pressure at anaerobic threshold; SVer: stroke volume at erect rest; SVex: stroke volume at exercise; 
SVsr: stroke volume at supine rest; VO2: oxygen uptake; VO2/HR: oxygen pulse; VE/VCO2 at AT: ventilatory equivalent for carbon dioxide at anaerobic 
threshold; WHO FC: World Health Organisation functional class. 
  
       
 
PBFsr SVsr PBFer SVer PBFex SVex 
 
6MWD r=0.42, p<0.01 r=0.42, p<0.001 r=0.41, p<0.01 r=0.42, p<0.01 r=0.56, p<0.01 r=0.55, p<0.01 
       WHO FC r=-0.47, p<0.01 r=-0.50, p<0.01 r=-0.25, p=0.12 r=-0.45, p<0.01 r=-0.29, p=0.07 r=-0.41, p<0.01 
       NT-proBNP ρ=-0.65,p<0.01 ρ=-0.71, p<0.01 ρ=-0.49, p<0.05 ρ=-0.50, p<0.01 ρ=-0.78, p<0.01 ρ=-0.74, p<0.01 
       CAMPHOR  r=-0.26, p=0.14 r=-0.40, p<0.05 r=-0.29, p=0.06 r=-0.43, p<0.01 r=-0.42, p<0.01 r=-0.50, p<0.01 
       Peak VO2 ρ =0.58, p<0.01 ρ=0.63, p<0.01 ρ=0.56, p<0.01 ρ=0.56, p<0.01 ρ=0.78, p<0.01 ρ=0.77, p<0.01 
       Peak VO2/HR r=0.57, p<0.01 r=0.66, p<0.01 r=0.51, p<0.01 r=0.62, p<0.01 r=0.72, p<0.01 r=0.82, p<0.01 
       VE/VCO2 at AT ρ=-0.64, p<0.01 ρ=-0.67, p<0.01 ρ=-0.60, p<0.01 ρ=-0.62, p<0.01 ρ=-0.65, p<0.01 ρ=-0.72, p<0.01 
       PETCO2 at AT r=0.60, p<0.01 r=0.58, p<0.01 r=0.60, p<0.01 r=0.62, p<0.01 r=0.64, p<0.01 r=0.71, p<0.01 
       
 
 
97 
 
Table 3.3.4. Correlates of IGR measurements (continued)  
r: Pearson correlation coefficient; ρ: Spearman correlation coefficient. 
CO: cardiac output; DLco: diffusing capacity for carbon dioxide; mPAP: mean pulmonary artery pressure; PBFer: pulmonary blood flow at erect rest; PBFex: 
pulmonary blood flow at exercise; PBFsr: pulmonary blood flow at supine rest; PVR: pulmonary vascular resistance; RAP: right atrial pressure; SvO2: mixed 
venous saturation; SVer: stroke volume at erect rest; SVex: stroke volume at exercise; SVsr: stroke volume at supine rest; TD: thermodilution. 
 
       
 
PBFsr SVsr PBFer SVer PBFex SVex 
 
RAP ρ=-0.45, p=0.03 ρ=-0.50, p=0.01 ρ=-0.20, p=0.35 ρ=-0.29, p=0.16 ρ=-0.25, p=0.21 ρ=-0.35, p=0.09 
       mPAP r=-0.42, p=0.04 r=-0.50, p=0.01 r=-0.01, p=0.97 r=-0.25, p=0.22 r=-0.39, p=0.05 r=-0.47, p=0.02 
       CO by TD r=0.70, p<0.01 r=0.63, p<0.01 r=0.57, p<0.01 r=0.51, p=0.01 r=0.79, p<0.01 r=0.71, p<0.01 
       SV by TD r=0.79, p<0.01 r=0.80, p<0.01 r=0.58, p<0.01 r=0.67, p<0.01 r=0.85, p<0.01 r=0.83, p<0.01 
       PVR ρ=-0.78, p<0.01 ρ=-0.79, p<0.01 ρ=-0.48, p=0.02 ρ=-0.51, p<0.01 ρ=-0.82, p<0.01 ρ=-0.82, p<0.01 
       SvO2 r=0.57, p<0.01 r=0.51, p=0.01 r=0.28, p=0.18 r=0.27, p=0.20 r=0.61, p<0.01 r=0.55, p<0.01 
       % predicted DLco r=0.01, p=0.97 r=0.03 p=0.88 r=0.12, p=0.59 r=0.02, p=0.92 r=0.23, p=0.27 r=0.12, p=0.58 
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3.3.5 Discussion 
Data analysis from this study showed that in patients with precapillary PH, IGR 
PBF and SV measured at supine rest, erect rest and submaximal exercise (40% 
WRmax) correlate with other markers of disease severity including 6MWD, WHO 
FC, NT-proBNP, CAMPHOR, CPET variables and haemodynamics measured at 
RHC, but there was no correlation with lung function.  
Correlations between 6MWD and IGR measurements were stronger during 
submaximal exercise than at rest but overall only modest. Limitations of the 
6MWT may explain the relatively loose relationships. Performance at the 6MWT 
can be influenced by many factors unrelated to PH such as coexisting 
cardiopulmonary, neurological and musculoskeletal abnormalities, subject 
volition and walking efficiency. It is also subject to a ceiling effect in its ability 
to detect clinical change in fitter patients 70;93. On the other hand, IGR PBF and 
SV are direct measures of right heart function and hence closely linked to 
disease severity. They are not affected by an ceiling effect or subject volition if 
exercise is performed at standardised submaximal work rates. There were 
strong correlations between peak VO2 (r=0.76-0.80) and submaximal exercise IGR 
measurements. This indicates that IGR PBF or SV measured at 40% WRmax could 
be used as surrogate markers of peak exercise capacity and this would provide 
an objective assessment independent of patient effort.  
3.3.6 Conclusions 
Resting and submaximal exercise IGR PBF and SV correlate with other 
conventional markers of disease severity and may be used as alternative 
outcome measures in PH.   
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3.4 Use of inert gas rebreathing haemodynamic 
measurements to detect treatment response in 
precapillary pulmonary hypertension 
3.4.1 Summary 
Rationale: Haemodynamic measurements may be superior to 6MWD as outcome 
measures in PH as they are directly linked to the mechanisms of disease and are 
not subject to a ceiling effect. The aim of this study was to determine if 
treatment response in precapillary PH could be detected by PBF and SV 
measured non-invasively using the IGR method at rest and during submaximal 
constant-load exercise. 
Methods: Twenty four patients with precapillary PH receiving de novo or 
modified PAH-specific therapy were studied. Isotime metabolic variables, IGR 
PBF and SV were measured at rest and during submaximal constant-load 
exercise at 40% WRmax alongside conventional outcome measures, at baseline 
and after 3 months of new therapy.  
Results: At follow-up there was a significant increase in IGR PBF (supine rest: 
mean 0.7±0.9 l/min, erect rest: 0.7±0.8 l/min, exercise: 0.8±1.0 l/min, 
p<0.005) and SV (supine rest: 7±10 ml, erect rest: 10±11 ml, exercise: median 6 
(IQR 3-11) ml, p<0.005). There was a trend for 6MWD to increase by 17±42 m or 
29 (13-47) m (p=0.061), whereas WHO FC, NT-proBNP or CAMPHOR score were 
unchanged. In patients with higher baseline 6MWD, IGR measurements were 
more sensitive than 6MWD in detecting treatment response. 
Conclusions: Non-invasive IGR haemodynamic measurements could be used to 
detect treatment response in patients with precapillary PH and may be more 
responsive to change than 6MWD in fitter patients.  
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3.4.2 Introduction 
An impaired exercise SV and consequently CO response is the fundamental 
pathophysiological consequence of PAH 15. PAH-specific therapy is aimed at 
reducing PVR and right ventricular afterload, thereby improving CO response to 
exercise. Measurement of CO at RHC would allow direct monitoring of disease 
progression and treatment response, but serial RHC is inconvenient in clinical 
practice owing to its invasive nature. As a result, 6MWD, a measure of functional 
exercise capacity, has been used as a simple surrogate marker of exercise CO, 
and has been established as the primary end-point in most clinical trials of PAH 
therapy 89. However, several factors exist which may compromise the reliability 
of this test as an outcome measure, such as subject volition, comorbid 
respiratory and musculoskeletal abnormalities, and a ceiling effect in its ability 
to detect clinical change in fitter patients 70;93. Additionally, it is subject to a 
learning effect 168.   
Measurement of CO by the IGR method could be an alternative outcome 
measure to 6MWD. It is a direct measurement of haemodynamics and is hence 
disease-specific. Cardiac output is not subject to a ceiling effect due to its 
linear relationship with peak VO2 and so, when combined with exercise, may be 
more sensitive than 6MWD in detecting early change in fitter patients 78. As SV 
reaches its maximum at around 40-50% maximal work rate 169, maximal SV could 
be measured during submaximal constant-load exercise to give an objective 
measurement independent of patient effort. This form of exercise would also 
allow isotime comparison of metabolic variables which were shown to be more 
sensitive than variables measured at peak exercise in demonstrating improved 
exercise capacity from therapeutic interventions in COPD 112;113;170. Cardiac 
output measured non-invasively by the IGR method has been validated against 
the TD and Fick methods in patients with PH and interstitial lung disease 132-134.   
The aims of this study were to determine if response to PAH-specific therapy in 
patients with precapillary PH could be detected by changes in IGR 
haemodynamic measurements and also by isotime comparison of metabolic 
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indices of cardiac function (VO2 and VO2/HR) and ventilatory efficiency (VE/VCO2 
and PETCO2), at rest and during submaximal constant-load exercise.  
3.4.3 Methods 
Study subjects 
The inclusion criteria were incident patients diagnosed with precapillary PH 
including WHO group I PAH (except CHD) and CTEPH started on de novo PAH-
specific therapy, and prevalent patients in whom PAH-specific therapy was 
modified. Patients who were unable to perform a 6MWT or CPET were excluded.  
Study design 
Study patients underwent a symptom-limited incremental CPET and a 6MWT at 
baseline (described in Chapters 2.6 and 2.5.1 respectively). On a separate day 
within two weeks they performed a second 6MWT using a telemetric metabolic 
device (described in Chapter 2.5.2) and submaximal constant-load CPET with 
IGR measurements on the same day 30 min apart and in this order. These two 
tests were repeated after 3 months of new PAH-specific therapy. In addition, 
conventional outcome measures including WHO FC, NT-proBNP and CAMPHOR 
score were recorded at baseline and follow-up.  
IGR and isotime metabolic measurements during submaximal constant-load 
exercise 
The IGR method is described in Chapter 2.7.4. Duplicate PBF measurements 
were made after 10 min of rest in the supine position and again after 10 min of 
rest on the upright cycle ergometer. There was an interval of 5 min between 
duplicate PBF measurements to ensure complete washout of inert gases from 
the lungs. The patient then underwent a constant-load CPET. After 3 min of 
cycling, PBF was measured while the patient continued to cycle. SaO2 and HR 
were measured continuously by pulse oximetry and 12-lead ECG. Breath-by-
breath respired air was collected via a mouthpiece with the nose clipped and 
moving averages of metabolic data over eight breaths were obtained. End-
exercise values were defined as the highest of the last eight averaged values 
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and were used for isotime analysis at baseline and follow-up. Isotime analysis 
refers to comparison of measurements made at standardised time with an 
identical workload history. Stroke volume was derived from PBF and HR (PBF 
divided by HR). Ca-vO2 was calculated from VO2 and PBF (VO2 divided by PBF). 
The exercise protocol was repeated after 15-20 min of rest. Duplicate 
measurements in each step were averaged to give the final results. The work 
rate remained the same for submaximal constant-load exercise at follow-up. 
Statistical analysis 
Statistical analysis was performed using Statview version 5.0.1 (SAS Institute, 
Cary, NC, USA) and Graphpad Prism version 5.00 (Graphpad Software, La Jolla, 
CA, USA). Assuming a treatment-induced change in 6MWD of 40 m and a SD of 54 
m based on data from a group of patients with IPAH receiving PAH-specific 
therapy 44, the sample size required to detect a treatment effect with 80% 
power and 5% two-tailed level of significance by paired t test would be 17. A 
post-hoc power calculation was performed using data observed in this study. 
Continuous variables were tested for normality using D’Agostino and Pearson 
omnibus normality test. Normally distributed variables are shown as mean ± SD 
and non-normally distributed variables are shown as median (IQR). Categorical 
variables are presented as number (%). Comparison between baseline and 
follow-up 6MWD, NT-proBNP, CAMPHOR, IGR and isotime metabolic 
measurements were made by paired t test or Wilcoxon signed rank test 
depending on data distribution. Comparison between baseline and follow-up 
WHO FC was made by Chi-squared test. Correlation between two variables that 
were both normally distributed was determined by Pearson correlation 
coefficient (r), and otherwise by Spearman correlation coefficient (ρ). Post-hoc 
analysis was carried out by stratifying patients into high and low 6MWD groups 
using the median baseline 6MWD. Comparison of baseline characteristics 
between 6MWD subgroups was made by unpaired t test or Mann-Whitney U test 
depending on data distribution. A p value <0.05 was defined as statistically 
significant. 
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3.4.4 Results 
Patient characteristics 
Twenty four patients were recruited and their characteristics are shown in table 
3.4.1. Incremental CPET abnormalities were consistent with moderately severe 
exercise impairment due to pulmonary vascular disease (table 3.4.2). Other 
factors such as the use of digoxin, beta-blockers and diuretics were unchanged 
during the study period. None of the study patients were involved in exercise 
programmes or had evidence of exercise induced right-to-left shunt. The mean 
time interval between baseline testing and follow-up assessment was 3.3 months 
(range 2.4−4.5).  
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Table 3.4.1. Patient Characteristics 
  
Age, years 59±15 
Female, n (%) 8 (33) 
Aetiology, n (%) 
 
    IPAH 12 (50) 
CTDPAH 2 (8) 
PoPH 1 (4) 
CTEPH 8 (33) 
Sarcoidosis 1 (4) 
Baseline haemodynamics 
 
    RAP, mmHg 7±5 
mPAP, mmHg 48±13 
CO, l/min 3.9 (3.3-5.3) 
CI, l/min/m2 2.2±0.7 
PVR, Wood units 10.6±5.7 
SvO2, % 65±11 
De novo monotherapy (n=22), n (%) 
 
Intravenous epoprostenol 1 (4) 
Sildenafil 13 (54) 
Bosentan 6 (25) 
Ambrisentan 2 (8) 
Combination therapy (n=1), n (%) 
 
Nebulised iloprost added to  
sildenafil 
1 (4) 
Agent change (n=1), n (%) 
 
Bosentan changed to sildenafil 1 (4) 
Data are expressed as mean ± SD, median (IQR) or n (%). 
CI: cardiac index; CO: cardiac output; CTDPAH: connective tissue disease 
associated pulmonary arterial hypertension; CTEPH: chronic thromboembolic 
pulmonary hypertension; IPAH: idiopathic pulmonary arterial hypertension; 
mPAP: mean pulmonary artery pressure; PoPH: portopulmonary hypertension; 
PVR: pulmonary vascular resistance; RAP: right atrial pressure; SvO2: mixed 
venous saturation. 
  
 
 
105 
 
Table 3.4.2. Incremental cardiopulmonary exercise test characteristics 
  Peak VO2, l/min 0.971±0.355 
Peak VO2/kg , ml/min/kg 12±4 
Peak VO2, % predicted 55±19 
Peak work rate, Watts 61 (47-97) 
Peak work rate, % predicted 56±23 
VO2 at AT, l/min 0.694±0.173 
VO2 at AT, % predicted peak VO2 42±11 
Peak HR, beats/min 132±27 
Peak HR, % predicted 85±12 
Peak VO2/HR, ml 7±2 
Peak VO2/HR, % predicted 70±24 
Peak VE, l/min 62.4 (52.6-81.1) 
VE/VO2 at AT 48 (40-56) 
VE/VCO2 at AT 51 (47-64) 
PETCO2 at AT, mmHg 24±5 
End-exercise PETCO2, mmHg 20±5 
Resting SaO2, % 95±3 
End-exercise SaO2, % 90±6 
RER 1.16±0.15 
Data are expressed as mean ± SD or median (IQR).  
AT: anaerobic threshold; HR: heart rate; PETCO2: end-tidal carbon dioxide 
partial pressure; RER: respiratory exchange ratio; SaO2: arterial oxygen 
saturation; VE: minute ventilation; VO2: oxygen uptake; VO2/HR: oxygen pulse; 
VE/VCO2: ventilatory equivalent for carbon dioxide; VE/VO2: ventilatory 
equivalent for oxygen.  
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Conventional outcome measures 
After 3 months of new therapy, 6MWD increased from 384±115 m to 401±111 m 
(mean change 17±42 m; median change 29 (3-47) m, p=0.061). There were no 
significant changes in WHO FC (baseline: 50% in FC II and 50% in FC III; follow-
up: 8% in FC I, 54% in II and 38% in FC III, p=0.215), NT-proBNP (baseline: 
1145±1319 pg/ml; follow-up: 1014±1066 pg/ml, p=0.436) or CAMPHOR score 
(baseline: 33±21; follow-up: 30±21, p=0.435).  
IGR and isotime metabolic measurements  
After 3 months of new therapy, IGR measurements at supine rest, erect rest and 
submaximal exercise increased significantly at follow-up (table 3.4.3). The 
change in PBF with therapy was 0.7±0.9 l/min at supine rest, 0.7±0.8 l/min at 
erect rest and 0.8±1.0 l/min at submaximal exercise. The change in SV with 
therapy was 7±10 ml at supine rest, 10±11 ml at erect rest and 6 (3-11) ml at 
submaximal exercise. Isotime VO2 increased by 0.025±0.042 l/min (p=0.010) and 
VO2/kg by 0.3±0.6 ml/min/kg (p=0.012). Ca-vO2 decreased by 1.6±3.0 ml/dl 
(p=0.021) and RER by 0.02±0.05 (p=0.025). There were no significant changes in 
VO2/HR, VE/VCO2 or PETCO2 (table 3.4.4). There were modest correlations 
between therapy-induced changes in IGR and isotime metabolic measurements 
during constant-load exercise (figures 3.4.1 and 3.4.2). The mean or median % 
change in IGR measurements from baseline was greater than that for 6MWD 
(figure 3.4.3).  
In the post-hoc analysis the high 6MWD group (477±80 m) were significantly 
younger and had less severe exercise impairment on incremental CPET than the 
low 6MWD group (291±47 m) (table 3.4.5). Six-minute walk distance improved by 
34±25 m (p<0.001) and isotime VO2 by 0.033±0.031 l/min (p=0.009) with new 
therapy in the low 6MWD group whereas neither variable changed significantly in 
the high 6MWD group. In comparison, there remained a significant improvement 
in IGR measurements in both groups (table 3.4.6). Stratified isotime metabolic 
data are shown in table 3.4.7  
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Table 3.4.3. IGR measurements during submaximal constant-load exercise  
    
Baseline Follow-up p value 
        
       HR, beats/min 
   Supine rest  81±15 79±11 0.519 
Erect rest  84±16 80±11 0.155 
Exercise  114±18 112±16 0.274 
Exercise response* 31±9 33±11 0.408 
    PBF, l/min 
   Supine rest  4.0±1.0 4.7±1.4 0.002 
Erect rest  3.2±0.6 3.9±0.9 <0.001 
Exercise  5.3±1.7 5.7 (4.1-8.1) 0.003 
Exercise response* 2.1±1.5 2.1±1.6 0.921 
    SV, ml 
   Supine rest  53±22 58 (44-68) 0.002 
Erect rest  40±13 50±15 <0.001 
Exercise  48±18 56±21 0.004 
Exercise response* 8±12 5±13 0.176 
              
Data are expressed as mean ± SD or median (IQR).  
*Defined as change from rest to end of exercise. 
HR: heart rate; IGR: inert gas rebreathing; PBF: pulmonary blood flow; SV: stroke 
volume. 
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Table 3.4.4.  Isotime metabolic measurements during submaximal 
constant-load exercise  
  
  End-exercise values 
  
Baseline Follow-up p value 
       HR, beats/min 113±19 109±20 0.134 
VO2, l/min 0.792±0.197 0.817±0.203 0.010 
VO2/kg, ml/min/kg 10±2 11±2 0.012 
VO2/HR, ml 7±2 8±2 0.079 
Ca-vO2, ml/dl 16.3±3.8 14.7±3.6 0.021 
VE, l/min 42.1±9.2 39.7±8.4 0.087 
VE/VCO2 56.3±15.2 54.0±15.5 0.182 
VE/VCO2 slope  55.6±16.5 52.3±16.7 0.076 
PETCO2, mmHg 23±6 24±6 0.188 
SaO2, % 92 (88-96) 91±6 0.338 
RER 0.90±0.07 0.88±0.06 0.025 
              
Data are expressed as mean ± SD or median (IQR).  
Ca-vO2: arteriovenous oxygen content difference; HR: heart rate; PETCO2: end-tidal 
carbon dioxide partial pressure; RER: respiratory exchange ratio; VE: minute ventilation; 
VO2: oxygen uptake; VO2/HR: oxygen pulse; VE/VCO2: ventilatory equivalent for carbon 
dioxide; SaO2: arterial oxygen saturation. 
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Figure 3.4.1. Correlation between therapy-induced changes in submaximal 
exercise SV and isotime metabolic measurements 
 
 
 
ρ: Spearman correlation coefficient.  
∆PETCO2: change in end-tidal carbon dioxide partial pressure; ∆SVex: change in exercise 
stroke volume; ∆VE/VCO2: change in ventilatory equivalent for carbon dioxide; ∆VO2: 
change in oxygen uptake; ∆VO2/HR: change in oxygen pulse.  
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Figure 3.4.2. Correlation between therapy-induced changes in submaximal 
exercise PBF and isotime metabolic measurements 
 
 
 
r: Pearson correlation coefficient; ρ: Spearman correlation coefficient. 
∆PBFex: change in exercise pulmonary blood flow; ∆PETCO2: change in end-tidal carbon 
dioxide partial pressure; ∆VE/VCO2: change in ventilatory equivalent for carbon dioxide; 
∆VO2: change in oxygen uptake; ∆VO2/HR: change in oxygen pulse. 
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Figure 3.4.3. Percentage changes in IGR measurements and 6MWD from 
baseline 
 
 
Non-normally distributed variables are represented by box and whiskers plots. The 
whiskers represent the minimum and maximum values and the box represents the 25th 
and 75th percentiles. The line in the box represents the median. Normally distributed 
variables are represented by dot plots. The line represents the mean. 6MWD: six-minute 
walk distance; er: erect rest; ex: exercise; IGR: inert gas rebreathing; PBF: pulmonary 
blood flow; sr: supine rest; SV: stroke volume. p values refer to comparison of variables 
between baseline and follow-up by paired t test or Wilcoxon signed rank test. 
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Table 3.4.5 Patient characteristics of 6MWD subgroups  
    
 
High 6MWD   
 
 
Low 6MWD  
 
p value 
            Patient number, n 12 12 - 
Age, years 52±13 70 (59-75) 0.026 
Female, n (%) 2 (17) 6 (50) 0.083 
  
       Haemodynamics 
 
       RAP, mmHg 9±5 6±4 0.229 
mPAP, mmHg 48±15 48±12 0.988 
CO, l/min 4.5±1.8 4.1±1.2 0.475 
CI, l/min/m2 2.3±0.8 2.2±0.7 0.641 
PVR, Wood units 10.1±5.4 9.8 (6.5-14.9) 0.583 
SvO2, % 66±10 64±12 0.727 
  
       Conventional outcome  
measures  
       6MWD, m 477±80 291±47 <0.001 
WHO FC, II/III, n 8/4 4/8 0.103 
NT-proBNP, pg/ml 782±816 1442±1599 0.277 
CAMPHOR 28±22 38±20 0.274 
  
      CPET characteristics 
 
      Peak VO2, l/min 1.152±0.386 0.789±0.208 0.012 
Peak VO2/HR, ml 8±2 6±2 0.009 
VE/VCO2 at AT 49.3±8.9 63.1±19.6 0.047 
PETCO2 at AT, mmHg 26±4 22±6 0.055 
  
  
Data are expressed as mean ± SD, median (IQR) or n (%).  
6MWD: six-minute walk distance; CAMPHOR: Cambridge Pulmonary Hypertension 
Outcome Review; CI: cardiac index; CO: cardiac output; CPET: cardiopulmonary 
exercise test; mPAP: mean pulmonary artery pressure; NT-proBNP: N-terminal pro-
brain natriuretic peptide; PETCO2 at AT: end-tidal carbon dioxide partial pressure at 
anaerobic threshold; PVR: pulmonary vascular resistance; RAP: right atrial pressure; 
SvO2: mixed venous saturation; VO2: oxygen uptake; VO2/HR: oxygen pulse; VE/VCO2 
at AT: ventilatory equivalent for carbon dioxide at anaerobic threshold; WHO FC: 
World Health Organisation functional class. 
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Table 3.4.6. IGR measurements during submaximal constant-load exercise in 6MWD subgroups 
   
High 6MWD group (n=12)   Low 6MWD group (n=12) 
     
   
Baseline Follow-up p value  Baseline Follow-up p value 
   
 
6MWD, m  477±80 477±97 0.991 
 
291±47 325±61 <0.001 
          PBF, l/min 
       Supine rest  4.1±0.9 5.0±1.4 0.013 
 
3.8±1.2 4.3±1.3 0.068 
Erect rest  3.3±0.5 4.1±1.0 0.012 
 
3.1±0.7 3.8±0.8 0.004 
Exercise  5.6±1.8 6.5±2.1 0.031 
 
5.0±1.7 5.6±1.9 0.030 
        SV, ml 
       Supine rest  55 (38-73) 64±18 0.084 
 
47 (29-62) 57 (37-62) 0.010 
Erect rest  43±10 52±14 0.027 
 
37 (24-42) 48±16 0.001 
Exercise  52±17 62±21 0.030 
 
44±19 49±19 0.064 
        
Data are expressed as mean ± SD or median (IQR). 
6MWD: six-minute walk distance; IGR: inert gas rebreathing; PBF: pulmonary blood flow; SV: stroke volume.  
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Table 3.4.7. Isotime metabolic measurements during submaximal constant-load exercise in 6MWD subgroups  
   
High 6MWD group (n=12) 
  
Low 6MWD group (n=12) 
        
   
Baseline Follow-up p value  Baseline Follow-up p value 
 
  
 
HR, beats/min 108±17 103±16 0.079 
 
118±19 114±22 0.394 
VO2, l/min 0.873±0.220 0.889±0.230 0.332 
 
0.703 (0.605-0.798) 0.731 (0.634-0.817) 0.009 
VO2/kg, ml/min/kg 11±2 12±2 0.297 
 
9 (8-10) 9 (8-11) 0.009 
VO2/HR, ml 8±2 9±3 0.163 
 
6 (5-7) 7 (6-8) 0.203 
Ca-vO2, ml/dl 16.7±2.5 14.8±3.1 0.054 
 
15.9±4.9 14.7±4.2 0.186 
VE, l/min 42.6±11.1 35.5 (32.4-43.2) 0.045 
 
41.7±7.5 41.5±7.5 0.908 
VE/VCO2 51.3±13.1 48.6±14.2 0.284 
 
60.9±16.0 58.9±15.5 0.443 
VE/VCO2 slope  49.9±13.2 43.1 (34.8-58.1) 0.638 
 
61.3±18.0 56.5±16.5 0.157 
PETCO2, mmHg 25±6 26±6 0.229 
 
22±6 23±5 0.632 
SaO2, % 94±3 94±4 1.000 
 
89±6 88±6 0.218 
RER 0.91±0.07 0.86±0.06 0.005 
 
0.90±0.06 0.90±0.04 0.942 
Data are expressed as mean ± SD or median (IQR). 
6MWD: six-minute walk distance; Ca-vO2: arteriovenous oxygen content difference; PETCO2: end-tidal carbon dioxide partial pressure; RER: 
respiratory exchange ratio; SaO2: arterial oxygen saturation; VE: minute ventilation; VO2: oxygen uptake; VO2/HR: oxygen pulse; VE/VCO2: 
ventilatory equivalent for carbon dioxide. 
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Correlation between 6MWD and IGR measurements 
At baseline, 6MWD correlated with submaximal exercise PBF (r=0.52, p=0.008) 
and SV (r=0.47, p=0.021). At follow-up, 6MWD correlated with supine rest PBF 
(r=0.46, p=0.025) and SV (ρ=0.42, p=0.041), submaximal exercise PBF (ρ=0.53, 
p=0.010) and SV (r=0.54, p=0.008). There was no significant correlation between 
6MWD and erect rest IGR measurements or between therapy-induced changes in 
6MWD and IGR measurements.  
Metabolic measurements during the 6MWT 
These results are separately presented and discussed in Chapter 4.  
Post-hoc power calculation 
This was performed using data on treatment effect and SD observed in this study 
for conventional outcome measures, IGR and isotime metabolic measurements 
(table 3.4.8). Much larger sample sizes would be required for conventional 
outcome measures (50 to 268) and isotime metabolic variables (24 to 100) to 
detect a treatment effect compared to IGR measurements (13 to 22). 
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Table 3.4.8. Post-hoc power calculation 
   
 
Treatment effect Required sample size* 
     
   Conventional outcome measures 
  6MWD, m 17±42 50 
WHO FC 0.5 to 0.38† 268 
NT-proBNP, pg/ml 131±738 252 
CAMPHOR 3±15 199 
   IGR measurements 
  PBF, l/min 
  supine rest 0.7±0.9 16 
erect rest 0.7±0.8 13 
exercise 0.8±1.1 17 
SV, ml 
  supine rest 7±10 19 
erect rest 10±11 12 
exercise 7±11 22 
   Isotime metabolic measurements 
  VO2, l/min 0.025±0.042 24 
Ca-vO2, ml/dl 1.6±3.0 30 
VO2/HR, ml 0.5±1.3 54 
VE/VCO2 2.3±8.1 100 
PETCO2, mmHg 1±4 100 
      
* To detect a treatment effect with 80% power and a two-tailed significance level of 0.05 by 
paired t test.  
† To detect a change in the proportion of WHO FC III patients from 0.5 to 0.38 by Chi-squared 
test.  
6MWD: six-minute walk distance; CAMPHOR: Cambridge Pulmonary Hypertension Outcome 
Review; Ca-vO2: arteriovenous oxygen content difference; IGR: inert gas rebreathing; NT-
proBNP: N-terminal pro-brain natriuretic peptide; PBF: pulmonary blood flow; PETCO2: end-tidal 
carbon dioxide partial pressure; SV: stroke volume; VO2: oxygen uptake; VO2/HR: oxygen 
pulse; VE/VCO2: ventilatory equivalent for carbon dioxide; WHO FC: World Health Organisation 
functional class. 
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3.4.5 Discussion 
This study is the first to show that PBF and SV measured non-invasively at rest 
and during submaximal constant-load exercise by the IGR method could be used 
to detect the effect of proven PAH-specific therapy in a group of patients with 
precapillary PH. The sample size required for IGR measurements to detect a 
treatment effect was considerably smaller than that required for conventional 
outcome variables, suggesting that IGR measurements may be more sensitive 
outcome measures. In the post-hoc analysis, IGR measurements were able to 
demonstrate a treatment effect in both high and low 6MWD groups whereas 
6MWD did not change with therapy in the high 6MWD group. This finding would 
suggest that IGR measurements may be more sensitive than 6MWD in detecting 
therapy-induced changes in fitter patients.  
Improvement in IGR measurements with therapy was observed across supine 
rest, erect rest and submaximal exercise. In addition, the exercise response in 
PBF or SV was unchanged with therapy. Therefore, resting IGR measurements 
appear to be as sensitive as submaximal exercise measurements in detecting a 
treatment effect in this study population. The prognostic significance of SV has 
been demonstrated in a previous study using cardiac MRI 44. In a group of 
patients with IPAH, a low SV at baseline predicted survival independently. More 
importantly, change in SV with PAH-specific therapy was more predictive of 
survival than change in 6MWD in multivariate analysis, confirming a correlation 
between SV and clinical outcome. The inability of 6MWD to demonstrate a 
treatment effect in patients with higher 6MWD in this study concurs with the 
finding from a previous study which showed that haemodynamic indices 
measured at RHC were more sensitive than 6MWD as outcome measures in 
patients walking >450 m 68. The precise mechanism behind this observation is 
unclear but is thought to be related to the ceiling effect of 6MWD.  
Metabolic variables during incremental CPET have been shown to have 
prognostic significance, but previous studies using these variables as outcome 
measures in PAH showed mixed results 171. The use of metabolic variables to 
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assess treatment response in PH is revisited in this study using isotime 
comparison at submaximal constant–load exercise. At follow-up there was a 
small significant increase in VO2 and decrease in Ca-vO2 consistent with an 
improved exercise CO secondary to therapy, but no change in the metabolic 
indices of ventilatory efficiency. There is therefore no conclusive evidence from 
this study to support the use of isotime metabolic variables to assess treatment 
response, but it does add to the current body of literature on the use of CPET in 
PAH, an area where more research is required.  
Stroke volume measured at supine rest was greater than that at erect and 
comparable to that at submaximal exercise, as a result of a greater preload and 
lower PVR in the supine position 172. This gives rise to a smaller % therapy-
induced change in PBF and SV at supine rest compared to erect rest despite 
similar absolute changes. There was no significant increase in the exercise 
response of PBF or SV after 3 months of new therapy. This indicates that the 
increase in submaximal exercise PBF or SV at follow-up was a result of an 
increase in resting values combined with an unchanged exercise response. The 
increase in SV with new therapy was not accompanied by an increase in isotime 
VO2/HR. This may be owing to the fact that a reduction in SV would be 
compensated by an increase in Ca-vO2 and vice versa, thereby attenuating 
changes in VO2/HR 
41. Directly measured SV would therefore be more sensitive 
than VO2/HR in detecting clinical change.  
There was no correlation between therapy-induced changes in submaximal 
exercise IGR measurements and 6MWD, and this may be related to the 
limitations of 6MWD previously discussed. In addition, published reference 
equations for 6MWD show that only 44-60% of normal inter-subject variance can 
be explained by physiological factors such as age, gender, height and weight 63-
66. This suggests that there are other undefined determinants of performance at 
the 6MWT which may outweigh the influence of disease in an individual, 
especially in those who are mildly affected. These factors would add to the 
noise of 6MWD measurements and mask any clinical change secondary to 
therapy. On the other hand, submaximal exercise IGR measurements are 
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markers of PH-specific change and unaffected by patient volition or a ceiling 
effect.  
Although the findings in this study are preliminary, the use of IGR measurements 
in PH warrants further studies, especially in specific patient groups. IGR 
measurements would allow more reliable assessment of therapy-induced 
changes in patients with comorbid conditions affecting 6MWD, such as patients 
with connective tissue disease. They may be superior to 6MWD as outcome 
measures in clinical trials focused on patients with less advanced disease. 
Resting measurements could be used to assess patients who are too disabled to 
perform a 6MWT. In addition, simultaneous measurement of SV and VO2 would 
allow determination of Ca-vO2, which may be reduced in patients with peripheral 
muscle dysfunction confounding exercise limitation, a recognised phenomenon 
in PAH 164. In this setting, exercise training may have an adjunctive role to 
medical therapy in improving exercise capacity 165;166. 
This study has a number of limitations. It was underpowered to detect changes 
in WHO FC, NT-proBNP and CAMPHOR score with new therapy. The aetiology of 
PH in the study population was heterogeneous, including patients with CTEPH 
and one patient with sarcoidosis, but this reflects the real-life nature of the 
study population. Although PAH-specific therapy is currently not approved in 
CTEPH, there is some evidence from several uncontrolled studies and one 
randomised controlled trial to support its efficacy. Its off-label use in patients 
with inoperable disease, persistent PH after surgery or as a bridge to surgical 
intervention is recommended by current guidelines 2;5;173. In sarcoidosis, the 
mechanisms limiting exercise may differ from PAH or CTEPH, but excluding this 
patient did not affect the results of the analyses. Patients in WHO FC IV were 
not included as they were unable to perform exercise tests. Prevalent patients 
were included whose response to new therapy might be less marked than that 
seen in treatment-naive patients, but the number was small and this would not 
have affected the comparison between 6MWD and IGR measurements. Repeat 
RHC data were not available at follow-up to assess treatment efficacy, but this 
was not the aim of the study. The present study was designed to determine if 
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the effect of proven PAH-specific therapy could be detected by IGR 
measurements alongside conventional outcome measures in patients with 
precapillary PH representative of those seen in routine clinical practice. Lastly, 
in the absence of a placebo-controlled arm, we cannot completely exclude the 
possibility that changes in IGR measurements after new or modified PAH 
treatment had occurred by chance, which is an inherent problem with real-life 
observational data. To confirm the results from this study, the ability of IGR 
measurements to detect treatment effect should ideally be compared with 
6MWD and other conventional outcome measures in randomised controlled drug 
trials.  
3.4.6 Conclusions 
This study is the first to show that non-invasive resting and submaximal exercise 
IGR haemodynamic measurements could be used to detect treatment response 
in precapillary PH. The data analysis also suggests that these measurements may 
be more sensitive than 6MWD in detecting the effects of therapy in fitter 
subjects. In comparison, other conventional outcome measures and isotime 
metabolic variables were less responsive to change.  
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4 USE OF END-TIDAL CARBON DIOXIDE PARTIAL 
PRESSURE TO DETECT TREATMENT 
RESPONSE IN PRECAPILLARY PULMONARY 
HYPERTENSION 
4.1 Summary 
Rationale: PETCO2 is a metabolic index of ventilatory efficiency and is reduced 
at rest and during exercise in patients with PH in proportion to disease severity. 
The aim of this study was to determine if PETCO2 measured during the 6MWT 
could be used to detect treatment response in patients with precapillary PH. 
Methods: Twenty four patients with precapillary PH receiving de novo or 
modified PAH-specific therapy were studied. Distance walked and metabolic 
variables during the 6MWT were measured at baseline and after 3 months of 
new therapy.  
Results: Metabolic data during the 6MWT were available for analysis in 20 
patients. VO2, VCO2, VE, HR, VO2/HR and VE/VCO2 increased while PETCO2 
decreased towards a plateau during the test. RER increased and SaO2 decreased 
progressively throughout the test. Compared with incremental CPET, patients 
had greater arterial desaturation and reached a lower peak VE during the 6MWT. 
At follow-up, there were trended improvements in 6MWD (384±115 to 401±111 
m, p=0.061) and end-of-walk RER (1.09±0.16 to 1.03±0.14, p=0.068), but no 
significant changes in other metabolic variables. Therapy-induced changes in 
6MWD correlated with changes in end-of-walk VO2 (ρ=0.67, p=0.003), VO2/HR 
(ρ=0.50, p=0.004), VE/CO2 (ρ=0.46, p=0.049) and the nadir of PETCO2 (ρ=0.48, 
p=0.039).  
Conclusions: The study provided further insights into the ventilatory response 
during the 6MWT, but did not yield conclusive information on the use of PETCO2 
during the 6MWT to detect treatment response in patients with precapillary PH 
due to its small sample size.   
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4.2 Introduction 
Six-minute walk distance is used as a simple surrogate of peak exercise capacity 
in PH, but observed increase in 6MWD with therapy may not reflect improved 
right heart function or haemodynamic status, and could be brought about by 
other unrelated mechanisms such as improvements in walking efficiency or 
subject motivation. Measuring the ventilatory and gas exchange responses 
during 6MWT would provide mechanistic insights into improved performance and 
allow assessment of PH-specific changes. This was performed in a group of 20 
PAH patients, and the results were compared with those obtained during a 
standard incremental CPET 69. Deboeck et al showed that VO2, VCO2, VE, VO2/HR 
and HR increased whereas SaO2 decreased in the first 2 to 3 min of the 6MWT 
and reached a plateau thereafter. VE/VCO2 increased in the first min, then 
returned to baseline value and remained constant. The walking speed was on 
average constant throughout the 6MWT. Compared with incremental CPET, VO2 
achieved during 6MWT tended to be higher than peak VO2, whereas VE, RER and 
HR were significantly lower. Plateau VO2/HR and arterial desaturation were 
greater during the 6MWT. Plateau VE/VCO2 during the 6MWT was equivalent to 
that observed at AT of the CPET. These findings support the notion that the 
6MWT corresponds to a sustainable submaximal aerobic effort, and that patients 
with PAH exercise at a higher aerobic capacity but lower ventilatory stress 
during the 6MWT compared with a standard incremental CPET. A recent study 
showed that resting PETCO2 measured at the beside using a handheld capnograph 
could be used to differentiate patients with PAH from those with pulmonary 
venous hypertension and those without PH, and that resting PETCO2 improved in 
patients who had clinical response to new or escalated epoprostenol therapy 174. 
However, no studies have looked at changes in ventilatory variables during the 
6MWT and the mechanisms behind improved 6MWD following PAH-specific 
therapy. 
  
A low PETCO2 at rest, AT and peak exercise is characteristic of the CPET response 
in PH patients. The degree of reduction correlates with disease severity 175 and 
has prognostic significance 94. PETCO2 at rest and during exercise normalise with 
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effective therapy and therefore may be a potential marker of treatment 
response. PETCO2 is reproducible and can be readily measured using a handheld 
capnograph as demonstrated in a study on the use of bedside PETCO2 to detect 
pulmonary embolism 176. The aim of this study was to determine if PETCO2 during 
the 6MWT could be used to detect treatment response in patients with 
precapillary PH.  
 
4.3 Methods 
4.3.1 Study subjects 
This study was carried out in conjunction with the study described in Chapter 
3.4. The inclusion and exclusion criteria are as described in Chapter 3.4.3.   
4.3.2 Study design 
This is described in Chapter 3.4.3. In brief, study patients underwent a 
symptom-limited incremental CPET and a 6MWT at baseline. On a separate day 
within 2 weeks, they performed a second 6MWT with ventilatory measurements. 
This was repeated after 3 months of new PAH-specific therapy.  
4.3.3 Ventilatory measurements during 6MWT 
The use of a portable metabolic device during 6MWT is described in Chapter 
2.5.2. VO2, VCO2, VE, VE/VO2, VE/VCO2, VO2/HR, PETO2, PETCO2, RER, HR and SaO2 
were measured continuously for 3 min at rest, during the walk test and for 3 
min in recovery. The values achieved at the end of the 6MWT were used for 
comparison between baseline and follow-up 6MWT, and with the peak values 
achieved at the incremental CPET. Exercise response is defined as changes in 
ventilatory variables from rest to the end of the 6MWT. The physiological 
response during the 6MWT was studied by plotting VO2, HR, VO2/HR, VE, 
VE/VCO2, PETCO2 and SaO2 against time. 
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4.3.4 Statistical analysis 
Statistical analysis was performed using Statview version 5.0.1 (SAS Institute, 
Cary, NC, USA) and Graphpad Prism version 5.00 (Graphpad Software, La Jolla, 
CA, USA). Continuous variables were tested for normality using D’Agostino and 
Pearson omnibus normality test. Normally distributed variables are shown as 
mean ± SD and non-normally distributed variables are shown as median (IQR). 
Categorical variables are presented as number (%). Comparison of ventilatory 
variables between baseline 6MWT and incremental CPET, and that between 
baseline and follow-up 6MWT were made by paired t test or Wilcoxon signed 
rank test depending on data distribution. Post-hoc analysis was carried out by 
stratifying patients into high and low 6MWD groups using the median baseline 
6MWD. Correlation between two variables that were both normally distributed 
was determined by Pearson correlation coefficient (r), and otherwise by 
Spearman correlation coefficient (ρ). A p value<0.05 was defined as statistically 
significant. 
4.4 Results 
4.4.1 Patient characteristics  
The results are described in Chapter 3.4.4 
4.4.2 Ventilatory response during the 6MWT 
The ventilatory and gas exchange responses during the 6MWT are shown in 
figure 4.1. VO2, VCO2, VE, HR and VO2/HR increased rapidly in the first 2 min, 
then at a slower rate reaching a plateau at 4 min. PETCO2 decreased and 
VE/VCO2 increased in the first min and reached a plateau thereafter. RER 
increased and SaO2 decreased progressively throughout the test. 
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Figure 4.1. Changes in oxygen uptake, carbon dioxide output, heart rate, oxygen pulse, ventilatory 
equivalent for carbon dioxide, respiratory exchange ratio, oxygen saturation and end-tidal carbon dioxide 
partial pressure during the 6MWT 
                         
6MWT: 6-minute walk test; PETCO2: end-tidal carbon dioxide partial pressure; RER: respiratory exchange ratio; SaO2: arterial oxygen saturation; VE: 
minute ventilation; VCO2: carbon dioxide output; VO2: oxygen uptake; VO2/HR: oxygen pulse; VE/VCO2: ventilatory equivalent for carbon dioxide.
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4.4.3 Comparison between 6MWT and CPET 
Baseline 6MWD correlated with peak VO2 measured at incremental CPET (r=0.74, 
p<0.001). Patients achieved a lower VE but experienced a greater degree of 
arterial desaturation during the 6MWT compared with incremental CPET (table 
4.1). No significant differences were demonstrated in VO2, VO2/HR, HR and RER. 
VE/VCO2 and PETCO2 achieved at the end of the 6MWT were comparable to those 
obtained at the AT of incremental CPET.  
 
 
 
Table 4.1. Comparison between 6MWT and incremental CPET  
 
 
 
  
6MWT  
(end-of-walk values) 
CPET  
(peak values) 
p value 
        
       HR, beats/min 126±20 129±27 0.790 
VO2, l/min 0.927±0.271 0.865 (0.673-0.953) 0.623 
VO2/kg, ml/min/kg 12±3 12±3 0.283 
VO2/HR, ml 7±2 7±2 0.049 
VE, l/min 53.1±14.6 64.2±16.9 <0.001 
VE/VCO2  54.2±14.7 52.0 (48.0-66.5)* 0.205 
PETCO2, mmHg 22±6 24±6* 0.112 
SaO2, %  86±7 91±6 <0.001 
RER 1.09±0.16 1.15±0.16 0.253 
              
Data are expressed as mean ± SD or median (IQR).  
*measured at anaerobic threshold. 
6MWT: 6-min walk test; CPET: cardiopulmonary exercise test; HR: heart rate; PETCO2: 
end-tidal carbon dioxide partial pressure; SaO2: arterial oxygen saturation; RER: 
respiratory exchange ratio; VE: minute ventilation; VO2: oxygen uptake; VO2/HR: 
oxygen pulse; VE/VCO2: ventilatory equivalent for carbon dioxide. 
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4.4.4 Changes in ventilatory variables with therapy 
After 3 months of new therapy, 6MWD improved from 384±115 to 401±111 m 
(mean change 17±42 m; median change 29 (3-47) m, p=0.061). There were no 
significant changes in resting, end-of-walk PETCO2  or PETCO2 nadir. Apart from a 
trended decrease in end-of-walk RER, there were no significant changes in other 
ventilatory variables (table 4.2). In the post-hoc analysis, 6MWD improved by 
34±25 m (<0.001) in the low 6MWD group (291±47 m at baseline) whereas it did 
not change significantly in the high 6MWD group (477±80 m at baseline). In 
contrast, none of the ventilatory variables changed significantly in the low 
6MWD group, but significant improvements were seen in end-of-walk HR (127±16 
versus 120±15 beats/min, p=0.002) and in the exercise response of VO2/HR (4±2 
versus 5±2 ml, p=0.037), HR (50±14 versus 45±9 beats/min, p=0.013) and PETCO2 
(-7±5 versus -3±3 mmHg , p=0.028) in the high 6MWD group. Baseline 
characteristics of the 6MWD subgroups are shown table 3.4.5 
4.4.5 Correlations of therapy-induced changes  
Therapy-induced changes in 6MWD correlated with those in end-of-walk VO2 
(ρ=0.67, p=0.003), VO2/HR (ρ=0.50, p=0.004) and VE/VCO2 (ρ=-0.46, p=0.049), 
and PETCO2 nadir (ρ=0.48, p=0.039) (figure 4.2). There were no significant 
correlations between therapy-induced changes in 6MWD and those in end-of-
walk PETCO2, VE, HR, RER or SaO2.  
4.4.6 Correlations between PETCO2 and conventional outcome 
measures 
Resting PETCO2 correlated with 6MWD at baseline (r=0.57, p=0.014) and at 
follow-up (r=0.56, p=0.017) and WHO FC at baseline (ρ=-0.53, p=0.025). End-of-
walk PETCO2 correlated with 6MWD at baseline (r=0.53, p=0.021) and at follow-
up (r=0.73, p<0.001), WHO FC at baseline (ρ=-0.52, p=0.023), NT-proBNP at 
baseline (r=-0.61, p=0.016) and at follow-up (r=-0.56, p=0.029). PETCO2 nadir 
correlated with 6MWD at baseline (r=0.59, p=0.007) and at follow-up (r=0.74, 
p<0.001), WHO FC at baseline (ρ=-0.50, p=0.029), NT-proBNP at baseline (r=-
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0.54, p=0.050) and at follow-up (r=-0.55, p=0.036), and CAMPHOR score at 
follow-up (r=-0.50, p=0.043).  
 
Table 4.2. Ventilatory measurements during the 6MWT  
 
  
End-of-walk 
  
Baseline Follow-up p value 
  
       HR, beats/min 126±20 124±11 0.498 
VO2, l/min 0.927±0.271 0.998±0.304 0.162 
VO2/kg, ml/min/kg 12±3 13±3 0.302 
VO2/HR, ml 7±2 8±3 0.161 
VE, l/min 53.1±14.6 51.4±14.5 0.452 
VE/VCO2 54.2±14.7 51.4±15.2 0.205 
VE/VCO2 slope  59.1±17.9 55.1±18.5 0.153 
Resting PETCO2, mmHg 29±7 28±6 0.862 
PETCO2, mmHg 22±6 23±6 0.162 
PETCO2 nadir, mmHg 21±6 22±6 0.108 
SaO2, %  86±7 86±8 0.720 
RER 1.09±0.16 1.03±0.14 0.068 
              
Data are expressed as mean ± SD or median (IQR).  
6MWT: six-minute walk test; HR: heart rate; PETCO2: end-tidal carbon dioxide partial 
pressure; PETCO2 nadir: the lowest point of end-tidal carbon dioxide partial pressure; 
RER: respiratory exchange ratio; SaO2: arterial oxygen saturation; VE: minute 
ventilation; VO2: oxygen uptake; VO2/HR: oxygen pulse; VE/VCO2: ventilatory 
equivalent for carbon dioxide. 
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Figure 4.2. Correlation between therapy-induced changes in 6MWD and ventilatory variables 
                      
∆6MWD: change in 6-minute walk distance; ∆PETCO2 nadir: change in nadir end-tidal carbon dioxide partial pressure; ∆VO2: change 
in oxygen uptake; ∆VO2/HR: change in oxygen pulse; ∆VE/VCO2: change in ventilatory equivalent for carbon dioxide.
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4.5 Discussion 
In this study, the effect of new PAH-specific therapy on the ventilatory response 
during the 6MWT was examined in a group of patients with precapillary PH. A 
trended improvement in 6MWD with therapy change was not accompanied by 
significant changes in ventilatory variables. However the observed moderate 
correlations between therapy-induced changes in 6MWD and those in VO2, 
VO2/HR, VE/VCO2 and PETCO2 nadir  would fit in with the mechanisms behind 
improved 6MWD. In addition, PH patients were found to exercise at a higher 
aerobic capacity with a greater degree of arterial desaturation but at lower 
ventilatory stress at the 6MWT compared with incremental CPET, confirming the 
findings of a previous study. 
Assuming the influences of subject volition and learning effect are negligible, 
improved 6MWD with new PAH-specific therapy would reflect improvements in 
exercise CO response and/or ventilatory efficiency. Accordingly, concurrent 
improvements in the CPET indices of cardiac function (VO2, VO2/HR) and/or 
ventilatory efficiency (VE/VCO2, PETCO2) would be expected. However, no 
significant changes in these variables were detected during the 6MWT at follow-
up. In the post-hoc analysis, 6MWD was found to be less sensitive in detecting 
treatment response in the high 6MWD group compared with the low 6MWD group 
(discussed in Chapter 3.4). When analyses of the ventilatory response during the 
6MWT were stratified by 6MWD subgroups, no changes in ventilatory variables 
with therapy were demonstrated in the low 6MWD group despite an improved 
6MWD, whereas several variables improved significantly in the absence of 
improved 6MWD in the high 6MWD group. This could be the result of statistical 
irregularities related to the small sample size, but does raise the possibility that 
ventilatory variables may be more sensitive than the distance walked during the 
6MWT in detecting a treatment effect in patients walking >450 m.  
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Based on a SD of 6mmHg observed in this study, the sample size required to 
detect a treatment effect in PETCO2 of 2mmHg with 80% power and 5% two-
tailed level of significance by paired t test would be 73. On the contrary, a 
recent study was able to demonstrate an improvement in resting PETCO2 in only 
14 PAH patients receiving new or escalated epoprostenol therapy 174. The fact 
that epoprostenol has more potent pulmonary vasodilatory effects than other 
oral agents may partly explain this discrepancy.  
4.6 Conclusions 
This study was underpowered to detect a change in PETCO2 during the 6MWT 
with new therapy, hence no conclusions can be drawn on its use to detect 
treatment response in patients with precapillary PH. However, it has confirmed 
previous findings on the ventilatory response during the 6MWT in PH patients, 
and more importantly provided useful preliminary data for future studies in this 
field.  
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5 THE ROLE OF PERCENT PREDICTED SIX-
MINUTE WALK DISTANCE IN PULMONARY 
ARTERIAL HYPERTENSION 
5.1 Summary  
Rationale: Absolute 6MWD predicts mortality in PAH, but varies greatly between 
normal individuals due to physiological factors such as age, gender, height and 
weight. The % predicted 6MWD adjusts for these factors and may predict 
mortality more reliably. The aim of the study was to compare the strength of 
mortality prediction by absolute and % predicted 6MWD in PAH at baseline and 
on treatment. 
Methods: % predicted 6MWD was calculated using four different reference 
equations in 137 IPAH and CTDPAH patients diagnosed between November 2000 
and November 2009. Cox proportional hazards and ROC analyses were used to 
compare the prognostic strength of absolute and % predicted 6MWD.  
Results: % predicted 6MWD was predictive of all-cause mortality at baseline 
(hazard ratios: 0.74-0.83 per 10% increase, p<0.05) and on treatment (0.67-0.75 
per 10% increase, p<0.01), but each respective area under the ROC curve was 
not significantly different from that of absolute 6MWD for predicting 2-year 
mortality at baseline (absolute versus % predicted 6MWD: 0.74 versus 0.71-0.75) 
or on treatment (0.77 versus 0.72-0.78). 
Conclusions: % predicted 6MWD may help clinicians interpret the 6MWT, but its 
prognostic value is not superior to that of absolute 6MWD.  
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5.2 Introduction 
Absolute 6MWD has been used as the primary end-point in most clinical trials of 
new PAH-specific therapy 2 and remains the principal outcome measure in PH. 
As a measure of submaximal exercise capacity, it correlates with variables of 
maximal CPET such as peak VO2 and VO2/HR 
46 and ventilatory equivalent 
measured at exercise treadmill testing 47. In addition, it correlates with markers 
of disease severity in PAH, such as WHO FC and pulmonary haemodynamics 46. 
Most importantly, the ability of baseline 6MWD to predict mortality has been 
demonstrated in a 12-week randomised controlled trial of intravenous 
epoprostenol therapy in IPAH 45, the only clinical trial showing a survival benefit 
of PAH-specific therapy. This was confirmed by subsequent observational studies 
on the long-term impact of PAH-specific therapy 57-60. However, there is ongoing 
debate as to whether % predicted 6MWD should be used instead of absolute 
6MWD as it gives a more accurate reflection of the functional impact of disease 
on an individual.  
As with other measurements of physical function, such as lung function and 
cardiopulmonary exercise capacity, 6MWD varies greatly between individuals 
due to physiological factors such as age, gender, height and weight, and 
pathological factors such as cardiopulmonary and musculoskeletal diseases. 
Adjusting for physiological variation should help clinicians interpret the result of 
the 6MWT and estimate the degree of exercise impairment due to disease in an 
individual. Several reference equations already exist to calculate % predicted 
6MWD based on an individual’s age, gender, height and weight 63-66. They have 
been derived from healthy adults sampled from populations in North America 
and Europe. What is not known is whether % predicted 6MWD is superior to 
absolute 6MWD at predicting mortality in PAH. The aim of this study was, 
therefore, to compare the relative strength of mortality prediction by absolute 
and % predicted 6MWD in PAH measured at baseline and on treatment, 
respectively, using four different published reference equations. 
 
 
134 
 
5.3 Methods 
5.3.1 Study subjects 
The study cohort was derived by a retrospective case note review of patients 
referred to the SPVU between November 2000 and November 2009. All 
consecutive incident cases of IPAH and CTDPAH treated with PAH-specific 
therapy were identified. Patients with recorded 6MWD at diagnosis or within 12 
months of starting treatment were included in this study. Patients with 
significant lung disease defined by lung function were excluded.  
5.3.2 Study design 
Baseline data including age, height, weight, lung function, 6MWD, WHO FC, RAP, 
mPAP, PVR, CI and SvO2, and follow-up data including 6MWD, WHO FC and all-
cause mortality were collected. Predicted 6MWD in each patient was calculated 
based on their age, gender, height and weight using each of four reference 
equations (table 5.1). Absolute 6MWD was expressed as a percentage of the 
predicted 6MWD.  
5.3.3 Statistical analysis 
Statistical analysis was performed using Statview version 5.0.1 (SAS Institute, 
Cary, NC, USA) and Graphpad Prism version 5.00 (Graphpad Software, La Jolla, 
CA, USA). Continuous variables were tested for normality using D’Agostino and 
Pearson omnibus normality test. Normally distributed variables are shown as 
mean ± SD and non-normally distributed variables are shown as median (IQR). 
Categorical variables are presented as number (%). Comparison of baseline 
characteristics between IPAH and CTDPAH patients was made by unpaired 
Student’s t test or Mann-Whitney U test depending on data distribution. Changes 
in absolute and % predicted 6MWD with PAH-specific therapy were assessed 
using paired Student’s t test. Comparison of WHO FC between IPAH and CTDPAH 
patients at baseline and changes with PAH-specific therapy were assessed using 
Chi-squared test. The relationship between 6MWD (absolute and each expression 
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of % predicted 6MWD) and other clinical markers of disease severity was 
determined by Pearson correlation coefficient if both variables are normally 
distributed or otherwise by Spearman correlation coefficient.  
Survival time was defined as time from the date of RHC to date of death or data 
cut-off on 30th November 2009. Patients who received lung transplantation or 
who were lost to follow-up were censored at the time of procedure or last 
clinical contact (clinic visit, telephone contact or renewal of drug prescription). 
Univariate Cox proportional hazards analysis was carried out to determine the 
association between all-cause mortality and age, gender, aetiology, lung 
function, haemodynamics, WHO FC, absolute 6MWD and each expression of % 
predicted 6MWD at baseline, and WHO FC, absolute 6MWD and each expression 
of % predicted 6MWD on treatment. Multiple bivariate Cox models, one for 
absolute 6MWD and one for each expression of % predicted 6MWD at baseline, 
were derived by including variables with p<0.2 in the univariate analysis to 
adjust for the effect of confounding. Correlation between candidate variables 
and the predictor of primary interest (absolute or % predicted 6MWD) was 
checked to limit collinearity. The variables would not be considered for 
inclusion if r or ρ is >0.70. The same variables were included to adjust 6MWD in 
each model to facilitate comparison. The bivariate Cox analysis was repeated 
for absolute 6MWD and each expression of % predicted 6MWD on treatment. 
Date of follow-up 6MWD was used as the index date for determining survival 
time for the analysis on treatment. 
To compare the relative prognostic strength among expressions of 6MWD against 
each other at baseline and on treatment respectively, and each corresponding 
expression of 6MWD at baseline versus on treatment, ROC analysis was used to 
determine their respective AUC for predicting 2-year mortality. The significance 
of differences in AUC was assessed using a paired z test. Optimal thresholds 
were identified by selecting the data point closest to the coordinate y=1 (100% 
sensitivity), x=0 (100% specificity) on the ROC curves. A p value <0.05 was 
defined as statistically significant. 
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 Table 5.1. Published reference equations for predicting 6MWD in healthy adults 
  Publication year          Study populations    Reference equations  R2 
          
Enright 64 1998 USA; 117 males,173 females; 
age 40-80 years 
males: (7.57 x Ht) – (5.02 x age) – (1.76 x Wt) – 309 0.40 
females: (2.11 x Ht) – (5.78 x age) – (2.29 x Wt) + 667  
  
 
Troosters 66 1999 Belgium; 29 males, 22 females; 
age 50-85 years 
218 + (5.14 x Ht) – (5.32 x age) – (1.8 x Wt) + (51.31 x gender) 0.66 
male=1, female=0 
  
 
Gibbons 65 2001 Canada; 41 males, 38 females; 
age 20-80 years 
868.8 – (age x 2.99) – (gender x 74.7)                                                               
male=0, female=1 
0.41 
  
Chetta 63 2006 Italy; 48 males, 54 females; 
age 20-50 years 
518.853 + (1.25 x Ht) – (2.816 x age) – (39.07 x gender)    0.42 
male=0, female=1 
    
 
  
 
   6MWD: six-minute walk distance; Ht: height in cm; Wt: weight in kg. R
2
 indicates the degree of inter-subject variance explained by the equation. 
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5.4 Results 
5.4.1 Patient characteristics 
137 patients were included in the cohort (IPAH 86, CTDPAH 51). The baseline 
characteristics of the study patients are outlined in table 5.2. During follow-up 
(median 2 years; range 1.2 months to 8.8 years), 41 patients died from all 
causes (IPAH 20, CTDPAH 21), two patients were lost to follow-up and two 
patients received lung transplantation. After receiving PAH-specific 
monotherapy (7% prostacyclin analogues, 46% endothelin receptor antagonists 
and 47% phosphodiesterase-5 inhibitors) for 4.1±1.8 months (median 3.5 months; 
range 2.2 to 11 months), absolute 6MWD and each expression of % predicted 
6MWD were 311±111 m, 59±18% (Enright 64), 48±15% (Troosters 66), 48±16% 
(Gibbons 65) and 58±19% (Chetta 63) respectively (n=110, all p<0.001 versus 
baseline). On treatment, 41% of patients were in WHO FC II, 54% in III and 4% in 
IV (n=123, p<0.005 versus baseline). At the time of death or censoring, 69% of 
patients remained on monotherapy and 31% were on combination therapy.  
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Table 5.2. Patient characteristics at baseline 
          
 
All patients Aetiology p value* 
 
 
IPAH CTDPAH  
 Patients, n 137 86 51 
 Age, years 60 (48-70) 60 (41-70) 62 (56-69) 0.175 
Female, n (%) 95 (69) 54 (63) 41 (80) 0.031 
Height (cm) 164±9 165±9 161±9 0.003 
  Weight (kg) 73±21 77±19 68±23 0.019 
Lung function, % 
predicted 
    FEV1 87 (75-97) 88 (76-96) 85 (74-99) 0.844 
FVC 99 (86-109) 101 (87-109) 98 (81-113) 0.482 
DLco 43 (29-61) 45 (28-66) 41 (32-50) 0.218 
WHO FC, n (%)  
    I and II 22 (16) 17 (20) 5 (10) 0.026 
III 104 (76) 59 (69) 45 (88) − 
IV 11 (8) 10 (12) 1 (2) − 
Haemodynamics 
    RAP, mmHg 6 (4-11) 6 (3-10) 7 (4-12) 0.399 
mPAP, mmHg 48 (38-57) 50 (42-60) 42 (35-54) 0.088 
CI, l/min/m2 2.1 (1.7-2.6) 2.2 (1.7-2.6) 2.0 (1.7-2.6) 0.924 
PVR, Wood units 10.5 (7.1-15.5) 10.6 (7.4-15.4) 9.7 (5.9-15.9) 0.357 
SvO2, % 63±8 64±8 63±9 0.598 
6MWD†  
    Absolute 6MWD, m 264±111 271±117 251±102 0.330 
6MWD, % predicted  
           Enright 50±19 50±20 50±19 0.946 
       Troosters 41±16 41±16 42±15 0.844 
       Gibbons 41±16 41±16 40±15 0.808 
       Chetta 49±19 49±20 49±18 0.921 
  
Data are expressed as mean ± SD, median (IQR) or n (%).   
*Comparing IPAH versus CTDPAH patients. †n=130.                                                      
6MWD: six-minute walk distance; CI: cardiac index; CTDPAH: connective tissue disease 
associated pulmonary arterial hypertension; DLco: diffusing capacity for carbon monoxide; FEV1: 
forced expiratory volume in one second; FVC: forced vital capacity; IPAH: idiopathic pulmonary 
arterial hypertension; mPAP: mean pulmonary artery pressure; PVR: pulmonary vascular 
resistance; RAP: right atrial pressure; SvO2: mixed venous saturation; WHO FC: World Health 
Organisation functional class.  
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5.4.2 Correlation with other markers of disease severity  
Baseline absolute and % predicted 6MWD correlated weakly with RAP (absolute 
6MWD ρ= -0.23, p<0.01 versus % predicted 6MWD by all equations ρ= -0.23 to -
0.25, p<0.01), CI (ρ= 0.24, p<0.01 versus ρ= 0.21 to 0.22, p<0.05), SvO2 (r= 0.21, 
p<0.05 versus r= 0.19-0.21, p<0.05) and WHO FC (ρ= -0.33, p<0.0005 versus ρ= -
0.32 to -0.34, p<0.005). Only % predicted 6MWD by Enright and Troosters 
equations correlated weakly with PVR (ρ= -0.23 and ρ= -0.19, both p<0.05). 
Neither absolute 6MWD nor % predicted 6MWD correlated with mPAP. 
5.4.3 Independent effect on mortality 
Age and % predicted DLco at baseline, absolute and % predicted 6MWD at 
baseline and on treatment, and WHO FC on treatment predicted all-cause 
mortality in univariate Cox proportional hazards analysis (table 5.3). The 
predictive value of absolute and % predicted 6MWD at baseline remained 
significant after adjusting for age, gender, aetiology but not % predicted DLco in 
bivariate Cox proportional hazards analysis (figure 5.1). Absolute 6MWD, and % 
predicted 6MWD by Gibbons and Chetta equations predicted mortality after 
adjusting for RAP, but % predicted 6MWD by Enright or Troosters equations did 
not. On treatment, absolute and % predicted 6MWD was predictive of mortality 
independently of WHO FC (except Enright equation), age, gender, aetiology, 
baseline % predicted DLco and RAP (figure 5.2). When combined with absolute 
or % predicted 6MWD on treatment, % predicted DLco at baseline no longer 
predicted mortality. 
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Table 5.3. Univariate Cox proportional hazards analysis 
 
Hazard ratio 95% CI p value 
    
Age at diagnosis, per decade increase 
 
(per decade increase) 
 
1.43 
 
1.11-1.86 
 
0.003 
 Gender 
   
Female 0.61 0.32-1.19 0.126 
Male (reference) − − − 
Lung function at baseline 
   
FEV1, per 10% predicted increase 1.09 0.91-1.31 0.383 
FVC, per 10 % predicted increase 1.07 0.91-1.26 0.426 
DLco, per 10 % predicted increase 0.75 0.63-0.90 0.002 
WHO FC at baseline  
   
I/II 0.60 0.18-2.02 0.296 
III 0.63 0.24-1.67 0.259 
IV (reference) − − − 
WHO FC on treatment  
   
I/II 0.13 0.04-0.43 <0.001 
III 
 
0.28 0.09-0.89 0.003 
IV (reference) − − − 
Aetiology 
   
CTDPAH 1.63 0.87-3.06 0.171 
IPAH (reference) − − − 
Haemodynamics at baseline 
   
RAP, per 5 mmHg increase 1.19 0.90-1.58 0.136 
mPAP, per 5 mmHg increase 1.01 0.91-1.12 0.797 
CI, per 1 l/min/m2 increase 0.83 0.49-1.39 0.487 
PVR, per 1 Wood unit increase 1.01 0.96-1.06 0.672 
SvO2, per 5% increase 0.93 0.73-1.19 0.601 
6MWD at baseline (n=130) 
   
Absolute 6MWD, per 50 m increase 0.78 0.67-0.95 <0.001 
% predicted 6MWD, per 10% increase  
   
 
Enright 0.83 0.69-0.99 0.022 
 
Troosters 0.77 0.62-0.96 0.010 
 
Gibbons 0.74 0.61-0.90 0.002 
 
Chetta 0.79 0.66-0.94 0.003 
6MWD on treatment (n=110) 
   
Absolute 6MWD, per 50 m increase 0.74 0.64-0.90 0.001 
% predicted 6MWD, per 10% increase   
   
 
Enright 0.75 0.61-0.93 0.009 
 
Troosters 0.68 0.53-0.89 0.003 
 
Gibbons 0.67 0.53-0.85 0.001 
 
Chetta 0.72 0.59-0.88 0.002 
      
See table 5.2 for abbreviations
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Figure 5.1. Bivariate Cox proportional hazards models of absolute and % predicted 6MWD by four different reference 
equations at baseline 
 
DLco: diffusing capacity for carbon monoxide; RAP: right atrial pressure.  
The unadjusted and adjusted hazard ratios (HR) for 6MWD are indicated by closed circles and the 95% CI by error bars.  
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Figure 5.2. Bivariate Cox proportional hazards models of absolute and % predicted 6MWD by four different reference 
equations on treatment 
 
DLco: diffusing capacity for carbon monoxide; RAP: right atrial pressure; WHO FC: World Health Organisation functional class.  
The unadjusted and adjusted hazard ratios (HR) for 6MWD are indicated by closed circles and the 95% CI by error bars.  
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5.4.4  Relative strength of mortality prediction 
ROC curves of absolute 6MWD and % predicted 6MWD by each of four reference 
equations at baseline and on treatment are shown in figure 5.3. There were no 
significant differences in AUC of absolute versus each expression of % predicted 
6MWD for predicting 2-year mortality at baseline or on treatment (table 5.4). In 
addition, there were no significant differences in AUC among % predicted 6MWD 
by the four reference equations. The optimal thresholds of absolute 6MWD and 
each expression of % predicted 6MWD at baseline and on treatment for 
predicting 2-year mortality had modest sensitivity and specificity. The 
thresholds of absolute 6MWD and % predicted 6MWD by equations from Troosters 
et al 66, Gibbons et al 65 and Chetta et al 63 on treatment had slightly higher 
sensitivity and specificity than those at baseline, but the respective differences 
in AUC between baseline and treatment did not reach statistical significance.  
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Figure 5.3. ROC curves of absolute and % predicted 6MWD by four different 
reference equations in predicting 2-year mortality 
 
 
6MWD: six-minute walk distance; ROC: receiver operating characteristics. All 
p>0.05 when area under ROC curves is compared among expressions of 6MWD 
at baseline and on treatment, respectively, by a paired z test. 
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Table 5.4. ROC analysis comparing the ability of absolute and % predicted 6MWD to predict 2-year mortality 
  
ROC curve area (95% CI) Optimal threshold Sensitivity/specificity p value 
     At baseline 
    Absolute 6MWD 0.74 (0.63-0.86) <295 m 0.83/0.59 <0.001 
% predicted 6MWD  
    Enright 0.71 (0.59-0.83) <51% 0.75/0.56 0.002 
Troosters 0.73 (0.62-0.85) <43% 0.79/0.57 <0.001 
Gibbons 0.75 (0.64-0.85) <43% 0.75/0.60 <0.001 
Chetta 0.74 (0.63-0.85) <53% 0.75/0.57 <0.001 
     On treatment 
    Absolute 6MWD 0.77 (0.64-0.90) <296 m 0.87/0.66 0.002 
% predicted 6MWD  
    Enright 0.72 (0.56-0.87) <53% 0.67/0.66 0.009 
Troosters 0.76 (0.63-0.90) <45% 0.80/0.67 0.002 
Gibbons 0.78 (0.64-0.91) <44% 0.87/0.72 0.001 
Chetta 0.78 (0.65-0.91) <53% 0.87/0.71 0.001 
          
6MWD: six-minute walk distance; ROC: receiver-operating characteristic.
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5.5 Discussion 
This study addresses an important clinical issue regarding the role of % predicted 
6MWD in the management of PAH. The data analysis showed that % predicted 
6MWD at baseline derived from currently available reference equations predicts 
all-cause mortality, but its prognostic ability is not superior to that of absolute 
6MWD despite adjusting for physiological inter-subject variance. In addition, 
there is no difference in the prognostic ability between each of the four studied 
reference equations. Assuming that the long-term prognosis of patients improves 
with PAH-specific therapy, 6MWD on treatment may be a stronger predictor of 
mortality than that at baseline, and hence the difference in the relative 
prognostic strength between absolute and % predicted 6MWD may be more 
apparent on treatment. However, this is not supported by the results of this 
analysis. % predicted 6MWD was not more predictive of mortality than absolute 
6MWD on treatment.  
% predicted 6MWD calculated from Troosters and Gibbons equations was slightly 
lower than that from Enright and Chetta equations. This disparity is due to 
differences in the 6MWT protocol used in the studies, such as the length of 
corridor, type and frequency of encouragement and the number of practice 
walks. A 50-m corridor was used by Troosters et al 66 and the best of 4 walks by 
Gibbons et al 65, which resulted in higher predicted absolute 6MWD. The 
equations were also derived from healthy adults in different age groups. 
Patients younger than 40 years of age were included by Chetta et al 63 and 
Gibbons et al 65 only. This highlights the importance of giving consideration to 
the characteristics of the study population and the 6MWT protocol used in 
deriving the reference equation when applying predicted values. The American 
Thoracic Society guidelines on 6MWT recognise that % predicted 6MWD is under-
utilised due to a lack of optimal reference equations 49. Only 40-66% of 
physiological inter-subject variance of 6MWD is explained by the currently 
available equations. Therefore, there are other factors influencing the 
performance at the 6MWT that have not been identified or accounted for. This 
may partly explain the failure to demonstrate the superiority of % predicted 
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6MWD by any of the four reference equations to absolute 6MWD in predicting 
mortality. 
There are other potential explanations for the negative findings in this study. It 
might be possible for patients with low or high 6MWD to dominate the analysis, 
thereby obscuring any prognostic difference between absolute and % predicted 
6MWD. However, this was not the case as the 6MWD data were normally 
distributed with few patients at either end of the range. The use of all-cause 
mortality rather than disease-specific mortality may also be relevant as this 
could shift the comparison of prognostic strength in favour of absolute 6MWD. 
For example, consider the case of a 40-year old male with severe PAH (height 
186 cm, weight 90 kg) and an 80-year old female with mild PAH (height 157 cm, 
weight 60 kg) both of whom walk the same 6MWD of 300 m and survive for 5 
years. This walk distance corresponds to 40% and 75% predicted, using Enright 
equation respectively, reflecting more severe disease in the male. The 40-year 
old male is more likely to die from PAH whereas the 80-year old female is more 
likely to die from other causes as she approaches the natural limit of life 
expectancy. In this scenario, absolute 6MWD is the better predictor of all-cause 
mortality as it has automatically incorporated the influence of age on mortality, 
with age being the most important physiological determinant of 6MWD. 
Conversely, % predicted 6MWD would be expected to perform better at 
predicting disease-specific mortality. All-cause mortality was used in this study 
to avoid the subjectivity associated with disease-specific mortality.  
The fact that there is a considerable amount of unexplained physiological 
variance in 6MWD raises concerns about its reliability as an outcome measure in 
PAH. Some clinicians propose that 6MWD should be used instead to set a 
treatment goal in individual patients based on their starting parameters, where 
inter-subject variance is not as relevant. To set an appropriate goal, the 
knowledge of predicted 6MWD in an individual is essential. Therefore, despite 
having no added prognostic information, % predicted 6MWD would help clinicians 
to ascertain the degree of improvement achievable should a goal-oriented 
treatment strategy be adopted.  
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The study has a number of limitations. Firstly, selection bias cannot be excluded 
as this is a retrospective study and gaps due to missing data are unavoidable. 14 
(10%) patients with no 6MWD data at baseline or within 12 months of starting 
treatment were excluded from the analysis. Secondly, patients were recruited 
over a relatively long period of time during which treatment approaches had 
evolved. This may have led to differences in prognosis of patients diagnosed in 
the earlier years compared to those diagnosed more recently. However, this is 
unlikely to have affected the main outcome of the analysis, namely the 
comparison between absolute and % predicted 6MWD. Finally, the reference 
equations were derived from healthy populations with differing age groups and 
hence no single equation was perfectly applicable to the study patients. 
5.6 Conclusions 
% predicted 6MWD may help clinicians quantify the functional impact of disease 
on an individual, but its prognostic ability is not superior to that of absolute 
6MWD. In addition, the prognostic ability of currently available reference 
equations is similar. To explore the role of % predicted 6MWD in the 
management of PAH further, efforts should be made to develop more robust 
reference equations using a standardised 6MWT protocol and sampling healthy 
adults from more representative populations, particularly in relation to age.  
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6 PREDICTING SURVIVAL IN PULMONARY 
ARTERIAL HYPERTENSION IN THE UNITED 
KINGDOM 
6.1 Summary 
Rationale: Prognostic equations in PAH have been developed from contemporary 
cohorts in the United States and France. It is not known if these would perform 
as well in the UK as a locally derived scoring scheme.  
Aims: To develop a UK risk score from a well-defined Scottish PAH cohort and to 
validate its prognostic performance against other published equations in a 
second independent UK PAH cohort.   
Methods: Baseline mortality predictors identified by multivariate Cox analysis in 
182 incident PAH patients were used to derive the Scottish Composite Score 
(SCS). Its prognostic performance in an independent UK PAH cohort was 
compared with the French Registry and PHC Registry equations using the BS.  
Results: The SCS based on age, gender, aetiology, RAP, CO and 6MWD predicted 
survival in the validation cohort (hazard ratio 1.7 per point increase, p<0.001) 
and provided further prognostic stratification in WHO FC III patients (hazard 
ratio 1.8 per point increase, p<0.001). It was more accurate than the French 
Registry equation in predicting 1-year survival (BS: 0.092 versus 0.146, p=0.001) 
and 2-year survival (0.131 versus 0.255, p<0.001). There was no significant 
difference in BS between the SCS and PHC Registry equation. 
Conclusions: The SCS predicts survival and can be used to supplement WHO FC 
in prognostication. It may perform better in UK populations than prognostic 
equations derived from other registry studies. 
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6.2 Introduction 
Pulmonary arterial hypertension remains an incurable disease associated with 
high morbidity and mortality despite expansion of effective pharmacological 
therapy in the last decade 2. As accurate prognostication is an integral part of 
disease management, considerable efforts have been made to identify 
prognostic factors and develop algorithms to predict patient outcome for 
clinical use. The first prognostic equation based on pulmonary haemodynamics 
(RAP, mPAP and CI at diagnosis) was derived from the NIH Registry study of 194 
patients with primary pulmonary hypertension (now classified as idiopathic, 
heritable and anorexigen-associated PAH) from 32 centres across the United 
States two decades ago before the advent of PAH-specific therapy 1. It has 
become obsolete but continues to be used as a benchmark for patient outcome 
without targeted therapeutic intervention. Survival analysis of a contemporary 
PAH cohort from the PHC Registry treated in a single centre in Chicago including 
demographics and functional measures identified the same haemodynamic 
variables as the NIH equation, and these were used to derive a new equation 
based on a similar methodological approach 72. Another prognostic equation 
based on gender, 6MWD and CO has been developed from the French Registry 
including incident and prevalent patients diagnosed up to 3 years prior to study 
entry 73;140. These two contemporary equations only apply to patients with 
idiopathic, familial and anorexigen-associated PAH whereas the equation 
developed from REVEAL included all patients in WHO group I PAH 71. Due to its 
large sample size, a greater number of variables were able to be incorporated in 
the prediction model compared with the French Registry and PHC Registry 
equations (13 versus 3 variables).  
These contemporary prognostic algorithms utilise baseline variables to calculate 
a predicted probability of survival at a certain time point during follow-up. 
Validation data on these equations published so far support their predictive 
value. The REVEAL equation and its simplified risk score (a 22-point scoring 
system) have been shown to have good discriminatory ability in a prospective 
PAH cohort of newly diagnosed patients 177. When the PHC Registry and French 
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Registry equations were applied to a prospective cohort of PAH patients 
followed up in four randomised controlled clinical trials and their extension 
studies, there was good agreement between predicted and observed survival 141. 
As these equations were developed from patient populations in the United 
States and France with differing demographics, healthcare systems and 
treatment approaches to the UK, they may not perform as well in UK PAH 
populations as a locally derived scoring scheme. The aims of this study were to 
develop a UK risk score to predict prognosis in PAH from a well-defined cohort in 
Scotland, and to validate its prognostic performance against other published 
prognostic equations in an independent UK PAH cohort.  
6.3 Methods 
6.3.1 Study design 
A retrospective cohort of incident and treatment naive patients diagnosed with 
WHO group I PAH in the SPVU between November 2000 and September 2009 
were used to derive the SCS. Exclusion criteria were PAH associated with 
congenital heart disease (CHD-PAH), long-term CCB responders, PCWP >15mmHg 
and significant lung disease (defined by lung function). The diagnosis of PAH was 
based on RHC in accordance with contemporary guidelines 2;145. Patients were 
subsequently treated with conventional therapy (long-term warfarin, diuretics 
or supplemental oxygen) and PAH-specific monotherapy (prostacyclin analogues, 
phosphodiesterase-5 inhibitors or endothelin receptor antagonists). Sequential 
combination therapy was initiated as clinically indicated. Baseline data on 
demographics, RHC, lung function, WHO FC, 6MWD, NT-proBNP and CAMPHOR 
score recorded within 3 months of diagnostic RHC and prior to starting PAH-
specific therapy were collected. The variables found to be independent 
mortality predictors in multivariate Cox analysis were included in the SCS. 
Weighted points were assigned to the threshold values of each variable 
identified by exploratory analysis. The SCS was obtained by summation of the 
points scored for each variable and finalised prior to validation in a cohort of 
incident and treatment naive idiopathic and heritable PAH patients treated in 
 
 
152 
 
the Pulmonary Vascular Disease Unit at Papworth Hospital (Cambridge) between 
January 2001 and December 2009. Patients with significant lung disease (defined 
by lung function), raised PCWP and long-term CCB responders were excluded. 
Baseline data were collected to apply the SCS, French Registry and PHC Registry 
equations. The ability of the SCS to predict survival over time and stratify 
patients into prognostic groups in the whole cohort and in WHO FC III patients 
was tested. The French Registry and PHC Registry equations were used to 
compute survival estimates at 1 and 2 years post-diagnosis. Their predictive 
accuracy was compared with that of the SCS using the BS. Patient consent was 
considered unnecessary by the local research ethics committee in the respective 
institutions.  
6.3.2 Statistical analysis 
Statistical analysis was performed using Statview version 5.0.1 (SAS Institute, 
Cary, NC, USA) and Graphpad Prism version 5.00 (Graphpad Software, La Jolla, 
CA, USA). Continuous variables were checked for normality using D’Agostino and 
Pearson omnibus normality test. Normally distributed variables are shown as 
mean ± SD and non-normally distributed variables are shown as median (IQR). 
Categorical variables are presented as number (%). Variables were compared 
using unpaired Student’s t test, Mann-Whitney U test or Chi-squared test 
depending on data type and distribution. 
Univariate Cox proportional hazards analysis was used to identify baseline 
mortality predictors in the derivation cohort. Survival time was calculated from 
the date of RHC to the date of death or data cut-off (1st May 2010). Patients 
who received lung transplantation or were lost to follow-up were censored on 
the date of procedure or last clinical contact. Significant continuous variables 
were transformed into categorised variables using threshold values identified in 
exploratory Cox analysis (see Appendix 3) and were assessed with their 
corresponding indicator variable coding for missing data (“missing” and “not 
missing”) in a multivariate Cox model using a backward selection procedure. 
The use of indicator variables was to allow inclusion of patients with missing 
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data in multivariate analyses. None of the indicator variables for missing data 
were predictive of survival. Gender was not significant in the univariate Cox 
analysis, but was entered in the multivariate model as its prognostic significance 
has been confirmed in previous studies. Aetiology was divided into 2 subgroups: 
connective tissue disease associated pulmonary arterial hypertension due to 
systemic sclerosis (CTDPAH-SSc) and WHO group I PAH others versus idiopathic, 
heritable, anorexigen-associated and CTDPAH non-SSc (reference subgroup). 
Anorexigen-associated PAH was included in the reference subgroup as these 
patients are regarded as having similar outcomes to those with idiopathic and 
heritable PAH. “WHO group I PAH others” included patients with 
portopulmonary hypertension, human immunodeficiency virus and pulmonary 
veno-occlusive disease. Variables with p<0.1 were retained in the final 
multivariate Cox model. Weighted points were assigned to each variable 
subgroup according to their adjusted hazard ratio in the final model, for 
example, 0 point was assigned to the reference subgroup with an adjusted 
hazard ratio of 1. For the other subgroups, 1 point was assigned if the adjusted 
hazard ratio was 2, 2 points if the adjusted hazard ratio was 3 and 3 points if 
the adjusted hazard ratio was 4.  
Kaplan Meier analysis was used to estimate survival rates and comparison 
between groups was made by the log-rank test for trend. Cox analysis was used 
to evaluate the ability of the SCS to predict survival in the validation cohort. 
The BS was used to assess the accuracy of the SCS, French Registry and PHC 
Registry equations in predicting 1- and 2-year survival in the validation cohort 
allowing for censoring. It measures the mean squared deviation of predicted 
probability from the actual outcome. A BS of 0 indicates perfect prediction. A 
BS of 0.25 indicates that the prediction is equivalent to the outcome occurring 
by chance alone. A lower BS indicates higher prediction accuracy. To compare 
the performance of the SCS with other equations, a point estimate of difference 
in BS between SCS and each equation and its 95% confidence interval was 
obtained from 200,000 bootstrap re-samples. A difference in BS of >0.02 was 
considered clinically relevant. A p value<0.05 was defined as statistically 
significant. 
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6.4 Results 
6.4.1 Derivation of the Scottish Composite Score 
Characteristics of the derivation cohort are summarised in table 6.1. 10% of 
patients received prostacyclin analogues (intravenous epoprostenol 7%, inhaled 
iloprost 2%, subcutaneous treprostinil 1%), 47% phosphodiesterase-5 inhibitors 
(sildenafil 45% and tadalafil 2%) and 44% endothelin receptor antagonists 
(bosentan 29%, sitaxentan 7% and ambrisentan 8%). After a median follow-up 
period of 25 months (range 0.1 to 113 months), 81 patients died from all causes, 
two patients received lung transplantation, one patient was lost to follow-up 
and two patients transferred care to another centre. The survival estimates for 
the whole cohort were 79% at 1 year, 68% at 2 years and 57% at 3 years. Out of 
the 17 baseline variables considered in the univariate Cox model, age, 
aetiology, % predicted DLco, RAP, CO, WHO FC, 6MWD, NT-proBNP and 
CAMPHOR score were significant mortality predictors (table 6.2). When these 
variables were categorised into 2 to 4 subgroups and assessed along with gender 
in a multivariate Cox model, age at diagnosis, gender, aetiology, RAP, CO and 
6MWD were retained as independent mortality predictors and were used to 
construct the SCS (0 to 8) (table 6.3).  
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Table 6.1. Baseline characteristics of the derivation cohort  
 All patients  Aetiology reference subgroup  
 
p value 
 
     Patient number, n 182 125 - 
Age, years 62 (48-73) 61 (45-71) 0.592 
Female, n (%) 125 (69) 81 (65) 0.477 
Aetiology, n (%) 
   Idiopathic PAH 97 (53) 97 (78) − 
Heritable PAH 2 (1) 2 (2) − 
CTDPAH 
  
− 
SSc associated 33 (18) − − 
non-SSc associated  26 (14) 26 (21) − 
WHO group I PAH others 
   PoPH 15 (8) − − 
HIV 1 (0.5) − − 
PVOD 8 (4) − − 
Lung function, % predicted 
   FEV1 87 (75-98)
*
 86±17
**
 0.605 
FVC 99 (86-112)
*
 98±19
**
 0.628 
DLco 42 (28-60)
‡
 44 (28-63)
‡‡
 0.645 
Pulmonary haemodynamics 
   RAP, mmHg 7 (4-11) 6 (4-10) 0.421 
mPAP, mmHg 47 (39-55) 48 (40-58) 0.459 
CO, l/min 3.6 (2.9-4.7) 3.6 (2.9-4.7) 0.929 
PVR, Wood units 10.8 (7.4-15.5) 11.2 (7.6-15.7) 0.596 
SvO2, % 64 (57-70) 65 (58-70) 0.789 
WHO FC, n (%)  
   I and II 25 (14) 19 (15) 0.899 
III 131 (72) 87 (70) − 
IV 26 (14) 19 (15) − 
6MWD, m  260±109
¶
 273±110
¶¶
 0.342 
NT-proBNP, pg/ml 1026 (298-2637)
§
 972 (316-2258)
§§
 0.856 
CAMPHOR 38 (27-57)
#
 40±18
##
 0.933 
Year of diagnosis 
   Prior to 2005 51 (28) 36 (29) 0.882 
2005 onwards 131 (72) 89 (71) − 
    
Data are expressed as mean ± SD, median (IQR) or n (%). 6MWD: six-minute walk distance; 
CAMPHOR: Cambridge Pulmonary Hypertension Outcome Review; CO: cardiac output; CTDPAH: 
connective tissue disease associated pulmonary arterial hypertension; DLco: carbon monoxide 
diffusing capacity; FC: functional class; FEV1: forced expiratory volume in one second; FVC: forced 
vital capacity; HIV: human immunodeficiency virus; mPAP: mean pulmonary artery pressure; NT-
proBNP: N-terminal pro-brain natriuretic peptide; PAH: pulmonary arterial hypertension; PoPH: 
portopulmonary hypertension; PVOD: pulmonary veno-occlusive disease; PVR: pulmonary 
vascular resistance; RAP: right atrial pressure; SvO2: mixed venous saturation; SSc: systemic 
sclerosis; WHO FC: World Health Organisation. *: n=171; ‡: n=158; ¶: n=177; §: n=96; #: n=76; **: n=117; 
‡‡
: n=108;
 ¶¶
: n=122;
 §§
: n=63; 
##
: n=51. 
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Table 6.2. Univariate Cox proportional hazards analysis in the derivation 
cohort 
 
Hazard ratio  95% CI  p value  
  
    Age at diagnosis, per decade increase  1.32 1.12-1.57 0.010 
Gender  
   Female 0.76 0.47-1.23  0.260 
Male (reference) 
   Aetiology subgroups -  -  0.001 
WHO group I PAH others
†
 3.21 1.79-5.76 <0.001 
CTDPAH-SSc 1.74 0.98-3.09 0.057 
CTDPAH non-SSc 1.29 0.67-2.50 0.445 
Idiopathic or heritable PAH (reference) 
   Lung function  
   FEV1, per 10% increase 0.07 0.00-3.02 0.165 
FVC, per 10% increase 0.32 0.02-5.32 0.892 
DLco, per 10% increase  0.80 0.70-0.91 <0.001 
Pulmonary haemodynamics 
   RAP, per 5 mmHg increase 1.30 1.08-1.57 <0.001 
mPAP, per 5 mmHg increase 1.03 0.96-1.10 0.480 
SvO2 , per 5% increase 0.95 0.83-1.09 0.464 
PVR, per 5 Wood units increase 1.13 0.95-1.33 0.170 
CO, per l/min increase 0.83 0.68-1.01 0.058 
WHO FC      -  -  0.010 
 I and II  0.30 0.12-0.72 0.007 
 III  0.49 0.28-0.85 0.010 
 IV (reference)  
   6MWD, per 100m increase 0.61 0.50-0.67  <0.001 
NT-proBNP, per 200 pg/ml increase  1.02 1.00-1.04  0.036 
CAMPHOR, per 5 points increase 1.16 1.04-1.29 0.008 
Year of diagnosis 
    2005 onwards  1.15 0.71-1.86 0.572 
 2000-2005 (reference)  
           
6MWD: six-minute walk distance; CO: cardiac output; CTDPAH: connective tissue disease 
associated pulmonary arterial hypertension; DLco: carbon monoxide diffusing capacity; FEV1: 
forced expiratory volume in one second; FC: functional class; FVC: forced vital capacity; mPAP: 
mean pulmonary artery pressure; NT-proBNP: N-terminal pro-brain natriuretic peptide; PAH: 
pulmonary arterial hypertension; PVR: pulmonary vascular resistance; RAP: right atrial pressure; 
SvO2: mixed venous saturation; SSc: systemic sclerosis; WHO: World Health Organisation. 
†
: includes portopulmonary hypertension, human immunodeficiency virus, pulmonary veno-
occlusive disease. 
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Table 6.3. Multivariate mortality predictors and derivation of the Scottish 
Composite Score  
Variables Categories HR (95% CI) Points 
       
Age, years ≥ 70 2.20 (1.35 - 3.61)  1 
<70 (reference) - 0 
Gender  Male 2.01 (1.15 - 3.51) 1 
Female (reference) - 0 
Aetiology  CTDPAH-SSc or group I 
PAH others† 
2.33 (1.42 - 3.82) 1 
Idiopathic, heritable, 
anorexigen-associated 
PAH or CTDPAH non-SSc 
(reference) 
 
- 0 
6MWD, m  <50 5.04 (2.33 - 10.89) 3 
50-149 3.45 (1.48 - 8.05) 2 
150-299 2.48 (1.28 - 4.79) 1 
≥ 300 (reference) - 0 
RAP, mmHg  ≥ 10 1.50 (0.90 - 2.49) 1 
<10 (reference) - 0 
CO, l/min  <3 2.18 (1.32 - 3.61) 1 
≥ 3 (reference) - 0 
 
6MWD: six-minute walk distance; CO: cardiac output; CTDPAH: connective tissue disease 
associated pulmonary arterial hypertension; HR: hazard ratio; PAH: pulmonary arterial 
hypertension; RAP: right atrial pressure; SSc: systemic sclerosis. 
†
: includes portopulmonary hypertension, human immunodeficiency virus and pulmonary veno-
occlusive disease. 
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6.4.2 Validation of the Scottish Composite Score  
Out of 119 patients in the validation cohort, 99 patients had complete data to 
calculate the SCS (table 6.4). 38 patients died and four received lung 
transplantation during follow-up (median 29 months, range 0.3 to 102 months). 
The 1-year, 2-year and 3-year survival estimates for patients in whom SCS was 
available were 87%, 74% and 68%, which was not significantly different from 
those in whom SCS was not available (log-rank p=0.196). The risk of death 
increased with the SCS (hazard ratio 1.7 per point increase, 95% CI 1.4-2.1, 
p<0.001). When patients were stratified into 3 SCS risk groups - “high risk” = 4-8 
(n=23), “intermediate risk” = 2-3 (n=44) and “low risk” = 0-1 (n=32), there was a 
significant difference in survival between groups (p<0.001 by log-rank test for 
trend) (figure 6.1). The SCS further stratified WHO FC III patients (hazard ratio 
1.8 per point increase, 95% CI 1.4-2.4, p<0.001) (n=66, 30 deaths). When these 
patients were stratified into 3 SCS risk groups (“high risk” = 4-8, “intermediate 
risk” = 2-3, “low risk” = 0-1), there was a significant difference in survival 
between groups (p<0.001 by log-rank test for trend) (figure 6.2). 
6.4.3 Comparison of prognostic equations 
When the SCS, French Registry and PHC Registry equations were applied to the 
validation cohort to predict 1-and 2-year survival, the SCS had a lower BS than 
both equations, but only the comparison with the French Registry equation 
reached statistical significance (table 6.5).  
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Table 6.4. Characteristics of the validation cohort 
 
Derivation cohort  
 
Validation cohort  
 
p value 
  
         
Patient number, n 182 99 - 
Age, years 62 (48-73) 53 (42-69) 0.010 
Female, n (%) 125 (69) 72 (73) 0.479 
Aetiology, n (%) 
   Idiopathic 97 (53) 96 (97) − 
Heritable PAH 2 (1) 3 (3) − 
CTDPAH 
 
− − 
SSc associated 33 (18) − − 
non-SSc associated  26 (14) − − 
WHO group I PAH others 
   PoPH          15 (8)                −     − 
HIV          1 (0.5)                −     − 
PVOD            8 (4)                −     − 
Lung function, % predicted 
   
FEV1 87 (75-98)
* 84±15 0.038 
FVC 99 (86-112)* 97±17 0.094 
DLco 42 (28-60)
‡ 59±22‡‡ <0.001 
Haemodynamics 
   RAP, mmHg 7 (4-11) 9±6 0.013 
mPAP, mmHg 47 (39-55) 50 (42-59) 0.016 
CO, L/min 3.6 (2.9-4.7) 3.2 (2.6-3.8) 0.002 
PVR, Wood units 10.8 (7.4-15.5) 13.3±5.4 0.011 
SvO2, % 64 (57-70) 63±8 0.889 
WHO FC, n (%)  
   I and II 25 (14) 18 (18) 0.572 
III 131 (72) 66 (67) − 
IV 26 (14) 15 (15) − 
6MWD, metres  260±109
¶ 267±121 0.669 
NTproBNP, pg/mL 1026 (298-2637)
§ 2029 (330-4407)** 0.134 
CAMPHOR 38 (27-57)
# 38 (26-57)§§ 0.804 
    
Data are expressed as mean ± SD, median (IQR) or n (%).  
See table 6.1 for abbreviations.  
*
:n=171; 
‡
:n=158;
 ¶
: n=177; 
§
: n=96;
 #
: n=76; 
‡‡
: n=81; 
**
: n=45;
 §§
: n=49. 
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Figure 6.1. Kaplan Meier survival estimates of the validation cohort stratified 
by three Scottish Composite Score risk groups  
 
 
p<0.001 by log-rank test for trend 
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Figure 6.2. Kaplan Meier survival estimates of WHO FC III patients in the 
validation cohort stratified by three Scottish Composite Score risk groups 
 
 
WHO FC: World Health Organisation functional class. p<0.001 by log-rank test for trend   
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Table 6.5. Comparison of predictive accuracy between the Scottish 
Composite Score and other published prognostic equations 
  
Brier Score 95% CI p value  
  
   
  
Predicting 1-year survival 
   
French Registry equation 0.146 0.120 to 0.175 − 
PHC Registry equation 0.111 0.060 to 0.168 − 
SCS 0.092 0.058 to 0.130 − 
Difference: SCS – French Registry equation -0.055 -0.083 to -0.024 0.001 
Difference: SCS – PHC Registry equation -0.019 -0.059 to 0.017 0.328 
    
Predicting 2-year survival 
   
French Registry equation 0.255 0.210 to 0.302 − 
PHC Registry equation 0.189 0.133 to 0.250 − 
SCS  0.131 0.091 to 0.175 − 
Difference: SCS – French Registry equation -0.124 -0.176 to -0.070 <0.001 
Difference: SCS – PHC Registry equation -0.058 -0.122 to -0.002 0.060 
        
PHC: Pulmonary Hypertension Connection; SCS: Scottish Composite Score. A BS of 0 
indicates perfect prediction and 0.25 indicates a prediction equivalent to random chance 
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6.5 DISCUSSION 
The present study is the first to describe the derivation and validation of a risk 
score to predict prognosis in incident PAH patients based on UK data. The data 
analysis showed that the SCS, a 8-point simple scoring system based on age, 
gender, aetiology, RAP, CO and 6MWD at diagnosis, can be used to categorise 
patients into prognostic groups and provide further risk stratification in WHO FC 
III patients. When tested in an independent UK PAH cohort, the predictive 
accuracy of the SCS was comparable to that of the PHC Registry equation and 
may be greater than the French Registry equation. The prognostic significance 
of gender and aetiology demonstrated by previous studies was also confirmed. 
These findings add to the growing body of literature on prognostication in PAH 
and provide further insights into the use of contemporary prognostic equations 
derived from other registry studies. 
The predictive value of the French Registry, PHC Registry and REVEAL equations 
has been demonstrated in respective validation studies. However their 
applicability in other patient populations would be influenced by factors such as 
study population characteristics, treatment pathways and statistical 
methodology (table 6.6). The SCS was designed as a simple point-based risk 
score to stratify patients into prognostic groups whereas the other equations 
were developed to compute predicted survival probabilities at certain time 
points post-diagnosis. Both SCS derivation and validation cohorts were treated in 
single tertiary centres and this would ensure complete data capture and 
uniformity of care. On the contrary, the French Registry and REVEAL included 
national cohorts from selected centres, which may lead to selection bias, 
variations in clinical practice and patient outcome. The SCS was derived from a 
strictly incident and treatment naive patient cohort whereas French Registry, 
PHC Registry and REVEAL equations from mixed incident and prevalent cohorts. 
The inclusion of prevalent patients would introduce survivor bias as these 
patients have survived long enough to be recruited in the study and would have 
a better prognosis than those who die early from severe disease or lack of 
response to PAH therapy. This was clearly demonstrated by comparing survival 
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between incident and prevalent cohorts in the French Registry study 140. In order 
to remove this survivor bias, authors of the French Registry equation estimated 
survival from time of diagnosis as opposed to time of enrolment and only 
considered patients to be at risk from their time of study entry. This adjustment 
for the time delay between diagnosis and study entry in prevalent patients was 
not adopted in the derivation of the PHC Registry or REVEAL equations. The 
study period of the PHC Registry spanned both pre- and post- modern treatment 
eras. Changes in patient prognosis over this period due to treatment advances 
are probable and this may have affected the survival analysis. These factors, in 
addition to variations in health care systems and treatment approaches, would 
impact on the performance of these prognostic algorithms in different clinical 
settings.  
It is well recognised that patient outcome differs according to PAH aetiology. 
Patients with CHD-PAH were excluded from this study as they have a distinct 
haemodynamic profile and natural history from other PAH patients 178. 
Pulmonary arterial hypertension associated with SSc is known to confer a worse 
prognosis than idiopathic PAH despite a similar degree of haemodynamic 
derangement for reasons that are not fully understood 74;179. When PAH 
associated with different types of connective tissue disease including mixed 
connective tissue disease, overlap syndromes and rheumatoid arthritis were 
grouped together and compared with CTDPAH-SSc in the derivation cohort, 
CTDPAH-SSc conferred a worse prognosis. This would be consistent with the 
findings from a UK-wide epidemiology study 88. Patients with idiopathic, 
heritable, anorexigen-associated PAH are regarded as having similar outcomes 
as they share clinical and pathophysiological features 180. Hence the grouping of 
aetiologies in the SCS would be consistent with findings from previous studies. 
An alternative approach to developing the risk score is to focus on patients with 
idiopathic, heritable, anorexigen-associated PAH and exclude other subgroups 
especially those with SSc given its worse prognosis. As interaction between 
aetiology and other mortality predictors may alter their prognostic 
characteristics, a given predictor may perform differently in different aetiology 
subgroups. While focusing on one homogeneous patient group may allow the 
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development of a more accurate model prediction for that particular group, a 
single risk score applicable to all PAH patients would be simpler to use and more 
readily adopted in routine clinical practice. The premise of this study was to 
develop a simple composite risk score that could be used to risk stratify patients 
regardless of PAH aetiology while taking in account the influence of aetiology on 
survival.  
There is also increasing evidence to support a gender difference in patient 
outcome and this is confirmed by the present study. More females are affected 
by PAH than males, but they have a better prognosis 73;181. Recent analysis of 
patients enrolled in REVEAL showed that males had a higher mPAP and RAP at 
diagnosis and those aged ≥60 years had lower survival rates compared with 
females aged ≥60 years 182. Sex hormones are thought to play a role, but the 
precise mechanisms remain to be elucidated. The individual prognostic value of 
other component variables in the SCS has also been demonstrated in other 
studies (age 71;72;181, 6MWD 44;46;58-60;71;73, RAP 43;44;59;60;71;138, CO 73).   
Algorithms advising on the initial choice of drugs and the use of combination 
therapy advocated by current guidelines on PAH management are primarily 
based on WHO FC as its prognostic value has been firmly established 2;5;173. 
However, WHO FC may not be a sufficiently reliable measure of functional 
status as wide variation in clinicians’ assessment has been reported 183. The 
differences between WHO FC I or II and IV are clear-cut, but WHO FC III 
encompasses patients with a wide range of functional capacity. The results of 
this study showed that the SCS could provide further risk stratification in WHO 
FC III patients and hence supplement WHO FC in clinical assessment. Variables 
measured during follow-up may be more predictive of long-term outcome than 
those measured at baseline evaluation as they would capture the impact of 
treatment response and disease progression on survival. A recent study has 
confirmed the prognostic impact of changes in outcome variables during the 
course of disease and demonstrated the importance of incorporating them into 
risk assessment 184, but there are currently no published prediction tools 
specifically developed to address this issue. We propose that the SCS could be 
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used to assess the initial risk of mortality in the one to two year time horizons 
with a view to develop a risk score incorporating changes in mortality predictors 
over time for repeated use during follow-up.  
This study has several limitations. Missing data were unavoidable due to the 
retrospective nature of the study. As measurements of NT-proBNP and CAMPHOR 
score were not introduced into clinical practice until 2004, there were fewer 
data compared to other baseline variables which may have introduced bias 
against them in multivariate survival analyses despite statistical adjustment. 
The derivation cohort consisted of patients with heterogeneous aetiologies of 
PAH with relatively small numbers in some subgroups. However, this simply 
reflects the relative incidence of different PAH aetiologies in a real-life clinical 
cohort. The data on vasoreactivity status at diagnosis were incomplete, so the 
effect of a positive vasodilatory response on survival could not be assessed. Only 
one patient demonstrated sustained CCB response and was excluded from the 
study. This is based on the finding that long-term CCB responders have a better 
prognosis than non-CCB responders 185. As the number is small, the bias 
associated with this exclusion would be insignificant. There were no patients 
with rarer causes of WHO group I PAH such as schistosomiasis or chronic 
haemolytic anaemia in either the derivation or validation cohort, and only 
patients with idiopathic and heritable PAH were included in the validation 
cohort. Hence the performance of the SCS in other PAH subgroups is still to be 
validated. 17% of patients in the validation cohort did not have all the required 
variables to calculate the SCS. It was not possible to determine how the SCS 
would perform in these patients compared to other equations, but there was no 
difference in survival between patients with and without the SCS. Heart rate 
and SBP were measured in each patient at diagnosis but not recorded in the 
validation database and hence unavailable for this analysis. The REVEAL 
equation could not be included in the comparison as the systematic omission of 
these data would lead to bias in its performance. This is a limitation of database 
analysis that does not reflect the potential value of an assessment tool in 
clinical practice
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Table 6.6. Prognostic algorithms in pulmonary arterial hypertension 
  
Study population 
 
Recruitment period 
 
Variables 
 
End-point 
 
Validation 
           
 
 
         
French Registry equation 
73;140
  
idiopathic, familial and 
anorexigen-associated PAH 
 2002-2003, follow-up time 
3 years for all patients 
 6MWD, gender, CO  survival up to 3 
years post-diagnosis 
 Prospective 
validation in PAH 
cohorts from 
clinical trials 
 
n: 190, 29% Incident and 
71% prevalent cases 
    
  
    
  
 
  
Pulmonary Hypertension 
Connection Registry 
equation 
72
  
idiopathic, familial and 
anorexigen-associated PAH  
 1991-2007, median 
follow-up time 3.9 years, 
IQR 1.7 to 7.8 years, 
maximum follow-up time 
16.6 years 
 RAP, mPAP, CI  survival at number of 
years post-diagnosis 
 Prospective 
validation in PAH 
cohorts from 
clinical trials 
 
n: 282, incident and 
prevalent cases 
     
  
    
  
 
  REVEAL Registry equation 
and risk score 
71;177
 
 WHO group I PAH 
 
2006 onwards, mean 
follow-up time 1.4 years, 
range 0 to 2 years 
 age, aetiology, gender, renal 
insufficiency, SBP, HR, WHO 
FC, 6MWD, BNP or NT-
proBNP, RAP, PVR, 
presence of pericardial 
effusion, % predicted DLco 
1-year survival 
Prospective 
validation in newly 
diagnosed PAH 
patients from 
REVEAL  
 
n: 2716, 14% incident and 
86% prevalent cases 
    
    
  
 
 
      
 
 
 
           Scottish Composite Score 
 
WHO group I PAH (except 
for CHD-PAH) 
2000-2009, median 
follow-up time 2.1 years, 
range 3 days to 9.4 years 
age, aetiology, gender, 
6MWD, RAP and CO 
survival at number of 
years post-diagnosis 
Retrospective 
validation in an 
independent UK 
idiopathic and 
heritable PAH 
cohort 
 
 
n: 182, all incident cases      
 
6MWD: six-minute walk distance; BNP: brain natriuretic peptide; CHD-PAH: congenital heart disease associated pulmonary arterial hypertension; CI: cardiac index; CO: 
cardiac output; DLco: carbon monoxide diffusing capacity; HR: heart rate; mPAP: mean pulmonary artery pressure; NT-proBNP: N-terminal pro-brain natriuretic peptide;  
PAH: pulmonary arterial hypertension; PVR: pulmonary vascular resistance; RAP: right atrial pressure; SBP: systolic blood pressure; WHO FC: World Health Organisation 
functional class.    
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6.6 Conclusions 
The SCS is a simple multidimensional risk score combining the impact of 
demographics, pulmonary haemodynamics and functional status on survival in 
incident PAH patients. When validated in an independent UK idiopathic and 
heritable PAH cohort, it correlated with mortality and provided further risk 
stratification in WHO FC III patients. It may perform better in UK populations 
than prognostic equations derived from other registry studies, but further 
validation in wider PAH populations is required before firm conclusions on its 
clinical utility can be made. 
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7 MAJOR FINDINGS AND CONCLUSIONS 
The work in this thesis was undertaken to evaluate the use of novel non-invasive 
exercise variables and prognostic algorithms as alternative outcome measures to 
6MWD in PH. 
The ability of non-invasive haemodynamic measurements and isotime ventilatory 
variables measured at submaximal constant-load exercise to predict treatment 
response was investigated in patients with precapillary PH. The major findings 
were:- 
 The IGR method could be used to measure PBF and SV non-invasively at rest 
and during exercise with good intersession reproducibility.  
 Resting and submaximal exercise IGR PBF and SV correlate with conventional 
makers of disease severity including WHO FC, 6MWD, NT-proBNP and 
CAMPHOR score. 
 Resting and submaximal exercise IGR PBF and SV could be used to detect 
treatment response to PAH-specific therapy, and may be more sensitive than 
6MWD in detecting the effects of therapy in fitter patients walking >450 m.  
 Isotime ventilatory indices of cardiac function (VO2, VO2/HR) and ventilatory 
efficiency (VE/VCO2, PETCO2) at submaximal constant-load exercise were less 
useful in detecting treatment response.  
The ability of PETCO2 during the 6MWT to predict treatment response was 
investigated, but the study was under-powered to draw any conclusions from 
the negative results. 
 No significant changes were detected in ventilatory variables during the 
6MWT after new PAH-specific therapy except for a trended improvement in 
end-of-walk RER.  
 Therapy-induced changes in ventilatory indices of cardiac function (end-of-
walk VO2 and VO2/HR) and ventilatory efficiency (end-of-walk VE/VCO2 and 
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PETCO2 nadir) correlated with those in 6MWD. This is in keeping with the 
mechanisms behind improved 6MWD with therapy. 
The role of % predicted 6MWD in the management of PAH was explored in 
patients with IPAH and CTDPAH. 
 % predicted 6MWD adjusts for physiological inter-subject variance, but is not 
superior to absolute 6MWD in predicting survival in PAH at baseline or on 
treatment.  
A novel composite risk score was developed from a Scottish cohort of incident 
and treatment-naive PAH patients and then validated externally in an 
independent UK IPAH cohort.  
 The SCS combines prognostic information from age, gender, PAH aetiology, 
RAP, CO and 6MWD at baseline. 
 It could be used to stratify WHO group I PAH patients into risk groups in the 
one to two year time horizons and supplement WHO FC in prognostic 
assessment.   
 It may perform better in UK populations than other published prognostic 
equations derived from registry studies conducted in France and the United 
States.  
In conclusion, the aim of this thesis, namely to evaluate the use of novel non-
invasive outcome measures in PH, was achieved. The work on IGR 
haemodynamic measurements and the SCS was most fruitful and could be 
developed in several directions. The use of submaximal exercise IGR 
haemodynamic measurements should be explored further in patient groups 
where the ability of 6MWD to detect clinical change is most limited, such as 
CTDPAH patients with comorbid musculoskeletal or pulmonary abnormalities and 
fitter patients with early disease. Resting IGR haemodynamic measurements 
may be useful as outcome measures in WHO FC IV patients who are unable to 
perform exercise tests. Simultaneous measurement of VO2 and SV during 
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submaximal exercise may help to identify patients with impaired peripheral 
oxygen extraction who may benefit from exercise training. The use of PETCO2 
during 6MWT as an outcome measure warrants further investigation and power 
calculation for future studies could be performed using data from this work. 
Results on the prognostic performance of the SCS are encouraging but need to 
be confirmed in patients with CTDPAH and other WHO group I aetiologies. It 
would be of great interest to develop a composite risk score based on changes in 
outcome variables during the course of disease to capture the prognostic impact 
of disease progression and PAH-specific therapy.  
  
   
172 
 
APPENDIX 1. WORLD HEALTH ORGANISATION 
FUNCTIONAL CLASS   
Functional class I  Patients with PH but without resulting limitation of  
    physical activity. Ordinary physical activity does not  
    cause undue  dyspnoea or fatigue, chest pain, or near 
    syncope.  
Functional class II  Patients with PH resulting in slight limitation of  
    physical activity. They are comfortable at rest.  
    Ordinary physical activity causes undue dyspnoea or  
    fatigue, chest pain, or near syncope.  
Functional class III  Patients with PH resulting in marked limitation of  
    physical activity. They are comfortable at rest. Less  
    than ordinary physical activity causes undue dyspnoea 
    or fatigue, chest pain, or near syncope. 
Functional class IV  Patients with PH with inability to carry out any  
    physical activity without symptoms. These patients  
    manifest signs of right heart failure. Dyspnoea and/or 
    fatigue may even be present at rest. Discomfort is  
    increased by any physical activity. 
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APPENDIX 2. CAMPHOR QUESTIONNAIRE 
 
 
 
 
 
 
 
 
 
 
Please read this carefully 
 
 
On the following pages you will find some statements that  
have been made by people who have Pulmonary Arterial Hypertension. 
 
Please read each statement carefully.   
We would like you to put a tick in the box  next to ‘Yes’  
if you feel it applies to you and a tick in the  
box  next to ‘No’ if it does not 
 
Please choose the response that applies best to you 
at the moment 
 
 
© Galen Research & Papworth Hospital, 2004 
 
CAMPHOR 
 
Cambridge Pulmonary Hypertension 
Outcome Review 
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Symptoms 
 
 Please read each statement carefully and decide whether it applies to you  at the 
moment  
   
1.   My stamina levels are low   
Yes  
No  
 
  
2.   I have to rest during the day   
Yes  
No  
 
  
3.   I feel worn out 
Yes  
No  
   
4.   I get tired very quickly 
Yes  
No  
   
5.   I’m tired all the time 
Yes  
No  
 
  
6.   I feel very weak 
Yes  
No  
   
7.   I feel completely exhausted    Yes  
No  
   
8.   I want to sit down all the time Yes  
No  
 
  
9.   I soon run out of energy Yes  
No  
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10.   Everything is an effort 
Yes  
No  
   
11.   I get out of breath when I stand up 
Yes  
No  
 
  
12.   When I talk I get out of breath 
Yes  
No  
   
 
Please read each statement carefully and decide whether it applies to you  
at the moment 
 
   
13.   When I walk I get out of breath 
Yes  
No  
 
  
14.   I get breathless if I bend 
Yes  
No  
 
  
15.   I get breathless going up one step 
Yes  
No  
   
16.   I get breathless walking up a slight slope 
Yes  
No  
 
  
17.   I get breathless without doing anything 
Yes  
No  
 
  
18.   I get breathless climbing a flight of stairs 
Yes  
No  
 
 
  
19.   I have mood swings Yes  
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No  
 
  
20.   I get very down 
Yes  
No  
 
  
21.   I seldom feel happy 
Yes  
No  
   
 
 Please read each statement carefully and decide whether it applies to you  
at the moment  
 
   
22.   I’ve forgotten what it’s like to enjoy myself 
Yes  
No  
 
  
23.   I feel hopeless 
Yes  
No  
 
  
24.   It does get me down 
Yes  
No  
 
  
25.   I often feel anxious 
Yes  
No  
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Activities 
 
Please put a tick in the box  under the response which best describes your 
abilities at the moment.  Please respond to all 15 statements. 
 
Please describe your ability without the use of aids or assistance.  
However, do describe your ability taking into account oxygen if you use it. 
 
 
                              Please mark only one box. 
 
Able to do 
on own 
without 
difficulty 
Able to do 
on own 
with 
difficulty 
Unable to 
do on own 
 
1.   Cut your toenails    
2.   Have an all over wash    
3.   Get dressed    
            4. Walk around inside the house (not including climbing 
stairs) 
   
5.   Walk short distances on level ground    
6.   Walk longer distances on level ground    
7.   Walk up a slight incline    
8.   Climb a flight of stairs    
9.   Bend down to pick objects up from the floor    
10.   Stand for a short time    
11.   Stand for a long time    
12.   Lift heavy items    
13.   Carry heavy items    
14.   Do light jobs around the house or garden    
15.   Do heavy jobs around the house or garden    
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Quality of Life 
 
Please read each statement carefully and put a tick  next to the response that applies 
best to you  at the moment  
   
1.    I have to talk very quietly 
True 
Not True 
 
 
   
2.    I can't stay away from home 
True 
Not True 
 
 
   
3.  I've lost interest in food   
True 
Not True 
 
 
   
4.  I can't put energy into my close relationships 
True 
Not True 
 
 
   
5.  Walking for pleasure is out of the question     
True 
Not True 
 
 
   
6.  My condition puts a strain on my close relationships     
True 
Not True 
 
 
   
7.  I feel very isolated     
True 
Not True 
 
 
   
8.  I can’t do things on the spur of the moment      
True 
Not True 
 
 
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9.  I feel vulnerable when  I’m on my own     
True 
Not True 
 
 
 
   
10. It feels like my body has let me down     
True 
Not True 
 
 
   
11.  I feel as if I’m not in control of my life     
True 
Not True 
 
 
   
12. I feel dependent on other people     
True 
Not True 
 
 
   
Please remember to put a tick in only one of the alternative responses for 
each of the statements 
   
13. .Sometimes it’s too much effort to speak      
True 
Not True 
 
 
   
14. I feel as if I am a burden to people     
True 
Not True 
 
 
   
15.  Travelling distances is a problem       
True 
Not True 
 
 
   
16.    I don't like to be seen like this 
True 
Not True 
 
 
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17.    I feel that I'm losing my role in life 
True 
Not True 
 
 
   
18.    I worry that I neglect people close to me 
True 
Not True 
 
 
   
 
Please read each statement carefully and decide whether it applies to you  at the 
moment 
   
19.    I feel guilty asking for help 
True 
Not True 
 
 
   
20.  My condition limits the places I can go     
True 
Not True 
 
 
   
21.    I dislike having to rely on other people    
True 
Not True 
 
 
   
22.  I don’t want to talk to anybody    
True 
Not True 
 
 
   
23. I feel as if I let people down     
True 
Not True 
 
 
   
24.  I am reluctant to leave the house 
True 
Not True 
 
 
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25.   I’m unable to join in activities with my family and friends 
 
True 
Not True 
 
 
 
 
Thank you for taking the trouble to fill in this questionnaire. 
  
Please check all the pages to make sure that you have 
answered every statement 
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APPENDIX 3. TRANSFORMATION OF 
CONTINUOUS UNIVARIATE MORTALITY 
PREDICTORS IN THE DEVELOPMENT OF THE SCS 
Meaningful thresholds of age at diagnosis, RAP, CO, % predicted DLco, 6MWD, 
NT-proBNP and CAMPHOR score were identified by exploratory analysis. Each 
variable was dichotomised into two subgroups starting from a low threshold and 
analysed in a univariate Cox model as a categorised variable. This was carried 
out repeatedly with the threshold increasing by fixed increments. Care was 
taken to ensure there were sufficient patient numbers and deaths in each 
subgroup. The threshold that yielded the most significant hazard ratio was used 
to categorise the variable into two subgroups. If more than one meaningful 
threshold was identified, they were used to divide the variable into three or 
more subgroups. Different combinations were explored and the one that yielded 
the best separation of hazard ratios between subgroups was used to categorise 
the variable. The analyses on each variable are outlined as follows. 
Age - Step 1 (table A.1) 
The subgroup above the threshold was defined as the reference group. 
Thresholds of 40 years, 50 years, 60 years and 70 years yielded significant 
results. Age 70 years was chosen to be the upper threshold and further 
dichotomised Cox analysis was performed in patients aged <70 years to identify 
a lower threshold.  
Age - Step 2 (table A.2) 
No further significant thresholds were identified for age <70 years. So age was 
categorised into 2 subgroups, ≥70 years and <70 years. 
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Table A.1 Dichotomised univariate Cox analysis of age (Step 1) 
Threshold  (years) 
Total Nabove/Nbelow                             
(dead Nabove/Nbelow) 
Hazard
ratio  
p value  
<30 8/174 (3/78) 0.80 0.702 
<40 25/157 (6/75) 0.42 0.039 
<50 48/134 (14/67) 0.55 0.043 
<60 83/99 (28/53) 0.57 0.016 
<70 126/56 (47/34) 0.41 <0.001 
<80 176/6 (79/2) 0.80 0.752 
Nabove: number of patients above the threshold ; Nbelow: number of patients below the threshold. 
 
 
Table A.2. Dichotomised univariate Cox analysis of age in patients <70 years 
(Step 2) 
Threshold (years)  
Total Nabove/Nbelow                             
(dead Nabove/Nbelow)  
Hazard 
ratio  
p value  
<30 8/118 (3/44) 1.07 0.913 
<40 26/100 (7/40) 0.62 0.237 
<50 48/78 (14/33) 0.76 0.380 
<60 83/43 (28/19) 0.87 0.647 
Nabove: number of patients above the threshold ; Nbelow: number of patients below the threshold. 
 
   
184 
 
RAP - Step 1 (table A.3) 
The subgroup above the threshold was defined as the reference group. 
Thresholds of 5 mmHg and 10 mmHg yielded significant results. RAP 10 mmHg 
was chosen to be the upper threshold and further dichotomised Cox analysis was 
performed in patients with RAP <10mmHg to identify a lower threshold.  
RAP - Step 2 (table A.4) 
No further significant thresholds were identified for RAP <10mmHg. So RAP was 
categorised into 2 subgroups, ≥10 mmHg and< 10 mmHg. 
 
Table A.3. Dichotomised univariate Cox analysis of RAP (Step 1) 
Threshold (mmHg)  
Total Nabove/Nbelow                             
(dead Nabove/Nbelow)  
Hazard 
ratio  
p value  
<5 53/129 (17/64) 0.53 0.021 
<10 126/56 (50/31) 0.51 0.003 
<15 156/26 (68/13) 0.65 0.161 
<20 177/5 (80/1) 1.94 0.511 
Nabove: number of patients above the threshold ; Nbelow: number of patients below the threshold. 
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Table A.4. Dichotomised univariate Cox analysis of RAP in patients with 
RAP<10 mmHg (Step 2) 
Threshold (mmHg)  
Total Nabove/Nbelow                             
(dead Nabove/Nbelow)  
Hazard 
ratio  
p value  
<1 13/113 (4/46) 0.88 0.807 
<2 21/105 (7/43) 0.94 0.885 
<3 35/91 (11/39) 0.72 0.334 
<4 40/86 (12/38) 0.67 0.221 
<5 53/73 (17/33) 0.67 0.175 
<6 72/54 (25/25) 0.65 0.123 
<7 84/42 (32/18) 0.70 0.219 
<8 101/25 (38/12) 0.60 0.125 
Nabove: number of patients above the threshold ; Nbelow: number of patients below the threshold. 
 
 
CO - Step 1 (table A.5) 
The subgroup above the threshold was defined as the reference group. 
Threshold of 3.0 l/min yielded the most significant result. It was chosen to be 
the lower threshold and further dichotomised Cox analysis was performed in 
patients with CO >3.0 l/min to identify an upper threshold.  
CO - Step 2 (table A.6) 
No further significant thresholds were identified for CO >3.0 l/min. So CO was 
categorised into 2 subgroups, ≥3.0 l/min and <3.0 l/min. 
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Table A.5. Dichotomised univariate Cox analysis of CO (Step 1) 
Threshold (l/min)  
Total Nabove/Nbelow                             
(dead Nabove/Nbelow) 
Hazard 
ratio  
p value  
<2.0 4/176 (2/77) 0.87 0.844 
<2.5 17/163 (11/68) 1.77 0.080 
<3.0 46/134 (28/51) 2.05 0.002 
<3.5 82/98 (43/36) 1.59 0.042 
<4.0 108/72 (53/26) 1.44 0.132 
<4.5 126/54 (59/20) 1.36 0.233 
<5.0 142/38 (64/15) 1.20 0.519 
<5.5 161/19 (70/9) 0.99 0.981 
<6.0 168/12 (75/4) 1.52 0.415 
Nabove: number of patients above the threshold ; Nbelow: number of patients below the 
threshold. 
 
 
 
Table A.6. Dichotomised univariate Cox analysis of CO in patients with CO  
≥ 3.0 l/min (Step 2) 
Threshold (l/min)  
Total Nabove/Nbelow                             
(dead Nabove/Nbelow)  
Hazard 
ratio  
p value  
<3.5 36/98 (15/36) 1.10 0.760 
<4.0 62/72 (25/26) 1.06 0.844 
<4.5 80/54 (31/20) 1.04 0.882 
<5.0 96/38 (36/15) 0.92 0.792 
<5.5 115/19 (42/9) 0.77 0.487 
<6.0 122/12 (47/4) 1.23 0.691 
Nabove: number of patients above the threshold ; Nbelow: number of patients below the threshold. 
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% predicted DLco - Step 1 (table A.7) 
The subgroup above the threshold was defined as the reference group. 
Thresholds of 30%, 35%, 40%, 45%, 50%, 55% and 60% yielded similarly significant 
results. DLco 60% predicted was chosen to be the upper threshold and further 
dichotomised Cox analyses were performed in patients with DLco <60% to 
identify a lower threshold. 
% predicted DLco - Step 2 (table A.8) 
Thresholds of 30% and 40% yielded similarly significant results. So % predicted 
DLco was categorised into 3 subgroups differently, ≥60, 40-59, <40 or ≥60, 30-
59, <30. Both were assessed in the multivariate model sequentially.  
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Table A.7. Dichotomised univariate Cox analysis of % predicted DLco (Step 1) 
 
 
Threshold  
(% predicted)  
Total Nabove/Nbelow                             
(dead Nabove/Nbelow)  
Hazard ratio  p value  
<20 13/145 (8/58) 2.19 0.038 
<25 28/130 (15/51) 1.91 0.028 
<30 42/116 (23/43) 2.27 0.002 
<35 58/100 (32/34) 2.11 0.003 
<40 70/88 (37/29) 2.35 <0.001 
<45 87/71 (44/22) 2.35 0.001 
<50 95/63 (48/18) 2.60 <0.001 
<55 108/50 (51/15) 2.32 0.005 
<60 115/43 (55/11) 2.52 0.006 
<65 127/31 (57/9) 1.89 0.082 
<70 137/21 (59/7) 1.52 0.294 
<75 144/14 (62/4) 2.03 0.170 
<80 149/9 (64/2) 2.46 0.210 
Nabove: number of patients above the threshold ; Nbelow: number of patients below the threshold. 
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Table A.8. Dichotomised univariate Cox analysis of % predicted DLco in 
patients with DLco <60% predicted (Step 2) 
Threshold  
(% predicted)  
Total Nabove/Nbelow                             
(dead Nabove/Nbelow)  
Hazard ratio  p value  
<20 13/102 (8/47)) 1.76 0.142 
<25 28/87 (15/40) 1.50 0.183 
<30 42/73 (23/32) 1.79 0.035 
<35 58/57 (32/23) 1.63 0.076 
<40 70/45 (37/18) 1.85 0.034 
<45 87/28 (44/11) 1.79 0.086 
<50 95/20 (48/7) 2.14 0.061 
<55 108/7 (51/4) 1.47 0.461 
Nabove: number of patients above the threshold ; Nbelow: number of patients below the threshold. 
 
 
6MWD - Step 1 (table A.9) 
The subgroup above the threshold was defined as the reference group. 
Thresholds of 50 m,100 m, 150 m, 200 m, 250 m and 300 m yielded similarly 
significant results. A 6MWD of 300 m was chosen to be the upper threshold and 
further dichotomised Cox analyses were performed in patients with 6MWD <300 
m to identify a lower threshold. 
6MWD - Step 2 (table A.10) 
Thresholds of 150 m and 50 m yielded the most significant results. 
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6MWD - Step 3 (figure A.1) 
Dividing 6MWD into 4 subgroups, <50 m, 50-149 m, 150-299 m and ≥300 m and 
using ≥300 m subgroup as the reference group, there was an incremental 
increase in hazard ratio with each subgroup. The 6MWD <50 m subgroup had the 
worst outcome and the ≥300 m subgroup the best outcome.   
 
 
Table A.9. Dichotomised univariate Cox analysis of 6MWD (Step 1) 
Threshold (m)  
 
Total Nabove/Nbelow                             
(dead Nabove/Nbelow)  
Hazard ratio  p value  
     
<50 27/175 (21/66)  4.02 <0.001  
<100 36/166 (27/60)  4.17 <0.001  
<150  49/153 (36/51)  3.93 <0.001  
<200  80/122 (49/38)  2.94 <0.001 
<250  105/97 (63/24)  3.63 <0.001 
<300  130/72 (73/14)  4.13 <0.001 
<350  164/38 (79/8)  3.12 0.002 
<400  188/14 (85/2)  3.74 0.066 
<450  195/7 (86/1)  3.10 0.261 
Nabove: number of patients above the threshold ; Nbelow: number of patients below the threshold. 
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Table A.10. Dichotomised univariate Cox analysis of 6MWD in patients with 
6MWD <300 m (Step 2) 
Threshold (m) 
 
Total Nabove/Nbelow                             
(dead Nabove/Nbelow) 
Hazard ratio p value 
 
    
<50 27/103 (21/52)  2.76 <0.001 
<100 36/94 (27/46)  2.43 <0.001 
<150  49/81 (36/37)  2.52 <0.001  
<200  80/50 (49/24)  1.74 0.026 
<250  105/25 (63/10)  2.03 0.039 
    
Nabove: number of patients above the threshold ; Nbelow: number of patients below the threshold. 
 
 
 
 
Figure A.1. Distribution of hazard ratios among 6MWD subgroups  
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NT-proBNP - Step 1 (table A.11) 
NT-proBNP was log transformed and thresholds of 102.9 pg/ml, 103.0 pg/ml, 103.1 
pg/ml, 103.2 pg/ml and 103.3 pg/ml yielded significant results. These thresholds 
corresponded to NT-proBNP 794 pg/ml, 1000 pg/ml, 1259 pg/ml, 1585 pg/ml 
and 1995 pg/ml respectively.    
NT-proBNP - Step 2 (table A.12) 
Dichotomised Cox analysis was repeated using thresholds at 100 pg/ml 
increments from 900 to 2000 pg/ml. The subgroup above the threshold was 
defined as the reference group. All yielded significant results.  
NT-proBNP - Step 3 (table A.13) 
Using 2000 pg/ml as an upper threshold, no lower threshold was identified. 
NT-proBNP - Step 4 (table A.14) 
Using 900 pg/ml as a lower threshold, no upper threshold was identified. So NT-
proBNP was categorised into 2 subgroups, using thresholds at 100 pg/ml 
increments from 900 to 2000 pg/ml, each of which was tested in the 
multivariate model sequentially.  
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Table A.11. Dichotomised univariate Cox analysis of log NT-proBNP (Step 1) 
Threshold (pg/ml)  
Total Nabove/Nbelow                             
(dead Nabove/Nbelow) 
Hazard 
ratio  
p value  
<102.0 7/19 (2/37) 0.47 0.294 
<102.1 12/84 (4/35) 0.58 0.307 
<102.2 14/82 (6/33) 0.83 0.672 
<102.3 17/79 (7/32) 0.75 0.501 
<102.4 20/76 (7/32) 0.61 0.232 
<102.5 26/70 (8/31) 0.49 0.075 
<102.6 29/67 (10/29) 0.59 0.148 
<102.7 33/63 (12/27) 0.64 0.201 
<102.8 35/61 (13/26) 0.70 0.305 
<102.9 41/55 (13/26) 0.49 0.038 
<103.0 48/48 (15/24) 0.44 0.013 
<103.1 51/45 (15/24 ) 0.40 0.006 
<103.2 58/38 (18/21) 0.42 0.007 
<103.3 66/30 (22/17) 0.45 0.013 
<103.4 70/26 (26/13) 0.61 0.148 
Nabove: number of patients above the threshold ; Nbelow: number of patients below the threshold. 
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Table A.12. Dichotomised univariate Cox analysis of NT-proBNP (Step 2) 
Threshold (pg/ml)  
Total Nabove/Nbelow                             
(dead Nabove/Nbelow) 
Hazard 
ratio  
p value  
<900 43/53 (13/26) 0.41 0.009 
<1000 48/48 (15/24) 0.44 0.013 
<1100 49/47 (15/24) 0.43 0.012 
<1200 50/46 (15/24) 0.41 0.007 
<1300 53/43 (16/23) 0.42 0.009 
<1400 53/43 (16/23) 0.42 0.009 
<1500 54/42 (17/22) 0.45 0.013 
<1600 58/38 (18/21) 0.42 0.007 
<1700 60/36 (20/19) 0.47 0.020 
<1800 62/34 (20/19) 0.45 0.013 
<1900 64/32 (21/18) 0.44 0.012 
<2000 66/30 (22/17) 0.45 0.013 
<2100 66/30 (22/17) 0.45 0.013 
Nabove: number of patients above the threshold ; Nbelow: number of patients below the threshold. 
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Table A.13. Dichotomised univariate Cox analysis of NT-proBNP in patients 
with NT-proBNP <2000 pg/ml (Step 3) 
Threshold (pg/ml)  
Total Nabove/Nbelow                             
(dead Nabove/Nbelow) 
Hazard 
ratio  
p value  
<900 43/23 (13/9) 0..49 0.114 
<1000 48/18 (15/7) 0.56 0.225 
<1100 49/17 (15/7) 0.55 0.204 
<1200 50/16 (15/7) 0.42 0.118 
<1300 53/13 (16/6) 0.52 0.182 
<1400 53/13 (16/6) 0.52 0.182 
<1500 54/12 (17/5) 0.57 0.289 
<1600 58/8 (18/4) 0.46 0.168 
<1700 60/6 (20/2) 0.76 0.717 
<1800 62/4 (20/2) 0.62 0.514 
<1900 64/2 (21/1) 0.54 0.550 
Nabove: number of patients above the threshold ; Nbelow: number of patients below the threshold. 
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Table A.14. Dichotomised univariate Cox analysis of NT-proBNP in patients 
with NT-proBNP ≥900 pg/ml (Step 4) 
Threshold (pg/ml)  
Total Nabove/Nbelow                             
(dead Nabove/Nbelow) 
Hazard 
ratio  
p value  
<1000 5/48 (2/24) 0.85 0.830 
<1100 6/47 (2/24) 0.80 0.762 
<1200 7/46 (2/24) 0.57 0.446 
<1300 10/43 (3/23) 0.69 0.540 
<1400 10/43 (3/23) 0.69 0.540 
<1500 11/42 (4/22) 0.78 0.645 
<1600 15/38 (5/21) 0.62 0.342 
<1700 17/36 (7/19) 0.81 0.640 
<1800 19/34 (7/19) 0.73 0.482 
<1900 21/32 (8/18) 0.70 0.404 
<2000 23/30 (9/17) 0.70 0.401 
Nabove: number of patients above the threshold ; Nbelow: number of patients below the threshold. 
 
 
 
CAMPHOR - Step 1 (table A.15) 
The subgroup above the threshold was defined as the reference group. 
Threshold of 55 yielded the most significant result. It was chosen to be the 
upper threshold and further dichotomised Cox analysis was performed in 
patients with CAMPHOR <55 to identify a lower threshold.  
CAMPHOR - Step 2 (table A.16) 
No further significant thresholds were identified for CAMPHOR <55. So CAMPHOR 
was categorised into 2 subgroups, ≥55 and <55.  
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Table A.15. Dichotomised univariate Cox analysis of CAMPHOR score (Step 
1) 
Threshold   
Total Nabove/Nbelow                             
(dead Nabove/Nbelow) 
Hazard ratio  p value  
<15 5/71 (1/28) 0.34 0.287 
<20 9/67 (3/26) 0.70 0.556 
<25 18/58 (5/24) 0.46 0.115 
<30 23/53 (6/23) 0.48 0.112 
<35 28/48 (8/21) 0.41 0.041 
<40 39/37 (11/18) 0.38 0.016 
<45 44/32 (13/16) 0.42 0.026 
<50 48/28 (14/15) 0.61 0.098 
<55 55/21 (16/13) 0.30 0.002 
<60 62/14 (22/7) 0.43 0.060 
<65 68/8 (25/4) 0.61 0.369 
Nabove: number of patients above the threshold ; Nbelow: number of patients below the threshold. 
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Table A.16. Dichotomised univariate Cox analysis of CAMPHOR score in 
patients with CAMPHOR <55 (Step 2) 
Threshold 
Total Nabove/Nbelow                             
(dead Nabove/Nbelow) 
Hazard ratio p value 
<15 5/50 (1/15) 0.51 0.517 
<20 9/46 (3/13)  1.07 0.918 
<25 18/37 (5/11) 0.72 0.544 
<30 23/32 (6/10) 0.76 0.601 
<35 28/27 (8/8) 0.73 0.535 
<40 39/16 (11/5) 0.72 0.542 
<45 44/11 (13/3) 1.00 0.999 
Nabove: number of patients above the threshold ; Nbelow: number of patients below the threshold. 
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